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Aim: Failure of the functional β-cell mass to adapt to compensate for peripheral 
insulin resistance leads to the development of type 2 diabetes and gestational 
diabetes. The overall aim of this thesis was to study mechanisms regulating β-cell 
mass expansion, using pregnancy in mice as an experimental model in which the 
β-cell mass increases during gestation and returns to normal levels post-partum. 
The mechanisms underlying this adaptation are not well understood, although 
placental signals are thought to be involved. The first objective of the project was 
to analyse changes in the β-cell mass during pregnancy, and post-partum. The 
second objective was to quantify the expression of islet β-cell G protein-coupled 
receptors (GPCRs) and their placental ligands to identify novel placental signals 
potentially involved in β-cell adaptation to pregnancy. The third objective was to 
examine the effects of one of the novel placental signals, R-spondin 4 (RSPO4), 
on β-cell function. 
Methods: β-cell proliferation was quantified using immunohistochemical staining 
of pancreatic sections labelled with 5-bromo-2'-deoxyuridine (BrdU), a thymidine 
analogue. β-cell identity was confirmed by co-immunostaining for insulin and 
quantified by morphometric analysis. Islet GPCR and placental ligand mRNAs 
were quantified using a non-biased quantitative real time PCR (qRT-PCR) array 
approach. The effects of RSPO4 on insulin secretion, β-cell proliferation and 
survival were evaluated using radioimmunoassay, BrdU incorporation and 
caspase 3/7 apoptosis assays, respectively.  
Results: Mouse β-cells proliferated during pregnancy, peaking around gestational 
day 12, are the newly-formed β-cells which were not selectively lost post-partum. 
Placental expression of GPCR ligands was upregulated on day 12, and islet 
GPCR expression was differentially regulated during pregnancy. One candidate 
placental GPCR ligand, RSPO4, had pro-proliferative and insulinotropic effects in 
β-cells, consistent with an adaptive function during pregnancy. 
Conclusion: The placenta synthesizes many GPCR ligands, such as RSPO4, 
which have the potential to influence β-cell function during pregnancy, and which 
may have therapeutic potential in treating diabetes.  
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Chapter 1  
1.1 β-cells and diabetes 
1.1.1 Islets of Langerhans 
Islets of Langerhans, first identified in 1869, are the endocrine compartment of the 
pancreas and consist of four main types of endocrine cells: ~60% β-cells 
(secreting insulin), 20-30% α-cells (secreting glucagon), ~10% δ-cells (secreting 
somatostatin), <5% PP cells (expressing pancreatic polypeptide) and ~1%  ε-cells 
(expressing ghrelin) [1, 2]. Rodent islets have a central β-cell core surrounded by 
a mantle of other endocrine cells. In contrast, there are no anatomical subdivisions 
in human islets, in which β-cells are intermingled with other cell types within the 
islet [3]. In addition, all of the islet cell types have equal access to blood vessels 
within the human islet, and the endocrine cells are not organized in layers around 
blood vessels. These observations are consistent with functional segregation and 
a lack of synchronized oscillatory activity of human islets as opposed to mice [3]. 
Only individual β-cells and small regions of human islets show synchronizes 
oscillations of β-cell intracellular Ca2+ levels, that become neutralized by the out-
of-synch activity from other islet regions [3]. Islet α-, β-, δ-, ε- and PP cells are 
involved in maintaining energy balance and regulation of glucose metabolism 
through interconnected functions [4]. 
1.1.2 Insulin secretion and action 
Insulin is secreted by pancreatic β-cells and plays the key role in the regulation of 
glucose metabolism. The single human insulin gene, 1355 base pairs long, is 
located on chromosome 11,  while rodents possess two copies of the insulin gene 
[5]. Plasma glucose concentrations regulate the synthesis of insulin at 
transcriptional and post-transcriptional levels [6]. β-cell specific transcription 
factors Pdx-1 (Pancreatic and duodenal homebox), NeuroD1 (Neurogenic 
Differentiation 1) and MafA (V-Maf masculoaponeurotic fibrosarcoma oncogene 
homologue A) are crucial for regulation of insulin gene transcription by glucose [6]. 
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Insulin is expressed initially as preproinsulin (11.5 kDa) which is processed in the 
rough endoplasmic reticulum to a 9 kDa proinsulin precursor molecule. Proinsulin 
consists of chains A and B joined by C peptide. Proinsulin is packaged into 
secretory granules in the Golgi complex where it is being processed by 
endopeptidases (prohormone convertases 2 and 3) and carboxypeptidase H to 
insulin (5.8 kDa). Processing of proinsulin into insulin continues in the secretory 
granules. Under  normal physiological conditions, secretory granules contain more 
than 95% of insulin and less than 5% proinsulin [1].  
Insulin secretion is regulated by circulating nutrients as well as hormones and 
neural factors [7-9]. The main stimulus of insulin secretion is glucose stimulated 
insulin secretion (GSIS). Glucose is transported into β-cells through glucose 
transporters (GLUT1, 2 and 3 in humans, GLUT2 in rodents) followed by glucose 
phosphorylation by glucokinase. Formation of glucose-6-phosphate is the initial 
step of glycolysis. Glucose metabolism leads to an increased ATP concentration, 
closure of ATP-sensitive K+ (KATP) channels, depolarization of the β-cell 
membrane, opening of the voltage-dependent Ca2+ channels and increased influx 
of Ca2+. The resultant increase in intracellular Ca2+ initiates insulin secretion [10]. 
Glucose-induced insulin secretion is biphasic, with a rapid but short-lived first 
phase (5-10 min) followed by a slowly developing sustained second phase. The 
second phase of insulin secretion from isolated mouse islets is characterized by 
oscillations which have a period of 10-30 s [11]. On the other hand, insulin 
secretion from the perfused human pancreas is characterized by oscillations with a 
5-10 min period [12]. Type 2 diabetes mellitus (T2DM) is characterized by the loss 
of first-phase secretion and reduced second-phase secretion. In addition, 
decreased first-phase GSIS is a symptom of the early stage T2DM and impaired 
glucose tolerance [10].  
The main target tissues for insulin are skeletal muscle, adipose tissue and liver. In 
the liver insulin promotes uptake and storage of carbohydrates, amino acids and 
fat, while at the same time reducing catabolic processes. Moreover, it inhibits 
glycogenolysis and gluconeogenesis while increasing glycogenogenesis in the 
liver. The main effects of insulin in the skeletal muscle are to stimulate glucose 
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transport and glucose storage in the form of glycogen as well as stimulation of 
glycolysis and the activity of tricarboxylic acid cycle. In adipose tissue, insulin 
stimulates glucose uptake, glycerol synthesis and triglyceride formation at the 
same time as blocking lipolysis [1]. Furthermore, insulin has anti-apoptotic and 
pro-proliferative properties in β-cells [13]. Insulin binds to the insulin receptor (IR) 
in target tissues and exerts its functions through a signalling cascade involving 
insulin receptor substrate proteins (IRS), phosphatidylinositol 3 (PI3)-kinase, 
AKT/protein kinase B (AKT/PKB) and mitogen activated protein kinase (MAPK) [1]. 
1.1.3 Diabetes 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease affecting 10% of 
adults suffering from diabetes and it is one of the most common chronic diseases 
of children [14]. In T1DM autoreactive lymphocytes kill β-cells as a result of 
defects in central and peripheral B and T cell tolerance [15]. The development of 
diabetes is associated with the presence of autoantibodies in more than 90% of 
patients with T1DM. In animal models, insulin has been identified as the primary 
initiating antigen whereas other autoantigens (e.g. glutamic acid decarboxylase 
(GAD65) and zinc transporter 8 (ZNT8)) have been associated with progression of 
the disease in humans [14]. There is a strong genetic factor involved in the 
pathogenesis of T1DM, mainly alleles within the major histocompatibility complex 
(MHC), which is manifested by the four-fold higher risk of developing islet auto-
antibodies by children who have a family history of T1DM compared to children 
with no family history [16]. However, 90% of patients with new onset disease do 
not have relatives with T1DM which suggests the importance of environmental 
factors leading to T1DM [14].  
T2DM is the most common type of diabetes, affecting 90% of diabetic patients. 
Genetically and epigenetically susceptible people develop T2DM when they fail to 
adapt to energy surplus [17]. Metabolic symptoms of T2DM include: a loss of β-
cell ability to compensate for the fuel surfeit, peripheral insulin resistance, 
increased production of endogenous glucose, increased glucagon secretion, 
reduced incretin response, hypoadiponectinemia, inflammation of adipose tissue, 
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and limited expansion of subcutaneous adipose tissue (SAT) [17]. Glucotoxic and 
glucolipotoxic mechanisms accelerate β-cell failure and the reduction in β-cell 
mass in patients suffering from T2DM. Many obese people do not develop T2DM 
because of partitioning of excess calories in SAT, which is related to increased β-
cell mass, development of minimal insulin resistance and increased expansion of 
SAT in relation to visceral adipose tissue (VAT) [17]. Insulin resistance is one of 
the main causes of T2DM and is characterized by hyperinsulinemia and 
hyperglycemia in fasting conditions, increased glycated haemoglobin (HbA1c), 
hyperlipidemia, impaired glucose and insulin tolerance, increased glucose 
production in the liver and loss of first phase insulin secretion [18]. It is believed 
that energy surfeit sensing is mediated by ATP and adenosine monophosphate-
activated protein kinase (AMPK) [18].  
Insulin resistance and insulin deficiency within the central nervous system (CNS) 
are referred to as type 3 diabetes mellitus (T3DM) [19]. It is believed Alzheimer’s 
disease (AD) represents T3DM. Initial cognitive impairments in Alzheimer’s 
disease are accompanied by dysfunctional glucose metabolism and energy 
balance in the brain [20]. Therefore, it has been proposed that T3DM is a major 
pathogenic factor in AD.   
Any degree of glucose intolerance with onset during pregnancy is classified as 
gestational diabetes mellitus (GDM) [21]. During pregnancy, the mother’s β-cell 
mass increases to compensate for the increased metabolic demand and 
impairment of those adaptive mechanisms can lead to GDM. GDM is a result of 
pre-existing insulin resistance or impaired β-cell expansion during pregnancy. The 
main independent risk factors for GDM are obesity as well as high energy and 
saturated fat diet [22, 23]. The weight gain of 2.3 to 10 kg/year in the 5 years 
preceding pregnancy elevates the risk of GDM [22]. In addition, mothers with low 
own birth weight are more likely to develop gestational diabetes [24]. GDM 
increases the risk of perinatal complications and developing T2DM in women and 
offspring postpartum [25-27]. A dysfunction in maternal β-cells leads to GDM and 
T2DM post-partum. Furthermore, a six-year study of the offspring of mothers with 
pregestational diabetes (T1DM and T2DM) and GDM revealed that maternal 
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diabetes is linked to obesity as well as poorer intellectual and psychomotor 
development of the offspring [27].  
1.2 Hormonal control of β-cell adaptation to pregnancy 
During pregnancy the mother undergoes major hormonal and metabolic changes 
to ensure a continuous supply of nutrients to the fetus (Figure 1.1). Adaptations to 
increased body weight and insulin demand in pregnant mice involve increased 
islet β-cell proliferation and islet volume, insulin synthesis, glucose-stimulated 
insulin secretion, glucose metabolism as well as upregulated expression of 
glucokinase and glucose transporters (GLUT2 and GLUT5) [28-33]. The mother 
develops insulin resistance during normal pregnancy to ensure a continuous 
supply of nutrients to the fetus. Impaired maternal β-cell adaptation leads to GDM 
and increases the risk of developing post-partum diabetes in rats and women [34, 
35]. The slow basal rate of adult β-cell proliferation is accelerated in response to 
an increased insulin demand resulting from pregnancy, obesity or insulin 
resistance [34, 36, 37]. During rodent pregnancy, the β-cell mass increases by 
2.6-fold [38]. The increase in the β-cell mass in human pregnancy is smaller than 
in rodents, a 1.4-fold increase in the pancreatic fractional area in the first trimester 
of pregnancy [39]. Furthermore, an increase in the human β-cell mass during 
pregnancy is mainly caused by an increased number of β-cells in new, small islets 
as opposed to an increase in the islet size due to a higher replication rate 
observed in rodent pregnancy [39]. There are limited data on the human β-cell 
mass adaptations during pregnancy but it has been shown that β-cell replication is 
not significantly changed during pregnancy [39]. In rodents, β-cell proliferation is 
maximal at gestational day 13-15, dropping to control values at day 18-19 [29, 34]. 
Despite the apparent differences between rodent and human adaptation to 
pregnancy, placental lactogen and prolactin (PRL) play a main role in β-cell 
upregulation during pregnancy and are central to the pregnancy adaptation 





Figure 1.1. Major hormonal changes in pregnant women during pregnancy. Estrogen 
(oestrogen) is involved in development of placenta and increases prolactin production. 
Progesterone stimulates maternal food intake and prevents rejection of the fetus by 
suppression of the maternal immune system. A rise in maternal circulating cortisol, growth 
hormone (GH), progesterone, tumour necrosis factor α (TNF-α) and a drop in plasma 
adiponectin are involved in decreasing maternal insulin sensitivity [40]. 
1.2.1 Lactogenic hormones 
Lactogenic hormones, including PRL and placental lactogens, stimulate the 
development of lactocytes in the mammary gland and lactation after parturition 
[41]. Lactogenic hormones affect the β-cell mass both in the mother and in the 
fetus during pregnancy. A rise in the levels of maternal serum PRL and placental 
lactogen in rodents is related to a 2-fold increase in the mother’s islet mass [29]. 
Moreover, in pregnant women, levels of PRL and placental lactogen (PL) are 
increased which parallels expansion of the β-cell mass [40]. The rapid rate of β-
cell replication observed in the fetus during gestation and infancy is crucial for 
determining the final adult β-cell mass [37, 42]. It has been also suggested that 
nutritional, genetic and environmental factors interfering with β-cell replication at 
this stage can influence the adult β-cell mass and the risk of developing diabetes 






Figure 1.2. Schematic representation of mechanisms involved in the lactogenic 
hormone-controlled regulation of β-cell mass in rodents. PRLR activation plays a 
main role in β-cell adaptation to pregnancy, leading to an increase in insulin secretion and 
β-cell proliferation. Glut-2 - glucose transporter 2, Jak2 - Janus kinase 2, PI3K - 
phosphatidylinozytol 3-kinase [43]. 
 
Furthermore, in rats, PRL facilitates glucose uptake and utilization through 
increased expression of GLUT2 and glucokinase as well as upregulated activity of 
pyruvate dehydrogenase and enhanced GSIS (Figure 1.2) [44, 45].  
Interestingly, glucose increases expression of rat islet prolactin receptor (PRLR) 
and potentiates the stimulatory effect of PRL on cell cycle gene expression 
(cyclins A2, B1, B2, D2 E1 and cyclin dependent kinase 1 (CDK1)) [45]. 
The importance of PRL in the process of maternal adaptation to insulin resistance 
is suggested by results of in vivo and in vitro experiments. For example, PRL and 
human PL (hPL) stimulate β-cell replication, GSIS and prolong β-cell survival in 
isolated human and rodent islets [40]. Overexpression of hPL in primary β-cells 
and insulionoma cells increases β-cell replication and extends β-cell lifespan [40]. 
A global knockout of PRLR in mice reduces the β-cell mass by 26-42%, as 
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compared to wild type littermates, and blunts GSIS responses [46]. Furthermore, 
islets of pregnant global heterozygous PRLR knockout mice are characterized by 
a changed expression pattern of various genes, including Janus kinase 2 (Jak2), 
AKT, menin and cell cycle suppressors p18 (cyclin-dependent kinase 4 Inhibitor C) 
and p21 (cyclin-dependent kinase inhibitor 1) as compared to wild type mice [47]. 
Mutations in the menin (multiple endocrine neoplasia type 1) gene are linked to a 
predisposition to hyperplasia of the parathyroid glands and pituitary as well as 
tumours of the endocrine pancreas [48]. Overexpression of menin in mice 
prevents β-cell mass expansion during pregnancy [49]. Moreover, during 
pregnancy in PRLR wild type mice expression of phospho-Jak2, IRS-2, phospho-
AKT, AKT and p21 is increased whereas menin and p18 expression is 
downregulated [47]. 
In the proposed mechanism of PRL action in mouse pregnancy, PRL increases 
expression of AKT leading to a rise in p21 expression. An elevated level of p21 
may prevent uncontrolled cell proliferation and stabilize cyclin D-CDK4 (cyclin-
dependent kinase 4) complex, ensuring regulated progression through cell cycle 
(Figure 1.2) [47]. In addition, downregulation of the menin/p18 complex and 
increased activation of Jak2 may be responsible for enhanced β-cell proliferation. 
These responses are blocked in pregnant PRLR heterozygous mice [47]. 
Within islets only β-cells express PRLR [43]. Binding of PRL to its receptor 
activates Jak2, which phosphorylates signal transducer and activator 5 (STAT5), 
leading to its translocation to the nucleus, where it activates expression of target 
genes (Figure1.2) [50]. It has also been shown that STAT5 action may be 
mediated by Bcl6 (B-cell lymphoma 6 protein) transcription factor [43]. Activation 
of STAT5 by PRL is biphasic, with peaks within 30 min and between 1 and 3 hours 
followed by prolonged activation after 4 hours [51]. Moreover, tonic stimulation of 
islets by either PRL or GH is required for responsiveness of islets to glucose in 
normal conditions in rats [50]. In addition, experimental data indicate that PL 
activates cyclin D2 expression, which is mediated by STAT5 [52]. A recent study 
on rat INS-1 β-cells has demonstrated that STAT5B overexpression mimics the 
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negative effects of PRL on expression of FoxO1 (Forkhead box protein O1), p27 
(cyclin-dependent kinase Inhibitor 1B), p57 (cyclin-dependent kinase inhibitor 1C) 
and menin [45]. PRL also activates insulin receptor substrates/phosphatidylinositol 
3-kinase (IRSs/PI3K) and the MAPK pathway in islets of neonatal and pregnant 
rats [53]. 
 
The peak of β-cell proliferation on gestational day 14 in pregnant mice 
coincidences with strong upregulation of β-cell serotonin-synthesizing enzymes, 
tryptophan hydroxylase 1 and 2 (TPH1/2) [54]. Brain knockdown of serotonin 
receptor 2C (HTR2C) in non-pregnant mice exacerbates symptoms of T2DM [55]. 
Experiments on mice involving serotonin agonists and antagonists have shown 
that lactogenic hormones induce TPH1/2 expression and serotonin synthesis in 
islets, which is consistent with a model where serotonin stimulates β-cell 
proliferation through its receptor, Gαq-coupled HTR2B [56, 57]. Just before 
parturition, β-cell proliferation and the β-cell mass decrease, returning to the pre-
pregnancy levels. This decrease is related to decreased expression of HTR2B and 
increased expression of Gαi-coupled HTR1D [56]. Serotonin also increases GSIS 
in pregnant mice through activation of HTR3 receptor, a cation-selective ion 
channel, and lowering the glucose threshold for insulin secretion [58]. Another 
function of serotonin is mood regulation, acting via CNS, which may explain the 
association between depression and diabetes (T2DM and GDM) [56]. Serotonin 
synthesised in β-cells plays an important role in mediating the effects of lactogenic 
hormones on islets.   
1.2.2 Hepatocyte Growth Factor signalling 
In experiments performed on pregnant rats Johansson and colleagues showed 
that proliferation of islet endothelial cells precedes β-cell proliferation [59]. In 
addition, endothelial cells can stimulate β-cell proliferation in vitro through 
secretion of hepatocyte growth factor (HGF). HGF expression is enhanced on 
gestational day 15, which correlates with maximum β-cell proliferation [59]. 
Knockout of the pancreatic HGF receptor (C-MET) in rats diminishes maternal β-
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cell proliferation and increases β-cell apoptosis on gestational day 15, resulting in 
reduced β-cell expansion, glucose intolerance, increased blood glucose and 
decreased plasma insulin, symptoms which are hallmarks of GDM [60], These C-
MET knockout rats are also characterized by reduced expression levels of islet 
PRLR, STAT5 and Forehead box M1 as well as upregulation of p27 mRNA. HGF 
may regulate gene expression through hepatocyte nuclear Factor-4α (HNF-4α) 
and ERK. Both HGF and HNF-4α activate ERK signalling cascade in β-cells [59]. 
In addition, HNF-4α is necessary for expansion of the β-cell mass in response to 
increased metabolic demand in pregnancy [61]. It is not yet clear whether HGF 
regulates β-cell expansion during pregnancy directly or indirectly through PRL/PL 
signalling.  
1.2.3 Glucocorticoids 
A stimulatory effect of lactogenic hormones on β-cell proliferation is counteracted 
by increased plasma levels of glucocorticoids post-partum in rats [62]. Three days 
after delivery of pups a burst of apoptosis and a drop in proliferation of maternal β-
cells is observed in rats, which correlates with DNA fragmentation and decreased 
phosphorylation of AKT, an anti-apoptotic kinase [63]. In addition, it has been 
shown that endoplasmic reticulum (ER) stress and unfolded protein response are 
involved in this process. In this mechanism C/EBP homologous protein (CHOP) 
increases expression of Tribble 3 (TRB3) which in turn inhibits AKT leading to 
increased β-cell apoptosis post-partum [63].  
Furthermore, β-cell renewal and function in late pregnancy and early lactation are 
modulated by STAT5B/glucocorticoid receptor (GR) complex [64]. Elevated levels 
of glucocorticoids post-partum trigger formation of a STAT5B/GR complex, which 
then activates transcription of dexamethasone-induced Ras-related protein 1 
(Rasd1) in pancreatic β-cells. Upregulation of Rasd1 causes reduced insulin 
secretion through inhibiting protein kinase A (PKA), protein kinase C (PKC) and 
ERK. PRL has the opposite to glucocorticoids effect on Rasd1 expression. 
Activation of Rasd1 expression by glucocorticoids represents a mechanism for 
reducing β-cell function during early lactation [64]. In addition, glucocorticoids are 
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responsible for the post-partum decrease in expression of sarcoendoplasmic 
reticulum Ca2+-ATPase 2 (SERCA2), leading to decreased insulin secretion during 
lactation. This effect depends on downregulation of signal transducer and activator 
of transcription 3 (STAT3) [65]. Furthermore, glucocorticoid-mediated 
dephosphorylation of phosho-ERK leads to reduced β-cell proliferation in lactating 
rats [66]. Dual-specificity phosphatase 1 (MKP1), downstream of glucocorticoids, 
is involved in this process [66]. 
Lactogens and glucocorticoids have also opposing effects on gene expression and 
differentially regulate fatty acid oxidation and GSIS in β-cells [44]. In rat insulinoma 
cells, PRL decreases expression of FoxO1 and genes involved in biogenesis of 
mitochondria and peroxisomes, including peroxisome proliferator-activated 
receptor γ coactivator 1-α (PGC-1α) and peroxisome proliferator-activated 
receptor α (PPARα) transcription factors whereas dexamethasone (DEX) and 
hydrocortisone stimulate expression of those proteins and uncoupling protein 2 
(UCP-2) [60]. FoxO1 induces apoptosis and inhibits proliferation in pancreatic β-
cells [44]. Down-regulation of FoxO1 by prolactin is mediated by STAT5. It has 
been proposed that PRL-mediated inhibition of FoxO1 expression constitutes a 
new mechanism for promoting β-cell proliferation and increased β-cell mass in late 
gestation, which counteract effects of the increased cortisol concentration at this 
stage of pregnancy [44]. 
1.2.4 Oestradiol 
Oestradiol may regulate β-cell expansion during pregnancy and in obese rats 
through repression of microRNA-338-3p [67]. On day 14 of gestation in rats, the 
peak of the β-cell mass expansion, increased expression of microRNA-144 and 
microRNA-451 is observed. At the same time, expression of microRNA-218 and 
micro-RNA-338-3p is downregulated. Deactivation of micro-RNA-338-3p in β-cells 
using specific anti-microRNA promotes proliferation and protects β-cells from 
apoptosis whereas its upregulation mimics the reduction of β-cells at the end of 
pregnancy [67]. Overexpression of microRNA-338-3p in rat islet cells prevents 
proliferation induced by oestradiol. In addition, in isolated rat islets, activation of 
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the G protein-coupled oestradiol receptor (GPR30) and the glucagon-like peptide 1 
(GLP-1) receptor leads to a decrease in the level of micro-RNA-338-3p [67]. The 
effect of oestradiol is cAMP-dependent [67]. Furthermore, maximum β-cell 
expansion in pregnancy correlates with increased expression of GPR30. 
Experimental data also suggests that in non-pregnant rats, incretins may control 
the level of microRNA-338-3p [67]. 
 
Maternal adaptations to pregnancy involve changes in plasma levels of a wide 
range of hormones. Lactogenic hormones play a central role in β-cell mass 
expansion and insulin secretion upregulation during pregnancy but other important 
factors, oestradiol and HGF, are also involved. Moreover, the regulatory 
mechanisms include glucocorticoids, which are responsible for the reversal of β-
cell expansion post-partum. Dysregulation of the β-cell mass expansion control 
mechanisms may result in GDM, leading to perinatal complications and 
development of T2DM in the mother and offspring post-partum.     
1.3 Placenta functions 
The placenta induces changes in the maternal blood flow, appetite and energy 
homeostasis in order to provide an ample supply of nutrients for itself and the 
fetus. Glucose is the main source of energy for the placenta and the fetus, 
crossing into the placenta from maternal circulation by facilitated transport. Human 
placental hormones, placental lactogens and placental growth hormone, enhance 
food intake in order to increase maternal blood glucose and maximise its transfer 
to the fetus [68]. They augment food intake during early pregnancy while triggering 
utilization of those reserves to support fetal growth and lactation at term [40, 69].  
Located on chromosome 17, human pituitary growth hormone (hGH-N, GH1), 
placental growth hormone (hGH-V, GH2) and placental lactogens (hPL-A, hPL-B, 
hPL-L) genes have high homology of amino acid sequences. The placenta 
secretes all of those hormones except hGH-N. 
By the end of the first trimester, progesterone and hPLs drive an increase in food 
intake and appetite, which, combined with a low metabolic demand of the fetus at 
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that stage, leads to increased deposition of fat [70]. Leptin, secreted by 
adipocytes, normally suppresses food intake signals in the hypothalamus. 
Consequently, dysregulation of energy balance mechanisms results in central 
leptin resistance [70]. In addition, the placenta secretes large quantities of leptin 
during pregnancy, which contributes to leptin resistance [71]. Results of 
experiments on rats suggest that this leptin resistance may cause central insulin 
resistance. Prolactin and placental lactogens may mediate the hormone-induced 
loss of response to leptin during pregnancy, acting on the hypothalamus [71]. 
Moreover, these hormones are known to stimulate β-cell mass expansion and 
insulin secretion, which facilitate fat deposition [40].  
Insulin resistance, increased lipolysis as well as augmentation of maternal plasma 
glucose levels, circulating triglycerides and free fatty acids during pregnancy 
ensure continuous supply of nutrients to the fetus. Placental GH plays a main role 
in insulin resistance. Transgenic mice, overexpressing human placental GH, show 
symptoms of insulin resistance as manifested by fasting and postprandial 
hyperinsulinemia and minimal glucose lowering in response to insulin injection 
[72]. In the skeletal muscle of those mice, insulin-stimulated GLUT-4 translocation 
to the plasma membrane and insulin receptor expression are reduced compared 
to the wild type controls. Furthermore, overexpression of placental GH in mice 
results in increased expression of the regulatory p85 monomer of PI3-kinase, 
which negatively competes with the p85-p100 heterodimer of the kinase for 
binding to IRS-1. This competition is manifested by a reduced ability of insulin to 
stimulate IRS-1-associated activity of PI3-kinase [72]. 
1.4 The role of chemokines during pregnancy 
Chemokines, also known as chemotactic cytokines, are small (8-15 kDa) signaling 
proteins, which are able to induce chemotaxis in responsive cells [73]. In addition 
to their immune system functions, those proteins are also involved in 
neoangiogenesis and tumour growth [74]. The chemokine protein family is 
comprised of more than 50 proteins. They are divided into four subfamilies (CXC, 
CC, C and CX3C) based on the occurrence and location of four distinct cysteine 
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residues that form intramolecular disulfide bonds [73]. Chemokines exert their 
functions through 20 G protein-coupled receptors (GPCRs), which has been 
identified to date. 
Chemokines are a part of a large cytokine protein family. Cytokines are 
glycoproteins taking part in mammalian reproduction physiology, decidualization, 
trophoblast differentiation, implantation, embryogenesis, maternal recognition of 
pregnancy, placental growth and function, as well as term labour, delivery and 
lactation [75, 76]. Notably, maternal tolerance of the semi-allogenic fetus is 
achieved through an increase in the ratio of anti-inflammatory (e.g. IL-4, IL-10) 
cytokines, secreted by T-helper type 2 (Th2) lymphocytes, and pro-inflammatory 
(e.g. IL-12) cytokines, secreted by Th1 cells, which is triggered by progesterone-
induced blocking factor 1 (PIBF) [77-79]. Furthermore, CCL2 and CCL5, secreted 
by decidua, attract dendritic cells (DCs) to the feto-maternal interface where they 
induce an increase in the ratio of the Th2/Th1 cells [80, 81]. Consequently, 
dysregulation of inflammatory mechanisms during pregnancy is implicated in 
aberrant placentation, preeclampsia and preterm labour [82-84].   
In early pregnancy, macrophages and uterine-specific natural killer cells 
infiltrate the implantation site where they are believed to be important modulators 
of trophoblast invasion and decidualization [85]. mRNA of macrophage and natural 
killer chemoattractants is upregulated in mouse endometrium during endometrial 
receptivity and early pregnancy. The upregulated cytokines include monocyte 
chemotactic protein-3 (CCL7), eotaxin (CCL11), fractalkine 
(CX3CL1), macrophage inflammatory protein-1β (MIP-1β), chemokine (C-C Motif) 
ligand 21 (CCL21), hemofiltrate CC chemokine-1 (HCC-1) and -4 (HCC-4) as well 
as macrophage-derived chemokine (MDC) [85]. At the same time, PIBF ensures 
success of gestation via IL-10 and INFγ-mediated inhibition of natural killer (NK) 
cell activity [77]. The main sources of chemokines are epithelial cells and, after 
decidualization, differentiated stromal cells [85, 86]. 
The importance of cytokine signaling during pregnancy is highlighted by the fact 
that inflammation-related cytokine exposure plays a role in altered brain 
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development and offspring obesity [87]. In addition, obese mothers are 
characterized by elevated plasma levels of inflammatory markers and an 
increased risk of pregnancy complications [87].      
1.5 G protein-coupled receptors 
G protein-coupled receptors comprise the largest and most diverse group of 
membrane proteins in eukaryotes. 329 orthologue pairs of non-olfactory GPCRs 
have been identified in human and mouse genomes, with 85% of average 
percentage similarity of the orthologue pairs [88]. The abundance of GPCRs in the 
mammalian genome is reflected in their importance as potential therapeutic 
targets. Drugs targeting GPCRs are the most profitable and the largest group of 
medicines developed in recent years [89]. GPCRs are involved in cellular signal 
transduction in response to hormones and neurotransmitters as well as visual, 
taste and olfactory stimuli. At the molecular level, seven transmembrane α-helical 
domains can be distinguished in their structure, with an extracellular N-terminus 
and cytosolic C-terminus. There are five classes of structurally distinct GPCRs: 
rhodopsin (class A), secretin (class B), glutamate (class C), adhesion and 
Frizzled/Taste2 [90, 91]. The rhodopsin family is the largest and most diverse of 
these families.  
 
GPCRs can function as monomers, homodimers, heterodimers and higher 
oligomers [92]. For example, the neurotensin NTS1 receptor monomer (class A) 
activates G proteins more efficiently than its dimeric form [93]. Receptor 
oligomerization can affect the nascent receptor membrane trafficking, 
pharmacology and signaling. The functional GABAB receptor, activated by γ-
aminobutyric acid (GABA), exists as a heterodimer of GABABR1 and GABABR2 
subunits. The GABABR1 subunit can reach the plasma membrane only after 
forming a complex with the GABABR2 subunit in the endoplasmic reticulum [94]. In 
addition, a functional heterocomplex of the serotonin receptor 5-HT2A and the 
glutamate receptor mGLUT2 has been shown to trigger unique cellular responses 
in the brain cortex of patients suffering from psychosis [95].    
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1.5.1 GPCR signalling  
Although GPCRs share many structural and functional features, individual 
receptors exert unique physiological functions. Signal transduction through these 
receptors is initiated by binding of an agonist to the extracellular ligand-binding 
pocket, leading to conformational changes that are propagated to the cytoplasmic 
part of the receptor, responsible for G protein binding [96]. Conformational 
changes of the receptor promote coupling with its cognate heterotrimeric G 
proteins. The receptor catalyzes an exchange of GTP for GDP on the Gα subunit 
and dissociation of the GTP-bound Gα from the Gβγ subunit heterodimer (Figure 
1.3). Free Gα and Gβγ subunits modulate activity of effector enzymes, including 
adenylate cyclase and phospholipase C, as well as ion channels, to generate 




Figure 1.3. G protein-coupled receptor signalling. GPCR agonists can activate either 
the G protein-dependent or G protein-independent pathways, including the β-arrestin 
signaling pathway. GRK – GPCR kinase, ERK - extracellular signal–regulated kinase 




Subsequently, second messengers change activity of protein kinases (e.g. PKA, 
PKC) that regulate transcription factors and/or enzymes involved in the 
intermediary metabolism. Signaling is terminated by the intrinsic GTPase activity 
of the Gα subunit followed by a return of the G protein to its heterotrimeric state 
[89]. This is followed by receptor internalization from the cell surface to reduce the 
biological response, to resensitise the desensitised receptor by recycling or to 
propagate signals in the cytosol [97].  
 
Within seconds of hormone binding, PKA/C kinases or G protein-coupled receptor 
kinases (GRKs) phosphorylate GPCRs. PKA/C-mediated phosphorylation leads to 
heterologous desensitization whereas GRK phosphorylation results in homologous 
desensitization (Figure 1.4). GRKs bind free Gβγ subunits, promoting subsequent 
β-arrestin binding to the receptor complex. β-arrestins recruit clathrin and β2-
adaptins (AP-2), inducing agonist-receptor complex clustering in clathrin-coated 
pits and endocytosis dependent on dynamin (Dyn). The main role of β-arrestin is 
to uncouple the receptor from the G protein. An important role in the receptor 
sequestration plays GPCR activated phospholipase D (PLD), which hydrolyses 
phospholipids (e.g. phosphatidylcholine) to generate phosphatidic acid (PA). PA 
facilitates vesicle formation through initiation of membrane curvature changes [98]. 
Upon internalization GPCRs can be recycled back to the plasma membrane 
(resensitisation) or transported to lysosomes where they are being proteolysed 
(downregulation) [99].  
   
One GPCR can signal through multiple signaling pathways and G proteins. For 
instance, the GLP-1 receptor can activate both Gαs and Gαq proteins, as well as 









Figure 1.4. Desensitization, internalization and recycling of GPCRs. Phosphorylation 
of the activated receptor by GRK kinases results in the β-arrestin recruitment and 
subsequent internalisation of the receptor in clathrin-coated vesicles. The internalised 
receptor can be either targeted for degradation in lysosomes or recycled back to the 
plasma membrane. H – hormone; E – effector, ion channels or enzymes that generate 
second messengers; AP-2 – β2-adaptins; β-arr – β-arrestin; Dyn – dynamin;              







1.5.2 G proteins 
G proteins are a group of heterotrimeric GTPases, consisting of a GTP-binding Gα 
subunit (39-52 kDa), which exhibits a GTPase activity, and a heterodimeric Gβγ, 
that is non-covalently bound to the Gα subunit. 20 mammalian Gα proteins are 
divided into four categories based on their sequence homology: Gαs, Gαi, Gαq 
and Gα12/13 [101].  
The Gαs family is represented by adenylate cyclase stimulatory Gαs and the 
olfactory subunit Gαolf.  
The Gαi family contains adenylate cyclase inhibitory Gαi1, Gαi2, Gαi3 and Gαio 
subunits. In addition, the Gαi family includes two retinal transducin Gα subunits 
(Gαt1, Gαt2), the taste Gα subunit gustducin (Gαgust) and Gαz. The Gαz subunit 
inhibits adenylate cyclase in pancreatic β-cells and has been reported to couple 
GPCRs to ion channels in neurons [102, 103].   
The Gαq family, which activates phospholipase C, contains Gαq, Gα11, as well as 
Gα14 and Gα15. 
The Gα12/13 family includes Gα12 and Gα13 subunits, responsible for Rho 
GTPase activation and regulation of cytoskeleton dynamics [104].  
Modulating the activity of Gα subunits and/or G protein-coupled receptors can 
have beneficial applications in T2DM treatment. Elevated levels of cAMP in β-cells 
contribute to augmented insulin secretion and cell proliferation [105, 106]. 
Activation of Gαs subunits has similar effects on β-cell secretory functions and 
proliferation as inhibition of the Gαi action. Gαi inhibition by pertussin toxin (PTX) 
results in improved glucose stimulated insulin secretion and abolishes an inhibitory 
action of somatostatin on insulin release, both in vivo and in isolated rat islets 
[106]. Likewise, mice overexpressing the catalytic PTX subunit S1 in β-cells are 
resistant to high-fat diet induced hyperglycemia [107]. In addition, Gαz knockout 
mice have increased GSIS, β-cell mass and are protected from high-fat diet 
induced glucose intolerance [102]. The beneficial effects of the Gαz knockout are 
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linked to constitutively increased cAMP production in pancreatic islets. In addition, 
noradrenaline-induced inhibition of insulin exocytosis is abolished by a Gαi1/2 
blocking protein in INS-1 β-cells [108]. Knockout of Gαio2 in mice has also been 
shown to enhance glucose stimulated insulin release and improve glucose 
tolerance [109]. However, mice with liver and adipose tissue deficiency of Gαi2 
have decreased glucose tolerance, insulin sensitivity and IRS-1 phosphorylation in 
those organs, implying a positive effect of Gαi2 on the insulin action [110].  
Incretins GLP-1 and GIP, acting through Gαs protein-coupled receptors, increase 
glucose-stimulated insulin secretion and β-cell mass [105, 111]. In addition, 
depletion of the GIP receptor in mice is associated with an impaired compensatory 
response to high fat diet, including inability to enhance β-cell proliferation and 
insulin secretion. Thus, GLP-1 and GIP analogues have been used to ameliorate 
T2DM symptoms, both in humans and animals [105, 112]. 
The Gαq family of G proteins also stimulates insulin secretion but in this case, 
adenylate cyclase is not involved. Gαq proteins activate phospholipase C, which 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into second messengers, 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Specific inactivation of 
Gαq and Gα11 in mouse pancreatic β-cells results in impaired glucose tolerance 
and insulin secretion [113]. Activation of cholecystokinin receptor B (CCKR), 
coupled to Gαq protein, by cholecystokinin and gastrin, has a stimulatory effect on 
basal and glucose-induced insulin secretion [114-116]. In addition, a combination 
therapy with epidermal growth factor (EGF) and gastrin increases β-cell mass and 
reverses hyperglycemia in diabetic NOD mice, an animal model of T1DM, whereas 
EGF and gastrin alone do not [117]. Similarly, a combination therapy of GLP-1 and 
gastrin, but not with GLP-1 and gastrin individually, restores normoglycaemia in 
NOD mice [118]. Interestingly, the GLP-1 receptor signals both through Gαs and 
Gαq proteins in hamster ovary cells [100].  
In pancreatic β-cells, the Gα12/13 proteins, through Rho GTPase activation and 




There are 6 known human Gβ subunits (36 kDa) and 12 Gγ subunits (7-8 kDa) 
[121]. Gβγ dimers can stimulate adenylate cyclase isoforms 2, 4 and 7 while 
inhibiting adenylate cyclase isoforms 1, 5 and 6 [122]. In the context of β-cell 
physiology, Gβ5 knockout mice are characterized by decreased plasma glucose 
levels, impaired glucose clearance and increased plasma insulin [123]. The 
diversity of GPCR-mediated responses can be attributed to both receptor 
oligomerisation and a high number of possible G protein heterotrimer 
combinations. 
1.5.3 Proteins modulating GPCR functions 
Receptor activity modifying proteins (RAMPs) regulate trafficking and function of 
calcitonin receptor-like receptor (CRLR). The RAMP family consists of 5 members 
(RAMP1–RAMP5). Experiment in Xenopus and human cell cultures showed that 
when CRLR heterodimerizes with RAMP1 it can act as the calcitonin gene-related 
peptide 1 (CGRP1) receptor whereas when heterodimerizes with either RAMP2 or 
RAMP3 it can form adrenomedullin receptors AM1 and AM2 respectively [124]. In 
addition, CRLR membrane trafficking, ligand induced internalisation, recycling and 
desensitisation depend on forming complexes with RAMPs [124, 125]. CRLR 
forms stable heteromeric complexes with RAMPs, which are maintained 
throughout their life cycle [126]. Furthermore, RAMPs can interact with the 
calcitonin receptor (CTR), vasoactive intestinal polypeptide/pituitary adenylate 
cyclase activating peptide receptor (VPAC1R), glucagon receptor, parathyroid 
hormone 1 and 2 receptors (PTH1R, PTH2R) and the calcium sensing receptor 
(CaSR) [127, 128]. 
GPCR localization and functions can also be modified by proteins containing post-
synaptic density of 95 kDa (PSD95)-disc large-zona occludens (PDZ) domains. 
PDZ domains are responsible for protein-protein interactions by binding to specific 
PDZ recognition motifs located at the protein C-terminus [129]. GPCRs containing 
the PDZ-binding motif include serotonin receptors (5-HT2A, HTR2B, 5-HT2C), 
somatostatin receptor 2 (SSTR2) and parathyroid hormone 1 receptor (PTH1R). 
PTH1R can couple to either Gαs or Gαi proteins, depending on the interaction with 
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the PDZ domain-containing Na+/H+ exchanger regulatory factor 2 (NHERF2), an 
inhibitor of the renal NHE3 Na+/H+ exchanger. In the renal cells expressing 
NHERF2, PTH1R couples to the Gαi proteins predominantly, whereas in the cells 
lacking NHERF2, the receptor couples to the Gαs family proteins [130]. Moreover, 
the PSD95 protein, containing a PDZ domain, binds β1-adrenergic receptor 
(ADRB1) and suppresses receptor endocytosis while membrane-associated 
guanylate kinase inverted-2 (MAGI-2) protein upregulates ADRB1 internalization 
[131]. 5-HT2C serotonin receptor interaction with the multi-PDZ domain protein 1 
(MUPP1) in the rat brain may be involved in GPCR signalosome assembling [132]. 
1.5.4 Signaling independent of G proteins 
β2-adrenergic receptor (ADRB2) binding to the PDZ domain of NHERF1 prevents 
NHERF1 from inhibiting the NHE3 Na+/H+ exchanger activity in the kidney [133]. 
 
GPCRs can also activate non-G protein-dependent signaling through mobilization 
of β-arrestin [134]. After endocytosis, GPCRs can activate signaling pathways 
downstream of G proteins. The internalized GLP-1 receptor stimulates the activity 
of endosomal adenylate cyclase and increases glucose stimulated insulin 
secretion in rat pancreatic β-cells [135].   
 
In addition, the β2-adrenergic receptor ligand ICI118551 functions both as an 
inverse agonist for Gαs-stimulated adenylyl cyclase and a Gαs-independent partial 
agonist for ERK1/2 kinase [136]. ERK1/2 activation by ICI118551 is inhibited in 
mouse embryonic fibroblasts lacking β-arrestin 1 and β-arrestin 2 proteins but can 
be restored by overexpression of β-arrestin 2, which suggests that β-arrestins 
mediate G protein-independent signaling. A similar mode of action was observed 
in the case of SR121463B, an arginine vasopressin receptor 2 (AVPR2) ligand 
[136]. β-arrestin-mediated activation of ERK1/2 involves formation of a multiprotein 
“signalosome”. Agonists of proteinase-activated receptor 2 (PAR2) promote 
formation of a protein complex consisting of internalized PAR2 receptor, β-arrestin 
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1, Raf-1 (a member of MAP kinase kinase kinase (MAP3K) family), and ERK1/2 
[137].   
1.6 WNT signalling 
1.6.1 WNT proteins and their receptors 
WNT1 proto-oncogene was first discovered in mouse mammary tumors [138]. 
Mammalian genomes contain 19 WNT genes, which encode proteins 
approximately 40 kDa in size. Even sponges and cnidarians, but not single cell 
organisms, harbor a few WNT genes, emphasizing the importance of WNT 
signaling in the evolution of multicellular species [139]. WNT proteins control 
tissue patterning, cell polarity, growth and proliferation [140, 141]. Moreover, WNT 
signalling plays a central role in development of skin, hair follicle, limbs, 
gastrointestinal tract, whiskers in mice as well as in intestinal stem cell 
maintenance [142]. 
WNT proteins exert their functions by activating heterodimeric receptor complexes, 
consisting of FZD (Frizzled) and single-pass transmembrane LRP5/6 subunits. 10 
mammalian FZD receptors belong to the highly conserved Frizzled class of 
GPCRs [143]. WNTs interact both with the FZD and LRP5/6 subunits of the 
receptor complex. Furthermore, most of WNT proteins have the ability to engage 
multiple FZDs [144]. Likewise, 19 WNTs and 10 FZDs give 190 possible 
interactions, reflecting the complexity of WNT signaling. 
1.6.2 Canonical WNT/β-catenin signaling 
In the absence of WNT, the Axin-APC-GSK3 complex resides in the cytoplasm, 
where it phosphorylates β-catenin, resulting in subsequent β-catenin ubiquitination 
and degradation in the proteasome (Figure 1.5). GSK3 shows a constitutive 
phosphorylase activity. The adenomatous polyposis coli (APC) protein has the 
capacity to bind many β-catenin molecules, while Axin is responsible for binding 





Figure 1.5. WNT/β-catenin signalling. The Axin-APC-GSK3 complex is responsible for 
the initiation of β-catenin degradation. WNT proteins activate the Frizzled-LRP receptor, 
which promotes deactivation of the Axin-APC-GSK3 complex by the cytosolic protein Dsh, 
leading to the β-catenin accumulation. R-spondins and their LGR receptors modulate the 
activity of the Frizzled-LRP complex. Dickkopf (DKK) proteins inhibit WNT binding to its 
receptor [146]. 
 
Binding of WNT to the FZD-LRP5/6 complex promotes association of Dishevelled 
(Dsh) protein with FZD and facilitates interaction between the cytoplasmic domain 
of LRP5/6 and Axin [147]. As a result, the Axin-APC-GSK3 complex falls apart, 
allowing β-catenin stabilisation and accumulation in the cytoplasm. Following 
translocation into the nucleus, β-catenin forms a complex with TCF transcription 
factor and activates target gene expression, including genes involved in the control 
of development and cell proliferation such as C-MYC oncogene, cyclin D1, and the 
metalloprotease matrilysin [148-151]. Dickkopf (DKK) proteins inhibit WNT 
signaling by binding LRP5/6 and disrupting FZD-LRP5/6 complex [152]. The role 
of R-spondins and their LGR receptors in the WNT signalling regulation is 
discussed in the next section. 
 
Moreover, WNT/β-catenin signaling is implied in regulation of β-cell proliferation 
and insulin secretion in mice. The conditioned medium from L cells secreting 
40 
 
WNT3A increases proliferation of INS-1 cells by 2-fold, compared to the control 
proliferation level, in a β-catenin-dependent fashion [153]. Purified WNT3A protein 
also stimulates proliferation of both MIN6 and mouse islet cells [154]. In addition, 
activation of WNT/β-catenin pathway in isolated mouse islets results in 
augmentation of insulin secretion [153]. The WNT-mediated increase in β-cell 
proliferation is associated with upregulated expression of cyclins D1 and D2 in β-
cells [153, 154]. The involvement of WNT signaling in the regulation of insulin 
secretion has also been confirmed by experiments on LRP5 knockout mice, which 
have impaired glucose-stimulated insulin secretion [155]. 
1.6.3 Regulation of the WNT pathway by R-spondins 
R-spondin 1 (Roof plate specific-spondin 1) was first discovered in the roof plate of 
developing mouse embryos [156]. There are four members of the R-spondin 
protein family, RSPO1-4. R-spondins are approximately 30 kDa in size and have 




Figure 1.6. Human R-spondin protein family.  Sig. Seq. – signalling sequence,          
FU-like CR – furine-like repeats, TSR – thrombospondin repeat, BR – basic amino acid-
rich domain, HSPG – heparan sulphate proteoglycan. Sequence homology within the 




However, R-spondins have the capacity to bind heparan sulphate proteoglycans 
(HSPG) of the cell surface and extracellular matrix. Consequently, this feature may 
hinder Xenopus RSPO2 and mouse RSPO1 detectability when they are secreted 
upon overexpression in human T293 cells into culture medium [156, 158]. On the 
contrary, overexpressed human RSPO1 is efficiently secreted from T293 cells 
[159]. 
 
RSPO1 regulates gonadal sex determination and skin differentiation. RSPO1 gene 
mutations in humans lead to XX male sex reversal [160]. R-spondin 1 protein has 
a mitogenic effect on intestinal crypt epithelial cells in mice [161]. In addition, the 
RSPO1 protein stimulates proliferation and inhibits apoptosis of MIN6 cells, as well 
as enhances glucose-independent insulin secretion [162]. Nonetheless, 
experiments on RSPO1 knockout mice revealed that RSPO1 has a negative effect 
on β-cell neogenesis from pancreatic ductal cells [163]. RSPO2 plays a key role in 
development of limbs, lungs and hair follicle in a WNT/β-catenin pathway-
dependent manner [164-166]. RSPO3 is involved in vascularization of the 
developing placenta [167]. Mutations in the RSPO4 gene cause anonychia, a mild 
disorder characterized by the absence of fingernails and toenails [168, 169]. R-
spondins 1-4 are expressed in mouse and human islets [162, 170]. However, only 
expression of RSPO1, RSPO3 and RSPO4 have been detected in MIN6 cells 
[162]. Furthermore, RSPO1, RSPO3 and their receptor LGR4 are expressed in the 
hypothalamus [171]. RSPO1 and RSPO3 injection in to the mouse third brain 
ventricle, bordering the hypothalamus, results in inhibition of food intake [171]. In 
the hypothalamus, LGR4 colocalises with neuropeptide Y, which stimulates food 
intake [172]. These observations, and the fact that insulin upregulates RSPO1 and 
RSPO3 gene expression in the hypothalamus, suggest a role for R-spondins in the 
regulation of energy homeostasis [171]. 
R-spondins associate with LGR (leucine rich repeat containing G protein coupled) 
4-6 receptors, mediating the enhancement of canonical WNT and WNT/PCP 
pathways signalling [173, 174]. The pro-proliferative action of RSPO1 is blocked in 
isolated mouse intestinal crypt epithelial cells of LGR4/LGR5 knockout mice, but 
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can be rescued by WNT3 overexpression [174]. LGR4-6 are approximately 100 
kDa in size, share 50% amino acid sequence homology and belong to the GPCR 
class A (rhodopsin-like) [175]. Moreover, LGR4 and LGR5 are expressed in 
human islets [170]. Although mouse LGR4 has not been directly demonstrated to 
associate with Gαs proteins its overexpression in osteoblasts results in an 
increase in intracellular cAMP levels and upregulation of cAMP-dependent PKA 
[176]. Notably, stimulation of mouse LGR4 and LGR5, stably expressed in 
HEK293 cells, by mouse RSPO1 and RSPO2 proteins at various concentrations 
does not lead to activation of Gαs, Gαq and Gαi protein signaling pathways [173]. 
R-spondins interact with extracellular domains of LRP5/6 and FZD and modulate 
positively WNT/β-catenin signaling [164, 177] (Figure 1.7). RSPO1, RSPO2 and 
RSPO3 are more potent at upregulating WNT pathway than RSPO4 [178].  
 
 
Figure 1.7. Regulation of WNT signalling by RSPO proteins. R-spondins stabilise the 
FZD-LRP complex and enhance WNT signalling. R-spondins bind LGR and interact with 
the FZD-LRP complex, which prevents Znrf3/Rnf43 ubiquitin ligases from the initiation of 







Znrf3/Rnf43 ubiquitin ligases bind the FZD-LRP receptor complex, causing 
polyubiquitination of lysines in the cytoplasmic domains of FZD, followed by 
endocytosis and receptor degradation (Figure 1.7). RSPO1 has been shown to 
interact with the extracellular domain of Znrf3 and to mediate association of Znrf3 
with LGR4, leading to membrane clearance of Znrf3 and enhancement of WNT 
signalling in human HEK293 cells [180]. R-spondin proteins increase endogenous 
levels of FZD proteins in HEK293 cells [180]. Moreover, human RSPO1 protein 
potentiates canonical WNT signalling by inhibiting internalization of LRP6 in 
HEK293 cells and stimulation of endogenous LRP6 phosphorylation in mouse 
embryonic fibroblasts (MEFs) [159, 181].  
In addition, R-spondins bind syndecans, proteoglycans controlling adhesion, 
differentiation and proliferation [182]. Syndecans are single trans-membrane 
domain proteins, carrying three to five heparan sulphate or chondroitin molecules, 
which confer the ability to associate with various growth factors and chemokines 
[183, 184]. An interaction of RSPO3 with LGR4, LGR5 and syndecan 4 activates 
the non-canonical WNT/planar cell polarity (PCP) pathway, involved in gastrulation 
and embryogenesis [185, 186]. RSPO3 binding to syndecan 4 and LGR4/5 
promotes endocytosis of the FZD receptor complex and signaling initiation, but 
does not involve LRP5/6 [185]. Syndecan 4 directly interacts with FZD and Dsh 
and mediates translocation of Dsh to the plasma membrane [187]. Subsequently, 
a complex of Dsh, Rho and Daam1 is formed in the cytoplasm. Daam1 mediates 
the Dsh and Rho interaction and Rho activation by guanine nucleotide exchange 
factors (GEFs), which catalyse an exchanged of Rho-bound GDP to GTP [188].  
Activated Rho initiates the activity of Drosophila Rho-associated kinase (Drok), 
resulting in myosin phosphorylation and rearrangement of the cytoskeleton [189]. 
The Rho activity can be switched off by GTPase-activating proteins (GAPs) [190]. 
There are many signalling pathways involved in the regulation of β-cell functions 
during pregnancy. Several of those pathways are discussed in this chapter but our 
knowledge of the β-cell adaptive responses is still limited. In the next part of this 
thesis I will be looking at some of these mechanisms in more detail. 
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1.7 Aims and objectives 
The overall aim of this thesis was to study mechanisms regulating β-cell mass 
expansion, using pregnancy in mice as an experimental model in which the β-cell 
mass increases during gestation and returns to normal levels post-partum. The 
mechanisms underlying this adaptation are not well understood, although 
placental signals are thought to be involved. Reduction of β-cell mass or failure to 
expand β-cell mass during pregnancy are hallmarks of T2DM and GDM 
respectively. Therefore, targeting mechanisms regulating β-cell mass expansion 
may help to develop new therapies for T2DM.  
 
The hypothesis tested in this thesis will be: 
1. Pregnancy and lactation stimulate β-cell proliferation, with selective loss of 
new β-cells post-partum.  
2. Novel proteins secreted by the placenta can enhance β-cell function during 
pregnancy. 
 
The first objective of the project was to analyse changes in the β-cell mass during 
pregnancy, and post-partum. The second objective was to quantify the expression 
of islet β-cell GPCRs and their placental ligands to identify novel placental signals 
potentially involved in β-cell adaptation to pregnancy. The third objective was to 









































Chapter 2  
2.1 Animals 
2.1.1 Mice for pancreatic islet BrdU staining 
Female CBA/Ca mice (MRC, UK) at 8 weeks of age were used. Mice were kept 
under a light–dark cycle of 12 h and were fed ad libitum with a normal diet. For 
pregnant mice, females were housed with a male and checked daily for the 
presence of a vaginal plug. The day a vaginal plug was observed was designated 
day 0 of pregnancy. Mouse gestational time is 19-21 days. Mice were given 5-
bromo-2'-deoxyuridine (BrdU), a thymidine analogue, which was incorporated into 
the DNA of proliferating cells, in their drinking water as a 1 mg/ml solution. 
Pregnant mice were given BrdU solution during gestational days 8-17 (Figure 2.1) 
and terminated on day 18. Another group of pregnant mice were given BrdU 
solution during gestational days 8-17 followed by water during days 1-10 post-








Post-partum mice were given BrdU solution for days 1-10 post-partum and were 
maintained with or without pups during that time. Non-pregnant control mice were 
given BrdU solution for 10 days or BrdU solution for 10 days, followed by water for 
a further 10 days (Figure 2.1). Mice were culled one day after finishing the 
treatment.  
2.1.2 Mice for placental GPCR ligand secretome and GPCRome 
analysis 
Female CD1 mice (Charles River, UK) at 8 weeks of age were used. Mice were 
kept under a light–dark cycle of 12 h and were fed ad libitum with a normal diet. 
Females were housed with a male and checked daily for the presence of a vaginal 
plug. The day a vaginal plug was observed was designated day 0 of pregnancy. 
On gestational day 12 or 18 mice were culled, followed by isolation of placentas 
and pancreatic islets. 
2.2 Immunofluorescence staining 
Mouse β-cell proliferation was measured using immunohistochemical (IHC) 
staining of pancreatic sections labelled with BrdU. Mouse pancreas samples were 
fixed with 4% paraformaldehyde/PBS solution overnight, embedded in paraffin 
wax and sectioned in 5 μm longitudinal sections of paraffin blocks. Details of 
immunostaining buffers are shown in Table 2.1. Pancreatic sections were 
rehydrated by washing with xylene (VWR) and decreasing concentration of 
ethanol (100%, 95% and 70% ethanol) (VWR), then washed with water and TBS, 
followed by permeabilization with 2M hydrochloric acid (VWR) for 20 min at 37°C. 
After washing with water and TBS, the sections were permeabilized with 0.05% 
trypsin solution (Sigma) for 15 min at 37°C and then washed with TBS. The 
sections were blocked with the blocking buffer for 15 min at room temperature and 
incubated with mouse anti-BrdU (1:100 dilution, Sigma) and guinea pig anti-insulin 
(1:200 dilution, Dako) primary antibodies for 2 h at 37°C. After incubation with the 
primary antibodies, the sections were washed with TBS and stained with FITC-
labelled anti-mouse (1:100 dilution, Jackson ImmunoResearch Laboratories) and 
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Alexa Fluo 594-labelled anti-guinea pig (1:100 dilution, Jackson ImmunoResearch 
Laboratories) antibodies for 1 h at room temperature. Sections were washed with 
TBS, mounted and visualized using a fluorescent microscope (Nikon Eclipse 
TE2000-U). Fluorescent images of islets were acquired in x 200 magnification, 
using NIS Elements BR20 software (Nikon).  
 
Table 2.1. Composition of buffers for IHC.  
 
Buffer Composition 
TBS (Sigma) 50 mM Tris, 150 mM NaCl, pH 7.6 
PBS (Sigma) 
137 mM NaCL, 2.7 mM KCL, 10 mM Na2HPO4 * 2H2O,  
2 mM KH2PO4, pH 7.4 
Blocking buffer (Sigma) 0.25% BSA, 0.25% Triton X100 in PBS 
  
2.2.1 Analysis of pancreatic β-cell proliferation  
For each islet image the number of BrdU labelled β-cells and the total number of 
β-cells were counted using ImageJ program. A minimum of 3 sections were 
analysed per animal and a minimum of 10 islets were counted per section. The 
results were expressed as the percentage of total β-cells that were positively 
stained with BrdU for each animal. 
2.2.2 Analysis of pancreatic β-cell area 
The cross-sectional area of individual β-cells was analysed on the same sections 
as those used for the proliferation analysis. The total β-cell area was calculated by 
tracing around the perimeter of the islet tissue and measuring the area by the 
ImageJ software (MicroSmarts LLC). A total number of β-cells was counted and 
the β-cell area divided by the number of β-cells to give the mean cross-sectional 
area of the individual β-cell. This measurement is an estimate of individual β-cell 
size as it does not take into account the fact that not all of the nuclei of β-cells in 
the section would be present. Therefore, this measurement is likely to 
overestimate the actual β-cell cross-sectional area. Nonetheless, it is a useful 
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method of comparing β-cell size between groups of animals analysed in the same 
way. 
2.3 Isolation of mouse pancreatic islets   
Female CD1 mice (Charles River) were culled by cervical dislocation followed by 
surgical opening of the abdominal cavity. The common bile duct was clamped at 
the ampulla of Vater and cannulated with a 27 gauge needle [191]. 3 ml of ice cold 
collagenase solution (3 mg/ml, Sigma) was injected to inflate the pancreas, which 
was then extracted, placed into a 50 ml centrifuge tube and kept on ice. The 
isolated pancreas was incubated for 15 min in a water bath at 37°C to digest the 
tissue. The digestion was terminated by re-suspending the digest with Minimum 
Eagles Medium (MEM) (Sigma), containing 10% Newborn Calf Serum (NCS) 
(Sigma), 2 mM L-glutamine (Sigma), 100 U/ml penicillin (Sigma) and 0.1 mg/ml 
streptomycin (Sigma). The tubes containing the pancreatic isolate were shaken by 
hand and centrifuged at 340 g, 10°C, for 15 min. The suspension was then filtered 
through a collector tissue sieve and spun in a centrifuge tube at 340 g, 10°C, for 1 
min. The tissue pellet was then resuspended in 25 ml of Histopaque-1077 
(Sigma). 10 ml of MEM was pipetted on the top of the Histopaque-1077 layer 
followed by a gradient centrifugation of at 700 g, 10°C, for 24 min. Isolated islets 
were recovered from the interface between the Histopaque-1077 and MEM, 
washed three times with MEM, placed on a plastic petri dish before being hand-
picked under a dissecting microscope and washed with Roswell Park Memorial 
Institute (RPMI) medium (Sigma), supplemented with 10% NCS, 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. The islets were 
incubated overnight at 37°C (95% air/ 5% CO2) before being used for total RNA 
isolation. 
2.4 RNA isolation 
The quality of isolated RNA is crucial for downstream applications, including 
complementary DNA (cDNA) synthesis and cDNA amplification using polymerase 
chain reaction (PCR). Mouse pancreatic islet, placenta and pancreatic MIN6 β-cell 
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total RNA was isolated using Qiagen RNeasy Mini kit, according to the 
manufacturer’s instructions. RLT lysis buffer, RNase-free water, wash buffers RW1 
and RPE were included in the kit package.  
2.4.1 Total RNA isolation from mouse pancreatic islets and 
pancreatic MIN6 β-cells 
Isolated mouse pancreatic islets (150-250 islets/animal/isolation) or a maximum of 
107 pancreatic MIN6 cells were resuspended in 600 µl of RLT lysis buffer. 
Subsequently, the lysate was transferred into a homogenization Qiagen 
QIAshredder spin column and centrifuged at room temperature for at 7000 g for 3 
min. 600 µl of 70% ethanol was added to the supernatant and mixed by pipetting. 
700 µl of the homogenate was then loaded into a spin mini column and centrifuged 
at 7000 g for 15 s. After discarding flow through, 350 µl of RW1 wash buffer was 
pipetted into the column, followed by centrifugation at 7000 g for 15 s. Flow 
through was discarded and DNase solution (10 µl DNase in 70 µl of RDD buffer, 
Qiagen) was then applied into column and incubated at room temperature for 15 
min. The incubation was stopped by adding 350 µl of RW1 buffer into the column, 
which was followed by centrifugation (7000 g for 15 s) and removal of flow 
through. The column was washed with 500 µl of RPE buffer at 7000 g for 15 s 
followed by adding 500 µl of RPE buffer into the column and centrifugation at 7000 
g for 2 min. The column was then transferred into a sterile 1.5 ml tube and RNA 
was eluted by adding 30 µl of RNase free water before centrifugation at 7000 g for 
1 min. RNA samples were quantified and immediately converted into cDNAs.    
2.4.2 Determination of RNA concentration 
Total RNA concentration was determined using the ND1000 spectrophotometer 
(Nanodrop). The device measured 260 and 280 nm absorbance (A260 and A280) in 
1.5 µl of the sample RNA solution. The A260 value was automatically converted 
into RNA concentration expressed as µg/µl. The A260/A280 ratio was used to 
evaluate purity of isolated RNA. RNA samples with A260/A280 ratios between 1.8 
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and 2.2 were considered sufficiently pure and were used for further experiments. 
Sample RNAs were converted immediately into cDNA. 
2.5 cDNA synthesis 
mRNAs were converted into cDNA by the process of reverse transcription, using a 
High Capacity Reverse Transcription Kit (Applied Biosystems). All of the reagents 
used were provided with the kit. A reaction mixture was prepared as described in 
Table 2.2.  
 
Table 2.2. Reverse transcription reaction mixture.   
  
 
Component Volume [µl] 
10x Reverse 









Nuclease-free water 4.2 
Total per reaction 10 
 
10 µl of the sample RNA solution (0.5-1 µg of RNA) was mixed with 10 µl of the 
reaction mixture in a 0.2 µl PCR tube. The tube was spun briefly and placed in a 
thermocycler (Bio-Rad T100). Reverse transcription was conducted using thermal 
cycler program conditions summarized in Table 2.3. cDNA samples were stored at 
-80°C. 
 
Table 2.3. Reverse transcription thermal cycler program conditions.  
 
 Step 1 Step 2 Step 3 Step 4 
Temperature [°C] 25 37 85 4 




2.6 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Real-time quantitative reverse transcription PCR is an efficient method of accurate 
gene expression quantification [192]. The PCR technique allows DNA sequence 
amplification in vitro [193]. In this technique, DNA polymerase synthesises 
complementary strands of the DNA template by extending sequence-specific 
oligonucleotide primers. DNA amplification is achieved in successive cycles of 
denaturation of double stranded DNA, annealing of primers to single stranded 
DNA and extension of newly synthesised DNA strands. Real-time PCR utilizes 
fluorescent SYBR Green hybridization probe, which emits signal only when bound 
with double stranded DNA, to monitor amplification in real time (Figure 2.2).  
 
 
Figure 2.2. SYBR Green-based product detection in real-time PCR. The SYBR Green 
probe hybridizes with double stranded DNA and emits green light when excited with blue 
light during the DNA amplification process, enabling monitoring of amplification [194]. 
 
Fluorescent signal intensity at the beginning of the exponential phase of cDNA 
amplification is proportional to the amount of target cDNA and thus the target gene 
expression level in the sample.     
53 
 
2.6.1 Normalization against mouse housekeeping gene 
Normalization against the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
reference housekeeping gene is necessary to determine the optimal cDNA 
concentration used for gene screening. A cDNA concentration, which produced 
the cycle threshold (Ct) value of 20, was used for gene expression screening and 
quantification, allowing efficient analysis of a few hundred genes in a single cDNA 
sample. The Ct value is defined as the number of cycles required for reaction 
fluorescence to exceed the background threshold level. The lower the Ct, the 
higher the amount of target cDNA in the sample. The stock cDNA solution (in 
triplicates) was diluted 1 in 10 and mixed in a 96-well plate with the QuantiFast 
SYBR Green Master Mix (Qiagen), water and the 5x GAPDH QuantiTect primer 
assay (Qiagen) (Table 2.4). 
 
Table 2.4. Reaction volumes for housekeeping gene expression normalization.  
 
Reagent Volume / well [µl] 
SYBR Green master mix 5 
cDNA (diluted 1 in 10) 1 
water 2 
5x GAPDH QuantiTect 
primer assay 
2 
Total volume 10 
  
The plate was centrifuged for 1 min at 500 g, placed in a Roche LC480 light cycler 
and run using real-time quantitative PCR program conditions shown in Table 2.5. 
Results were analysed using Roche LC480 light cycler software to determine the 
dilution factor required to generate a GAPDH gene Ct value of 20 for each cDNA 
sample. Figure 2.3 presents an example of GAPDH normalization results in 
pancreatic islet cDNA samples of non-pregnant mice. Individual melting curves, 
with the same single temperature peaks, correspond to the same DNA sequence 





















Pre-incubation 95 None 5 min 4.4 - 1 None 
Amplification 
95 None 10 s 4.4 - 
40 Quantification 
60 Single 30 s 2.2 - 
Melting curve 
95 None 5 s 4.4 - 
1 Melting Curves 65 None 1 min 2.2 - 
97 Continuous - 0.11 5 





Figure 2.3. GAPDH normalization in mouse islet cDNA samples of 8 non-pregnant 
mice. Sample cDNA was diluted to produce an amplification reaction Ct value of 20. A – 
amplification curves, B – melting curves, Ct – cycle threshold.  
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2.6.2 Screening for mRNA expression 
 
Quantitative RT-PCR was used to screen placental extracts for the expression of 
mRNAs encoding 126 potential islet GPCR ligands “secretome” on gestational day 
12 and 18 as well as 342 GPCR mRNAs in pancreatic islets from non-pregnant 
mice, and from islets isolated from gestational day 12 and day 18 animals (8 
animals in each group). In addition, expression of selected genes was analysed in 
mouse pancreatic MIN6 β-cells to confirm β-cell specific expression. cDNAs from 
8 mice in each group of animals was pooled and diluted to produce a GAPDH 
gene Ct value of 20. A single pooled cDNA replicate for each screened primer pair 
(QuantiTect primer assay, Qiagen) was analysed. 94 gene QuantiTect primer 
assays and a duplicate of GAPDH gene QuantiTec primer assay were analysed in 
a 96-well plate. A reaction mixture was prepared according to Table 2.6. Details of 
primers used for the GPCR ligand and GPCR gene expression analysis are 
presented in Appendix II. Screening qPCR reaction products were analysed by 
agarose gel electrophoresis to confirm amplicon size (section 2.6.3). 
 
Table 2.6. Reaction volumes for screening of mouse placental GPCR ligand genes 
and pancreatic islet GPCR genes.  
 
Reagent 
Vol reagent / well  
[µl] 
Vol reagent / plate 
[µl] 
SYBR master mix 5 528 
cDNA 1 105.6 
Water 2 211.2 
5x QuantiTect primer 
assay 
2 - 
Totals 10 844.8 
 
Only genes producing a specific product in the screening reaction, characterised 
by a single product melt curve peak and an agarose gel electrophoresis product 
band (section 2.6.3), corresponding to the size given in the QuantiTect primer 
assay specification, were quantified (section 2.6.4). 
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2.6.3 DNA agarose gel electrophoresis  
The molecular size of screening reaction products was analysed by agarose gel 
electrophoresis. After the gene expression screening, 10 µl of each product, mixed 
with 2 µl of the 6x loading buffer (Promega), was loaded onto a 2% agarose gel, 
containing 5 µg/ml ethidium bromide (Sigma). Electrophoresis was conducted in 
Tris/borate/EDTA (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 7.6) buffer 
(TBE) (Sigma) using a 100 bp DNA ladder (Promega) as a DNA size marker (50-
100 V, 1-2 h). DNA was visualized using a UV transilluminator (Syngene). Genes 
generating a single product band of the correct molecular size, in accordance with 
the QuantiTect primer assay specification, were quantified. 
2.6.4 Gene expression quantification  
Expression of genes, which produced positive results in the expression screening 
analysis, was quantified. Relative expression of target genes was determined by 
the 2-ΔΔCt method, using mouse glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene as a reference housekeeping gene [195]. Each of 
the gene primer assays was analysed in one replicate for each of the 8 mice per 
group. Reaction mixtures and the light cycler programme were used as described 
in Tables 2.4 and 2.5 of the house-keeping gene normalization chapter (section 
2.6.1). Expression of target genes relative to the GAPDH gene, quantified in 












2.7 Analysis of RSPO4 protein concentration in mouse plasma 
during pregnancy 
RSPO4 protein levels were determined in plasma samples of non-pregnant, 
gestational day 12 and gestational day 18 CD1 mice, using a colorimetric mouse 
R-spondin 4 (RSPO4) ELISA kit (Cusabio), according to the manufacturer’s 
instructions. Standard, standard diluent, biotin-antibody, HRP-avidin, washing 
buffer, substrate and stop solutions were provided with the kit. Mice were culled by 
cervical dislocation followed by cardiac puncture blood retrieval. Heparin was 
added as an anticoagulant into each sample, which was then centrifuged at 1000 
g, 4°C, for 15 min. Plasma supernatants were collected and stored at -80°C for 
further analysis. After thawing, plasma samples were centrifuged (1000 g, 4°C, 15 
min), 100 ul of each sample and standard were added per well and incubated at 
37°C for 2 h. Standards were prepared by a serial dilution of the concentrated 
standard stock solution in the standard diluent (2200-34.4 pg/ml) Subsequently, 
100 ul of the biotin-antibody were added to each well and incubated at 37°C for 1 
h. Wells were then washed 3 times with the washing buffer. 100 ul of horseradish 
peroxidase (HRP)-avidin were added to each well and incubated for 1 h at 37°C. 
Wells were then washed 5 times with the washing buffer and 90 ul of the substrate 
were added to each well. After 15 min of incubation at 37°C, 50 ul of the stop 
solution were added to each well. The optical density of the reaction product 
solution in each well was determined by a micro plate reader (Turner Biosystems) 
at 450 nm. A standard curve was prepared and sample RSPO4 concentrations 
were calculated from the curve.  
2.8 Culturing MIN6 β-cells  
The insulinoma MIN6 cell line was derived from a transgenic mouse expressing 
the simian virus 40 T antigen in pancreatic β-cells [196]. MIN6 cells express insulin 
and T antigen and exhibit morphological characteristics of pancreatic β-cells. 
Moreover, those cells retain physiological features of normal mouse islet β-cells 
including glucose-inducible insulin secretion, glucokinase activity as well glucose 
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transport and utilization [197]. High passage MIN6 cells (60-70 passages) have 
impaired insulin secretion as well as reduced glucose and lipid oxidation [198]. 
Therefore, MIN6 cells of up to 40 passages should be used for β-cell research as 
those cells retain normal β-cell functions [198]. In this work, MIN6 cells of 30-35 
passages were used for all the experiments. 
MIN6 β-cells were cultured in growth medium, Dulbecco's Modified Eagle 
Medium (DMEM) containing 25 mM glucose, at 37°C (5% CO2, 95% air) in a 
tissue culture incubator. Details of culture media used for MIN6 β-cell culturing are 
presented in Table 2.7. Growth medium was changed every 2-3 days. MIN6 cells 
were maintained as monolayers attached to the bottoms of 75 cm3 tissue culture 
flasks (ThermoScientific). The cells were passaged after reaching 70-80% of 
confluence. To detach cells from the flask bottom surface, growth medium was 
removed and cells were washed with PBS which was followed by addition of 
0.05% Trypsin/0.02% EDTA (Sigma) solution (3 ml). The flask was then incubated 
for 3 min at 37°C in a tissue culture incubator. The cells were resuspended in 7 ml 
of growth medium and centrifuged at 500 g for 3 min. The supernatant was then 
discarded and the cell pellet was resuspended in DMEM growth medium. The cells 
were either used in experiments or to inoculate a fresh tissue culture flask. MIN6 
cells of 30-35 passages were used for experiments.   
2.9 MIN6 β-cell proliferation assay  
The effect of mouse R-spondin 4 (RSPO4) protein (Cusabio) on β-cell proliferation 
was evaluated using a colorimetric ELISA assay (Roche) based on BrdU 
incorporation into DNA. BrdU was incorporated into the DNA of proliferating cells. 
The method uses an anti-BrdU antibody conjugated with peroxidase (anti-BrdU-
POD) which binds to the incorporated BrdU. Peroxidase catalyzes oxidation of a 
substrate, in the presence of hydrogen peroxide, into a detectable coloured 
product. FixDenat, BrdU, anti-BrdU-POD, wash and substrate solutions were 
included in the assay kit. 
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MIN6 cells were detached from the culture flask by incubation with 0.05% 
Trypsin/0.02% EDTA solution (Sigma) at 37°C for 3 min in a tissue culture 
incubator. The cell number and viability were measured in the cell suspension 
using Celltess™ automatic cell counter (Invitrogen). 20000 cells were plated per 
one well of a 96-well cell culture plate and cultured in 200 µl of the DMEM growth 
medium overnight (18 h) at 37°C (5% CO2, 95% air) in a tissue culture incubator. 
Details of culture media used for the MIN6 cell proliferation assay are presented in 
Table 2.7. Following the overnight incubation, growth medium was replaced with 
starving DMEM medium and cultured at 37°C for 48 h. After 48 h medium was 
replaced in each well with 200 µl of different media, depending on the treatment 
group: serum-free treatment DMEM medium containing RSPO4 protein, serum-
containing DMEM medium containing RSPO4 protein, serum-free DMEM medium 
without RSPO4 protein or serum-containing DMEM medium without RSPO4 
protein (6 wells per treatment) (Table 2.8). Four RSPO4 protein concentrations 
were tested: 35 pM, 350 pM, 3.5 nM and 35 nM (Table 2.8). Cells were cultured at 
37°C for 48 h. After 48 h, 10 µl of BrdU stock solution (10 µM) was added to each 
well and incubated at 37°C for 3 h in a cell culture incubator. Following BrdU 
labelling incubation, medium was removed from the plate, 200 µl of the FixDenat 
solution was added to each well and incubated for 30 min at room temperature. 
The FixDenat solution was then removed from the plate and 100 µl of the anti-
BrdU-POD solution was added to each well. After 90 min of incubation at room 
temperature, the anti-BrdU-POD solution was removed and the wells were washed 
three times with 200 µl of the washing solution. 100 µl of the substrate solution 
was added to each well followed by 5 min incubation of the plate on a plate shaker 
at room temperature. Addition of 25 µl of 1N H2SO4 solution (VWR) into each well 
stopped substrate conversion into a detectable coloured reaction product. Product 











Table 2.7. Culture media used for the MIN6 cell proliferation assay.  
 
   Medium Composition 
DMEM growth medium 
(Sigma) 
25 mM Glucose, 10% Fetal Bovine Serum (FBS),  
2 mM L-glutamine, 100 U/ml Penicillin, 100 µg/ml Streptomycin,  
50 µM 2-mercaptoethanol 
DMEM starving medium 
(Sigma) 
2 mM Glucose, 2 mM L-glutamine, 100 U/ml Penicillin,  
100 µg/ml Streptomycin, 50 µM 2-mercaptoethanol 
Serum-free DMEM, for 
RSPO4 protein treatment  
(Sigma) 
20 mM Glucose, 2 mM L-glutamine, 100 U/ml Penicillin,  
100 µg/ml Streptomycin, 50 µM 2-mercaptoethanol 
Serum-containing DMEM, 
for RSPO4 protein 
treatment  
(Sigma)  
20 mM Glucose, 10% Fetal Bovine Serum (FBS),  
2 mM L-glutamine, 100 U/ml Penicillin, 100 µg/ml Streptomycin,  





Table 2.8. Treatment map of the MIN6 cell proliferation assay.  
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2.10 MIN6 β-cell apoptosis assay 
The effect of mouse RSPO4 protein on β-cell apoptosis was analysed using 
Caspase Glo® 3/7 assay kit (Promega), based on luminescence. The kit assesses 
apoptosis by measuring the activity of caspase 3 and caspase 7, which are 
activated in the early stages of apoptosis. Caspase 3/7 activate a luminogenic 
substrate, generating amino-luciferin, which is then oxidised by luciferase to 
generate a luminescent signal. The luminescent signal intensity is proportional to 
the caspase 3/7 activity. Caspase Glo buffer and Caspase Glo substrate were 
provided with the kit. 
MIN6 cells were detached from the culture flask by incubation with 0.05% 
Trypsin/0.02% EDTA solution (Sigma) at 37°C for 3 min. The cell number and 
viability were measured in the cell suspension using Celltess™ automatic cell 
counter (Invitrogen). 20000 cells were plated per one well of a 96-well cell culture 
plate and cultured in 200 µl of the DMEM growth medium overnight (18 h) at 37°C 
(5% CO2, 95% air) in a tissue culture incubator. Table 2.9 shows details of culture 
media used for the MIN6 cell apoptosis assay. Following the overnight incubation, 
growth medium was removed from the plate and the plate wells were washed with 
200 µl of PBS (Sigma). PBS was replaced with 100 µl of a treatment solution in 
each well (2% serum DMEM with or without RSPO4 protein and cytokines) as 
presented on a plate treatment map in Table 10. Four RSPO4 protein 
concentrations were tested: 35 pM, 350 pM, 3.5 nM and 35 nM (Table 2.10). MIN6 
cell apoptosis was activated by Interleukin 1β (IL-1β), Tumor Necrosis Factor α 
(TNF-α) and Interferon γ (INF-γ) present in cytokine-containing treatment culture 
medium. The plate was incubated at 37°C for 20 h in a tissue culture incubator. 75 
µl was removed from each well followed by addition of 25 µl of Caspase Glo 
substrate reconstituted in Caspase Glo buffer. The plate content was mixed on a 
plate shaker for at 100 g at room temperature for 1 min, which was followed by 1 h 
incubation at room temperature. The generated luminescent signal (excitation: 
490nm, emission: 510-570 nm) was detected and analysed using Varitas 




Table 2.9. Culture media used for the MIN6 cell apoptosis assay.  
 
 
   Medium Composition 
DMEM growth medium 
(Sigma) 
25 mM Glucose, 10% Fetal Bovine Serum, 2 mM L-glutamine, 
100 U/ml Penicillin, 100 µg/ml Streptomycin,  
50 µM 2-mercaptoethanol 
2% serum DMEM 
(Sigma) 
25 mM Glucose, 2% Fetal Bovine Serum, 2 mM L-glutamine, 
100 U/ml Penicillin, 100 µg/ml Streptomycin,  
50 µM 2-mercaptoethanol 




25 mM Glucose, 2% Fetal Bovine Serum, 2 mM L-glutamine, 
100 U/ml Penicillin, 100 µg/ml Streptomycin,  
50 µM 2-mercaptoethanol,  







Table 2.10. Plate treatment map of the MIN6 cell apoptosis assay.  
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2.11 Measuring insulin secretion from MIN6 cells  
MIN6 cells were detached from the culture flask by incubation with 0.05% 
Trypsin/0.02% EDTA solution (Sigma) at 37°C for 3 min. The cell number and 
viability were measured in the cell suspension using Celltess™ automatic cell 
counter (Invitrogen). 25000 cells were plated per one well of a 96-well cell culture 
plate and cultured in 200 µl of DMEM growth medium at 37°C for 24 h (5% CO2, 
95% air) in a tissue culture incubator. Table 2.11 presents details of culture media 
and buffers used for the MIN6 cell insulin secretion assay. The next day medium 
was replaced in each well with 200 µl of low glucose DMEM and the plate was 
incubated overnight (16 h) at 37°C in a tissue culture incubator. Following the 
overnight incubation, medium was removed and the plate wells were washed with 
200 µl of low glucose Gey & Gey buffer. After the washing step, 200 µl of low 
glucose Gey & Gey buffer was added in wells followed by 2 h incubation at 37°C in 
a tissue culture incubator. The buffer was then removed, treatment solutions were 
added in wells according to a plate treatment map (Table 2.12) and the plate was 
incubated at 37°C for 1 h in a tissue culture incubator. A known insulin secretion 
potentiator phorbol myristate acetate (PMA) (Sigma) was used as a positive 
control of β-cell insulin secretion [199]. The plate was then centrifuged at 800 g for 
3 min and 150 µl of the supernatant were transferred into a new plate for 
determination of insulin concentration. Insulin concentration was measured in 












Table 2.11. Culture media and buffers used for the MIN6 cell insulin secretion 
assay.  
 
   Medium/Buffer Composition 
DMEM growth medium 
(Sigma) 
25 mM Glucose, 10% FBS, 2 mM L-glutamine, 100 U/ml Penicillin,  
100 µg/ml Streptomycin, 50 µM 2-mercaptoethanol 
Low glucose DMEM  
(Sigma) 
5.5 mM Glucose, 10% FBS, 2 mM L-glutamine, 100 U/ml Penicillin,  
100 µg/ml Streptomycin, 50 µM 2-mercaptoethanol 
Low glucose Gey & Ge 
buffer 
(Sigma) 
2 mM Glucose,111 mM NaCL, 5 mM KCL, 27 mM NaHCO3,  
1 mM MgCL2 x 6 H2O, 0.22 mM KH2PO4,  
0.28 mM MgSO4 x 7H2O, pH 7.4 
High glucose Gey & Gey 
buffer 
(Sigma) 
20 mM Glucose,111 mM NaCL, 5 mM KCL, 27 mM NaHCO3,  
1 mM MgCL2 x 6 H2O, 0.22 mM KH2PO4,  
0.28 mM MgSO4 x 7H2O, pH 7.4 
 
Table 2.12. Plate treatment map of the MIN6 cell insulin secretion assay.  
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 Low glucose Gey & Gey (2 mM 
glucose) 
High glucose Gey & Gey (20 mM glucose) 
 
2.12 Insulin radioimmunoassay 
 
The effect of RSPO4 protein on insulin secretion from MIN6 cells was measured 
using a radioimmunoassay (RIA) method. RIA is a highly sensitive technique used 
to analyse low, nanomolar/picomolar, antigen concentrations in biological 
samples. In insulin RIA, insulin is radioactively labelled with iodine-125 (125I) and 
bound to an anti-insulin mouse antibody. A limited and known amount of anti-
insulin antibody is used. A sample to be analysed is then added, resulting in a 
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competitive reaction of the 125I-labelled insulin (tracer) and the unlabelled insulin 
from the sample, with the anti-insulin antibody. As a result of the competition for 
the antibody, a certain amount of 125I-insulin will remain unbound to the antibody, 
and the amount of unbound radioactive insulin is proportional to the amount of 
unlabelled insulin in the sample. Free insulin and insulin bound to the antibody are 
separated and radioactivity of the labelled insulin bound to the antibody is 
measured. A standard curve, constructed using known concentrations of insulin, 
allows determination of the amount of insulin in the experimental samples. 
100 µl of 1 in 5 diluted samples or standard insulin solutions were mixed with 200 
µl of the 125I-insulin and anti-insulin antibody mixture, prepared in borate buffer 
(Table 2.13). Triplicates of insulin standards (0.04-10 ng/ml) and duplicates of 
samples were assayed. Tubes containing assayed samples and standards were 
incubated at 4°C for 48 h to establish equilibrium. Following the incubation, the 
antigen-antibody complexes were precipitated with 1 ml of the precipitation buffer 
and centrifuged (1300 g, 4°C, 15 min). The supernatant was discarded and 
radioactivity of the remaining pellet, expressed as counts per minute (cpm), was 
determined using 2470 Automatic Gamma Counter (PerkinElmer). A standard 
curve, generated by plotting cpm against standard insulin concentration, was used 
to quantify sample insulin concentration (ng/ml).  
 
Table 2.13. Culture media and buffers used for the insulin radioimmunoassay. 
 
   Buffer Composition 
Borate buffer 
(Sigma) 
133 mM Boric acid, 10 mM EDTA, 67.5 mM NaOH,  
1 mg/ml Bovine Serum Albumin (BSA), pH 8.0 
PBS buffer 
(Sigma) 
137 mM NaCL, 2.7 mM KCL, 10 mM Na2HPO4 * 2H2O,  
2 mM KH2PO4, pH 7.4 
Precipitation buffer 
(VWR) 





2.13 Statistical analysis 
For comparing two groups, obtained results were analysed by un-paired Student’s 
t-test with Welch’s correction. For comparing three and more groups, one-way 
analysis of variances (ANOVA) with Tukey’s (equal variances) or Dunnett’s T3 
(unequal variances) post hoc tests, or two-way ANOVA with Bonferroni’s post hoc 
test were used. Group variances were compared using Bartlett’s test for equal 
variances. Data were processed using Prism (GraphPad) or SPSS Statistics 23 
(IBM) software. Values were expressed as means ± standard error of the means 


























































Chapter 3  
3.1 Introduction  
During pregnancy, in response to the increased demand for insulin, the maternal 
islets adapt by increasing both the insulin secretory response and the β-cell mass. 
An increase in the maternal β-cell mass is achieved through upregulation of β-cell 
proliferation and islet volume during early and mid-stages of pregnancy [31, 32]. 
After parturition the β-cell mass rapidly reverts to non-pregnant levels, which is 
associated with a drop in β-cell proliferation and enhanced cell apoptosis. 
Placental lactogens (lactogen-I and lactogen-II) and prolactin are involved in 
upregulation of β-cells during pregnancy and are central to the pregnancy 
adaptation mechanism [30]. Moreover, lactogenic hormones induce serotonin 
synthesis in islets, which is related to upregulation of β-cell proliferation [56]. 
Serotonin activates its GPCR receptor HTR2B on the plasma membrane, leading 
to augmentation of the β-cell proliferation rate. At late stages of pregnancy and 
post-partum, the pro-proliferative effect of lactogenic hormones is counteracted by 
glucocorticoids, triggering suppression of β-cell proliferation and activation of cell 
apoptosis [62]. The drop in maternal β-cell proliferation rate at the end of 
pregnancy in rats correlates with an increase in maternal plasma cortisol 
concentration [200]. Prolactin and placental lactogens exert their functions through 
JAK kinase associated prolactin receptor, located in the cell membrane, whereas 
the glucocorticoid receptor (GCR) upon activation undergoes translocation from 
the cytosol to the nucleus, where it acts as a transcription factor. 
However, these β-cell adaptations to pregnancy and particularly their reversal 
post-partum are still poorly understood. It is not yet known whether there is a 
selective loss of proliferating “new” cells at late stages of pregnancy and post-
partum. 
 
The study described in this chapter aimed to characterise the changes in β-cell 
proliferation and mass during pregnancy and post-partum in the mouse. The 
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specific experimental objectives were: to measure pregnancy-dependent and 
postpartum changes in β-cell proliferation and size as well as to assess whether 
lactation affected post-partum changes in the β-cell mass. 
3.2 Methods 
CBA/Ca mice were given BrdU, which was incorporated into the DNA of 
proliferating cells, in their drinking water as a 1 mg/ml solution for 10 days (section 
2.1.1). Mice were culled one day after finishing the treatment. 
Immunohistochemical staining of pancreatic sections labelled with BrdU was then 
prepared (section 2.2). The sections were then visualized using a fluorescent 
microscope and images were acquired at x200 magnification. For each islet image 
the number of BrdU labelled β-cells and the total number of β-cells were counted 
using ImageJ software. The cross-sectional area of individual β-cells was 

























3.3.1 Changes in pancreatic β-cell replication during pregnancy 
β-cell proliferation in mice given a thymidine analogue BrdU for gestational days 8-
17 (early, mid-pregnancy) was significantly higher than in non-pregnant and post-
partum mice (Figures 3.1 and 3.2). Figure 3.1 presents micrographs of 




Figure 3.1. Fluorescent images of IHC stained islets. Pregnant mice (BrdU given for 
gestational days 8-17), post-partum mice left with pups (post-partum + pups) and post-
partum mice left without pups (post-partum - pups) (BrdU given for days 1-10 postpartum). 










Figure 3.2. Analysis of the average β-cell proliferation rate. Pregnant mice (BrdU 
given for gestational days 8-17, n=4), post-partum mice left with pups (post-partum + 
pups) and post-partum mice left without pups (post-partum - pups) (BrdU given for days 1-
10 postpartum, n=5). Non-pregnant control mice were given BrdU for 10 days (n=5). 
Values are expressed as means ± SEM; one-way ANOVA test * p<0.05, ** p<0.01, *** 
p<0.001.  
 
The β-cell size in pregnant mice was significantly increased compared to non-
pregnant control mice and mice left without pups post-partum. Figure 3.3 presents 
the average β-cell size of analysed mouse groups. 
 
The effects of lactation-related signals were investigated in post-partum mothers 
maintained for 10 days post-partum either with or without their litter. Female mice 
maintain lactation for as long as pups are present and fed regularly by the mother. 
Levels of lactation-related signals in mothers, such as prolactin, rapidly return to 
normal non-pregnant levels in the absence of their litter. Mice left with pups post-





Figure 3.3. Analysis of average β-cell size. Pregnant mice (BrdU given for gestational 
days 8-17, n=4), post-partum mice left with pups (post-partum + pups) and post-partum 
mice left without pups (post-partum - pups) (BrdU given for days 1-10 postpartum, n=5). 
Non-pregnant control mice were given BrdU for 10 days (n=5). Values are expressed as 
means ± SEM; one-way ANOVA test * p<0.05, ** p<0.01, *** p<0.001.  
 
compared to both non-pregnant mice and mice kept without litter post-partum 
(Figure 3.2). In the absence of lactation, post-partum β-cell proliferation returned 
to the non-pregnant level. Interestingly, the β-cell size of post-partum mice 
maintained with pups was increased compared to the non-pregnant control group 
whereas there was no statistically significant difference in the size of β-cells of 





3.3.2 Loss of β-cells post-partum 
It is well known that β-cell mass increases temporarily during pregnancy through 
increased proliferation and hypertrophy but starts to drop back to non-pregnant 
levels after parturition. The main mechanisms involved in the post-partum 
reduction in the β-cell mass are decreased proliferation and increased apoptosis. 
Nevertheless, it is not clear which β-cells are lost through apoptosis post-partum, 
the newly generated or the older pre-existing β-cells.  
 
In non-pregnant mice, the level of β-cell BrdU labelling was significantly higher 
immediately following BrdU treatment than in the case of samples taken from 
animals 10 days after the end of BrdU administration (6.9±0.6% vs 4.8±1.3%) 
(Figure 3.4). Therefore, in the non-pregnant mice, 31% of new β-cells, that 
proliferated over the initial BrdU labelling period of 10 days, were lost after the 




Figure 3.4. Analysis of the post-partum β-cell loss rate. Pregnant mice were orally 
administered BrdU for gestational days 8-17. After that period, mice were either culled 
(pregnant BrdU) or maintained for additional 10 days post-partum without BrdU treatment 
(pregnant BrdU + 10 days) before collection of the pancreas. Non-pregnant mice were 
given BrdU for 10 days and either culled (non-pregnant BrdU) or maintained for a further 
10 days without BrdU before pancreas collection (non-pregnant BrdU + 10 days). Values 




Interestingly, despite the increased β-cell apoptosis post-partum, loss of BrdU 
labelled β-cells in mice treated with BrdU for gestational days 8-17 and maintained 
for a further 10 days was small and not statistically significant (Figure 3.4). In mice 
administered BrdU from day 8 to 17 of pregnancy, 22.6±3.9% of β-cells were 
labelled positive for BrdU. When those mice were left for a further 10 days post-
partum, the percentage of BrDU labelled β-cells dropped to 18.6±4.6%, 





































It is likely that pituitary prolactin plays a role in the regulation of β-cell mass during 
lactation, given the high physiological levels of prolactin post-partum and extensive 
literature linking prolactin to β-cell proliferation [29, 47]. The β-cell proliferation rate 
in lactating mice is an effect of an interplay between pro-proliferative lactation 
related signals and anti-proliferative glucocorticoids [64]. Glucocorticoids levels 
increase post-partum, compared to pregnant and non-pregnant mice, which 
activates apoptosis leading to the post-partum drop in the β-cell proliferation rate. 
However, other physiological signals such as HGF, produced by islet endothelial 
cells, may also be involved in this process as it is been shown that HGF stimulates 
β-cell proliferation during pregnancy [59]. In addition, those non-placental signals 
may be also responsible for prolonging the β-cell hypertrophy seen during 
pregnancy in lactating mice.  
 
The data generated in this study show that pancreatic β-cells of pregnant mice 
(gestational day 8-17) had a higher proliferation rate than non-pregnant controls. It 
has been established that if the suckling stimulus of pups is removed post-partum 
the mother will stop lactating and plasma prolactin levels will drop to non-pregnant 
levels [201]. There was a significant drop in the β-cell proliferation rate 
immediately after parturition. In addition, the proliferation rate during lactation 
(mice kept with pups post-partum) was higher but not significantly different from 
the non-pregnant levels. Furthermore, ten days post-partum, a decrease in the β-
cell size from its peak in pregnancy was observed. However, β-cells of the 
lactating mice were significantly larger than the control β-cells, which suggests 
involvement of the lactation-related signals, including prolactin and growth 
hormone, in maintaining β-cell hypertrophy and increased β-cell mass post-partum 
[202]. On the contrary, the β-cell size of the non-lactating mice was not 
significantly different from the non-pregnant controls. A potential role of non-
placental signals in maintaining the augmented β-cell mass after parturition is 
supported by results of experiments on pseudopregnant mice. Pseudopregnant 
mice, generated through mating female mice with sterile males, have plasma 
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hormone levels mimicking those during pregnancy. Our team previously 
discovered that the pseudopregnant mice administered BrdU for days 4-12 of 
pseudopregnancy have significantly increased both the β-cell size and the 
proliferation rate, compared to the non-pregnant controls, but lower than in the 
pregnant mice administered BrdU for gestational days 4-12 [203].  
 
Moreover, the importance of lactation for improved β-cell function is highlighted by 
studies in breastfeeding women with GDM, who have a reduced risk of developing 
T2DM compared to non-breastfeeding mothers with GDM [204]. 
 
Growth hormone comprises a link between placental and non-placental signals 
involved in adaptations to pregnancy. In humans placenta is the main source of 
circulating growth hormone during pregnancy, replacing the pituitary growth 
hormone production until shortly before parturition [205]. However, expression of 
rat placental growth hormone decreases during pregnancy but increases in the 
pituitary [206]. Growth hormone takes part in increasing insulin resistance and 
supply of nutrients for the fetus during pregnancy but in vitro it is not as effective 
as prolactin at stimulation of β-cell proliferation and insulin secretion [207-209]. In 
addition, growth hormone is a member of the prolactin gene family and can bind to 
the prolactin receptor [210]. 
 
Scaglia and colleagues reported 2.6 times higher than the control β-cell 
proliferation rate at the end of pregnancy and a return of the β-cell proliferation 
rate to the control level 10 days post-partum [38]. In addition, the β-cell size was 
significantly decreased 10 days postpartum compared to the non-pregnant control 
mice. As opposed to the Scaglia’s results, in this study, the augmented β-cell size 
was observed 10 days post-partum. A different method of BrdU administration 
than in Scaglia’s experiments was used in this study, constant for 10 days in 
drinking water. Scaglia used intraperitoneal BrdU injections at gestational day 20 
and postpartum days 4, 8 and 10. In addition, Scaglia used rats in his 
experiments. Discrepancy between experimental protocols may explain 




The mechanisms underlying β-cells mass reduction post-partum include reduction 
of the β-cell size, decreased cell proliferation and augmented apoptosis [38, 62]. 
Apoptosis selectively targets β-cells within the islet during that time [211]. 
However, it is not known if that reduction concerns the entire β-cell population or 
whether the β-cells proliferating during pregnancy are preferentially lost after 
parturition. Some researchers suggest that apoptosis may depend on the β-cell 
localization within the islet, with apoptotic β-cells localized preferentially, but not 
exclusively, at the periphery of the islets [38]. On the other hand, other 
experimental results support the role of mitosis as the vulnerability factor. Post-
mitosis human β-cells are more vulnerable to apoptosis induced by islet amyloid 
polypeptide (IAPP) than non-dividing cells [211]. 
 
After termination of BrdU administration, BrdU labelling of β-cells drops with time 
proportionally to the rate of β-cell loss. Only proliferating cells are labelled with 
BrdU. Therefore, it is possible to measure the rate of proliferating β-cell loss by 
comparing the percentage of BrdU labelled cells just after finishing the BrdU 
administration with the percentage of BrdU labelled cells 10 days after finishing the 
BrdU treatment. In the pancreas collected from non-pregnant mice immediately 
after BrdU treatment there was BrdU labelling in 6.9±0.6% of β-cells, whilst in non-
pregnant mice, whose BrdU treatment was followed by a further 10 days of water 
administration alone, that value dropped to 4.8±1.3% of BrdU labelling. Thus, we 
can say that in the non-pregnant mice significant 31% of β-cells, which proliferated 
over a period of 10 days, were lost over the subsequent 10 days. These results 
were compared to mice sacrificed immediately after being given BrdU from day 8-
17 of pregnancy and mice administered BrdU from day 8-17 of pregnancy followed 
by water alone for 10 days post-partum. In principle, if β-cell mass returned to pre-
pregnancy levels through a selective loss of the “new” β-cells formed during 
pregnancy, the post-partum drop in BrdU labelling of β-cells after 10 days would 
have been greater than the 31% seen after 10 days in the non-pregnant mice. In 
contrast, only 18.6% of the β-cells proliferating during gestational days 8-17 were 
lost within 10 days post-partum, which was not statistically significant. Based on 
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these observations, we can conclude that the return to the non-pregnant β-cell 
mass after pregnancy was not achieved through a selective loss of “new” β-cells 

















































Analysis of the mouse placental GPCR ligand secretome 
















































Chapter 4  
4.1 Introduction 
During pregnancy, the mother undergoes major hormonal and metabolic changes, 
including increased β-cell mass, to ensure a continuous supply of nutrients to the 
fetus, as discussed in section 1.2. In mice, the highest rate of β-cell proliferation is 
observed on gestational days 13-15, dropping thereafter to reach almost control 
levels on day 18, just before parturition [32, 49]. Placental hormones and signalling 
through G protein-coupled receptors are crucial for those adaptive changes. 
 
The placenta, in addition to its functions in mediating oxygen/carbon dioxide and 
nutrients/waste products exchange between the mother and the fetus, is also a 
major endocrine organ, which induces a wide range of changes in the maternal 
physiology and energy homeostasis in order to provide an ample supply of 
nutrients for itself and the fetus [68]. Placental lactogens and growth hormone 
increase maternal food intake, triggering insulin resistance, which leads to 
elevated levels of plasma glucose [40, 208, 212]. Furthermore, placental lactogens 
play a main role in activation of maternal β-cell mass expansion during pregnancy 
[56, 57, 213]. 
 
Serotonin mediates the pro-proliferative and insulinotropic action of lactogenic 
hormones in maternal β-cells through activation of its GPCR receptor HTR2B, Gαs 
protein-coupled, during mid-pregnancy stages [56, 58]. However, just before 
parturition HTR2B expression in β-cells is downregulated while expression of 
another serotoni receptor HTR1D, Gαi protein-coupled, is increased, which 
coincidences with a drop in β-cell proliferation. Moreover, disruption of serotonin-
related GPCR signalling by knockdown of the brain serotonin receptor HTR2C in 
non-pregnant mice, increases the severity of T2DM [55]. These observations 
suggest that GPCR signalling plays a key part in the regulation of maternal β-cell 




GPCR receptors comprise the largest and most diverse group of membrane 
receptors in Eukaryotes. Many drugs targeting GPCRs have excellent therapeutic 
benefits. Analogues of GLP1R (GLP-1 receptor), exenatide and liraglutide, are 
used in therapies against T2DM [214, 215]. Our group has recently established 
that 293 GPCR genes are expressed in human islets and most of them have 
unknown functions in islet physiology [170]. The placenta synthesizes a wide 
range of hormones and peptides, many of which are established ligands for 
GPCRs. Our knowledge of the islet GPCRome allows us to predict which of these 
placental ligands the islet cells may be able to respond to.  
 
Therefore, in this study we will analyze expression of mouse known GPCR ligands 
in placentas and GPCRs in pancreatic islets at time of β-cell mass expansion 
(gestational day 12) and late pregnancy (gestational day 18), when β-cell mass 
expansion is terminated, to identify novel ligands/GPCRs, which may be involved 
in adaptive responses of islets to pregnancy. The prediction is that gene 
expression of GPCRs and/or corresponding GPCR ligands involved in β-cell mass 
upregulation during pregnancy will be higher on gestational day 12 than day 18. 
Analyzing expression of placental GPCR ligands and the corresponding islet 




















Pancreatic islets (non-pregnant mice) or placentas and pancreatic islets (pregnant 
mice on gestational days 12 or 18) were isolated from female CD1 mice at 8 
weeks of age, followed by isolation of placental and islet total RNA (sections 2.1.2, 
2.3, 2.4). mRNAs isolated from mouse placentas on gestational day 12 and 18 as 
well as mRNAs isolated from islets of non-pregnant, gestational day 12 and 18 
mice were converted into cDNAs, which were then used for quantitative RT-PCR 
gene expression studies (sections 2.5 and 2.6). Gene expression of 126 potential 
islet GPCR ligands (GPCR ligand secretome) and 342 islet GPCRs (GPCRome) 








































4.3.1 Analysis of the mouse placenta GPCR ligand secretome 
during pregnancy 
On gestational day 12, when β-cell proliferation is increased in mice, 79 out of 126 
analysed known GPCR ligand genes were expressed at detectable levels in 
mouse placentas (Figure 4.1) [29]. On gestational day 12, 35 placental GPCR 
ligand genes were upregulated while 17 genes were downregulated compared to 
gestational day 18 expression levels. 
 
On gestational day 18, characterised by decreased β-cell proliferation, expression 
of 62 placental GPCR ligand genes was detectable (Figure 4.2). On gestational 
day 18, 26 placental GPCR ligand genes were upregulated whereas 9 genes were 
downregulated compared to gestational day 12 expression levels. In addition, 
expression of 27 placental GPCR ligand genes did not change between 
gestational days 12 and 18. 
 
Approximately half of the GPCR ligand genes expressed in the placentas at both 
time points have known functions in pancreatic β-cells (Figure 4.3). 
  
Gene expression analysis of prolactin, placental lactogen-I and lactogen-II, known 
regulators of β-cell adaptations to pregnancy, in the placentas revealed that 
lactogen-II was the most highly expressed gene on both gestational day 12 and 
day 18 (Figure 4.4) [40]. The lactogenic hormones receptor (PRLR) belongs to the 
type I cytokine receptor family, activating Jak2 kinase, and does not belong to the 
GPCR family. In addition, lactogen-II expression dropped on gestational day 18 
compared to day 12 expression levels. Maternal plasma concentration of lactogen-
I increases during early pregnancy and peaks on gestational day 9 then drops 
sharply and remains constant until parturition in rodents [216, 217]. Maternal 
plasma concentration of lactogen-II is known to increase during mid-pregnancy, 
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peaking on days 12-13 of gestation and remaining high until parturition [216, 218]. 





Figure 4.1. Gestational day 12 mouse placental GPCR ligand secretome. Red – 
genes upregulated on gestational day 12 vs day 18 expression levels, black – genes not 
differentially expressed on gestational day 12 vs day 18 expression levels, blue – genes 
downregulated on gestational day 12 vs day 18 expression levels. Appendix II contains 
definitions of gene abbreviations. Values are expressed as means ± SEM, n = 4-8; 










Figure 4.2. Gestational day 18 mouse placental GPCR ligand secretome. Red – 
genes upregulated on gestational day 18 vs day 12 expression levels, black – genes not 
differentially expressed on gestational day 18 vs day 12 expression levels, blue – genes 
downregulated on gestational day 18 vs day 12 expression levels. Appendix II contains 
definitions of gene abbreviations. Values are expressed as means ± SEM, n = 4-8; 

















Figure 4.3. Effects of placental GPCR ligand genes expressed on gestational day 12 
(A) and day 18 (B) on human and/or rodent β-cell insulin secretion and β-cell 
proliferation. Stimulation – stimulatory effects of ligands on β-cell insulin secretion and/or 
β-cell proliferation, Inhibition – inhibitory effects of ligands on β-cell insulin secretion 
and/or β-cell proliferation, Stim/Inh – stimulatory or inhibitory effects of ligands on β-cell 
insulin secretion and/or β-cell proliferation depending on experimental conditions or 





Figure 4.4. Analysis of lactogenic hormones gene expression in the mouse 
placentas on gestational days 12 and 18. N – not detectable/not quantifiable 
expression. Values are expressed as means ± SEM, n=5; two-way ANOVA test ** p<0.01, 
*** p<0.001.   
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4.3.2 Analysis of the mouse pancreatic islet GPCRome during 
pregnancy 
In total, expression of 191 out of the 342 analysed GPCR genes was quantifiable 
in mouse pancreatic islets on gestational day 12 (Appendix III). 71 GPCR genes 
were differentially expressed in the islets on gestational day 12 compared to non-
pregnant expression levels (Figure 4.5). 36% of the genes differentially expressed 
on day 12 were upregulated compared to non-pregnant expression levels. In 
addition, 15 of those GPCR genes were upregulated compared to both non-
pregnant and gestational day 18 expression levels. 
 
Gene expression of 195 GPCR genes was quantifiable in pancreatic islets on 
gestational day 18 (Appendix III). Moreover, 66 GPCR genes were differentially 
expressed in the islets compared to non-pregnant expression levels (Figure 4.6). 
50% of the genes differentially expressed at that time point were upregulated 
compared to non-pregnant expression levels. In addition, 26 of those GPCR genes 
were upregulated compared to both non-pregnant and gestational day 12 
expression levels. 
 
Furthermore, on gestational day 12, there were 18 GPCR genes differentially 
expressed in the pancreatic islets compared to non-pregnant expression levels, 
with their corresponding ligands expressed in placentas (Figure 4.7). 38% of those 
GPCR genes were upregulated compared to non-pregnant expression levels.  
 
There were 13 GPCR genes upregulated in the islets on gestational day 12 
compared to non-pregnant and/or day 18 expression levels, whose ligands where 
also expressed in the placentas at that time point (Figures 4.9 and 4.10). 5 of 
those genes were chemokine or complement protein receptors (Figure 4.10). 
 
In comparison, at the gestational day 18, there were 17 GPCR genes differentially 
expressed in the pancreatic islets compared to non-pregnant expression levels, 
with their corresponding ligands expressed in the placentas (Figure 4.8). 58% of 
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those GPCR genes were upregulated compared to non-pregnant expression 
levels.  
 
PRLR, the lactogenic hormones receptor, gene expression in the islets was 
upregulated on both gestational days 12 and 18 compared to non-pregnant 
expression levels (Figure 4.11). 
 
A literature search was conducted to determine what was already known about the 
effect of activation of β-cell GPCRs whose expression was differentially expressed 
in islets on gestational days 12 and 18 compared to non-pregnant levels. The 
assumption behind this analysis was that those receptors whose expression was 
upregulated in pregnancy are more likely to be involved in β-cell adaptive 

















Figure 4.5. GPCR genes differentially expressed in mouse pancreatic islets on 
gestational day 12 compared to non-pregnant expression levels. Red – genes 
upregulated on gestational day 12 vs non-pregnant expression levels, black – genes 
downregulated on day 12 vs non-pregnant expression levels, triangle – genes 
upregulated on day 12 vs day 18 expression levels, circle – genes not differentially 
expressed on day 12 vs day 18 expression levels, square – genes downregulated on day 
12 vs day 18 expression levels. Appendix II contains definitions of gene abbreviations. 
Values are expressed as means ± SEM, n = 3-8; one-way ANOVA test, all the genes 







Figure 4.6. GPCR genes differentially expressed in mouse pancreatic islets on 
gestational day 18 compared to non-pregnant expression levels. Red – genes 
upregulated on gestational day 18 vs non-pregnant expression levels, black – genes 
downregulated on day 18 vs non-pregnant expression levels, triangle – genes 
upregulated on day 18 vs day 12 expression levels, circle – genes not differentially 
expressed on day 18 vs day 12 expression levels, square – genes downregulated on day 
18 vs day 12 expression levels. Appendix II contains definitions of gene abbreviations. 
Values are expressed as means ± SEM, n = 3-8; one-way ANOVA test, all the genes 







Figure 4.7. GPCR genes differentially expressed on gestational day 12 in mouse 
pancreatic islets, compared to non-pregnant expression levels, with their 
corresponding ligands expressed in placentas on gestational day 12. Little 
information on the specificity of FZD-WNT interaction is available due to the lack of 
purified and biologically active WNTs [219]. Therefore, WNT proteins labelled as a protein 
group were included in the figure. DARC is a non-specific receptor binding CC and CXC 
classes of chemokines. Red – genes upregulated on gestational day 12 vs non-pregnant 
(receptors) or day 18 (ligands) expression levels, blue – genes downregulated on day 12 
vs non-pregnant (receptors) or day 18 (ligands) expression levels, green – placental 
GPCR ligand genes not differentially expressed on day 12 vs day 18 expression levels. 
Appendix II contains definitions of gene abbreviations. Values are expressed as means ± 
SEM, n = 3-8; Student’s t-test (ligands) or one-way ANOVA test (GPCRs) were used, red 














Figure 4.8. GPCR genes differentially expressed on gestational day 18 in mouse 
pancreatic islets, compared to non-pregnant expression levels, with their 
corresponding ligands expressed in placentas on gestational day 18. Little 
information on the specificity of FZD-WNT interaction is available due to the lack of 
purified and biologically active WNTs [219]. Therefore, WNT proteins labelled as a protein 
group were included in the figure. Red – genes upregulated on gestational day 18 vs non-
pregnant (receptors) or day 12 (ligands) expression levels, blue – genes downregulated 
on day 18 vs non-pregnant (receptors) or day 12 (ligands) expression levels, green – 
placental GPCR ligand genes not differentially expressed on day 18 vs day 12 expression 
levels. Appendix II contains definitions of gene abbreviations. Values are expressed as 
means ± SEM, n = 3-8; Student’s t-test (ligands) or one-way ANOVA test (GPCRs) were 







Figure 4.9. Mouse GPCR genes upregulated on gestational day 12 in pancreatic 
islets, compared to non-pregnant or/and gestational day 18 expression levels, with 
their corresponding ligands expressed in placentas on gestational day 12. Red – 
ligand genes upregulated on gestational day 12 vs day 18 expression levels, blue – ligand 
genes downregulated on day 12 vs day 18 expression levels, green - ligand genes not 
deferentially expressed on day 12 vs day 18 expression levels, N – not detectable/not 
quantifiable expression, a – ligand genes expressed in the placentas on gestational day 12 
but not expressed on day 18. Appendix II contains definitions of gene abbreviations. 
Values are expressed as means ± SEM, n = 3-8; one-way ANOVA test * p<0.05, ** 








Figure 4.10. Mouse chemokine GPCR genes upregulated in pancreatic islets on 
gestational day 12, compared to non-pregnant or/and gestational day 18 expression 
levels, with their corresponding ligands expressed in placentas on gestational day 
12. DARC is a non-specific receptor, which binds both CC and CXC classes of 
chemokines whereas CCR3 binds non-specifically CC chemokines. Red – ligand genes 
upregulated on gestational day 12 vs day 18 expression levels, blue – ligand genes 
downregulated on day 12 vs day 18 expression levels, green - ligand genes not 
deferentially expressed on day 12 vs day 18 expression levels, N – not detectable/not 
quantifiable expression, a – ligand genes expressed in the placentas on gestational day 12 
but not expressed on day 18. Appendix II contains definitions of gene abbreviations. 
Values are expressed as means ± SEM, n = 3-8; one-way ANOVA test * p<0.05, ** 



















Figure 4.11. Gene expression of the mouse prolactin receptor in pancreatic islet 
during pregnancy. Values are expressed as means ± SEM, n = 3-8; one-way ANOVA 

























The main aim of this part of the study was to identify likely placental GPCR ligands 
that regulate β-cell function during pregnancy. To do so, gene expression of 
known GPCR ligands and GPCRs was quantified in the placenta and pancreatic 
islets respectively. The criteria used for determining potentially implicated 
ligand/receptor genes included novelty of the gene function in β-cells, known pro-
proliferative functions in other cell types, levels of gene expression as well as 
timing and a change of gene expression during pregnancy. In addition, the target 
positive regulator of β-cell function should have low probability of predictable 
serious side effects when used as a potential drug to improve β-cell function.   
 
More GPCR ligand genes were expressed and upregulated in placentas on 
gestational day 12 than day 18. A high number of GPCR ligand genes expressed 
in placentas during pregnancy may be related to its endo- and autocrine functions. 
Many of those genes are involved in the maintenance of placenta function, the 
regulation of maternal physiology as well as regulation of fetal growth and 
development. For example, placental WNT proteins are involved in placentation 
and organogenesis, chemokines modulate the immune response and prevent 
rejection of the fetus by the mother’s immune system while angiotensin regulates 
salt balance and maternal blood pressure during pregnancy [83, 220-222].  
 
Differences in the number of total and upregulated ligands expressed in the 
placentas between day 12 and 18 may result from different physiological dynamics 
of mid- and late pregnancy. The placenta has a high metabolic demand, utilising 
40% of oxygen delivered to the feto-placental unit [223]. Changes of the feto-
placental metabolic demand depend on the pregnancy stage and embryogenesis 
processes. In mice, blastocyst implantation takes place on gestational day 4 while 
placental development completes on gestational day 16, corresponding to day 8-9 
and week 13 of human pregnancy respectively [224]. Moreover, mouse gestational 
day 12 is characterized by dynamic changes in the developing genital system 
(gonad differentiation from a bi-potential to the sexually orientated state), presence 
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of 2 out of 7 rows of whiskers and heart chamber septation, while on day 18, 
thickening of the skin and whiskers elongation compared to day 17 as well as 
completion of nipple formation are observed [225-227]. Therefore, on day 12 the 
placenta is entering the period of maximum growth when the fetus is developing 
rapidly and the demands on the mother are greatest whereas on day 18 most of 
the fetal development is complete and the body of the mother is preparing to give 
birth and end the pregnancy. 
 
In addition, approximately half of the GPCR ligand genes expressed on both 
gestational day 12 and 18 have known functions in pancreatic β-cells. Some of 
those genes may be involved in the regulation of β-cell mass and function during 
pregnancy. Given the number of GPCRs and their corresponding ligands that are 
expressed it is impossible to study all of them in detail. Thus it is important to 
consider which GPCR systems are most likely to play a role in the adaptation of 
the maternal islets to pregnancy based on the information available. 
 
Expressed in the placenta on gestational day 12 growth hormone releasing 
hormone (GHRH), corticotrophin-releasing hormone (CRH) and somatostatin 
(SST) genes are elements of the placental hypothalamic-pituitary-adrenal (HPA) 
axis, responsible for the autocrine, paracrine and endocrine regulation of 
pregnancy physiology and stress responses [228, 229]. GH secretion from the 
pituitary gland, essential for pregnancy adaptations, is stimulated by GHRH and 
inhibited by somatostatin [230, 231]. Circulating GHRH concentrations in pregnant 
women are not significantly different from non-pregnant levels while GH 
concentrations are higher in pregnant compared to non-pregnant woman [232]. 
Furthermore, GH concentrations in cord blood are higher than in the maternal 
circulation which suggests that peripheral GHRH levels do not play an important 
role in maintaining circulating levels of GH during pregnancy. In the present study 
growth hormone releasing hormone receptor (GHRHR) expression in the islets did 
not change on gestational days 12 and 18 compared to non-pregnant levels. 
Although, GHRH gene expression was upregulated in the placentas on gestational 
day 12 compared to day 18, it has been shown that levels of plasma GHRH of 
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pregnant women do not differ from the non-pregnant levels [232]. Therefore 
GHRH was not chosen for further analysis. However, GHRHR antagonists 
stimulate proliferation and inhibit apoptosis of rat INS-1 β-cells [233]. 
 
Plasma concentrations of somatostatin in pregnant women rise from the eighth 
week until parturition and may play a part in relaxation of the gut [234]. In addition, 
expression of somatostatin receptor SSTR1 was upregulated in the islets on day 
12 vs non-pregnant expression levels while somatostatin expression in placentas 
on day 12 was upregulated compared to day 18 levels. Somatostatin was not 
subjected to further analysis because it has an inhibitory effect on proliferation of 
various cell types and inhibits insulin secretion [235]. 
 
CRH plays a main role in upregulation of glucocorticoids release from adrenal 
glands during a stress response and is involved in placentation and labor onset 
[236]. Rising levels of CRH in the fetal brain as well as cortisol and corticotrophin 
(ACTH) in fetal circulation are observed as gestation progress, which contributes 
to maturation of organ systems [237]. Furthermore, CRH-mediated stimulation of 
maternal cortisol production results in increased glucose levels in maternal 
circulation, available for the fetus [238]. CRH promotes insulin secretion in isolated 
rodent pancreatic islets and upregulates both insulin secretion and cell 
proliferation in INS-1 β-cells [239]. It also induces glucagon secretion in rat and 
ovine islets [240]. The stimulatory effect of CRH on insulin secretion in mouse 
islets is potentiated by arginine vasopressin (AVP) [241]. AVPR1B and AVPR2 are 
receptors for arginine vasopressin. Dimerization of arginine vasopressin AVPR1B 
receptor and corticotrophin-releasing hormone CRHR1 receptor is necessary for 
synergistic CRH/AVP-dependent regulation of ACTH and insulin release [242]. 
Interestingly, both islet AVPR1B and CRHR1 genes as well as placental CRH 
gene were upregulated on gestational day 12 compared to day 18 expression 
levels whereas placental AVP gene expression did not change on days 12 and 18. 
AVP synergistically with CRH stimulates insulin secretion in mouse islets and 
ACTH release in the pituitary, the effect mediated by CRHR1-AVPR1B 
heterodimer [242]. Low amounts of AVP and CRH do not have a stimulatory effect 
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on ACTH secretion but application of both proteins results in significant secretion 
of ACTH [243]. Similarly, in mouse pancreatic islets AVP and CRH independently 
stimulate insulin secretion but the CRH effect is potentiated by AVP [241]. In 
addition, AVP stimulates glucagon secretion in mice as well as glucagon secretion 
and proliferation of In-R1-G9 α-cells through AVPR1B activation [244, 245]. The 
effect of AVPR2 receptor activation on the function of the endocrine pancreas is 
unknown. AVPR2 exerts its functions through a Gαs protein-adenylyl cyclase  
signaling pathway and mediates water reabsorption in the kidney [246]. Human 
plasma AVP concentration increase during pregnancy compared to non-pregnant 
controls, which is linked to increased thirst and water retention [247, 248]. 
Moreover, AVP is expressed and can be metabolically cleared in the placenta 
while regulating blood flow in the organ [249, 250]. In this study, AVPR2 gene 
expression in the islets was upregulated on gestational day 12 compared to non-
pregnant and day 18 expression levels. AVP and CRH may be involved in 
upregulation of the β-cell function during pregnancy. However, these proteins were 
not used for further analysis because their stimulatory effects on β-cell proliferation 
(CRH) and insulin secretion (CRH and AVP) are already known. 
 
Chemerin (RARRES2), fractalkine (CX3CL1) and osteocalcin (BGLAP) genes 
were expressed in the placenta on gestational day 12. Moreover, protein products 
of those genes have been shown to be present in serum of pregnant women [251-
253].  
 
Chemerin gene expression in the placentas on gestational day 12 was increased 
compared to day 18 expression levels. Chemerin is produced in adipose tissue 
and regulates adipocyte differentiation, lipolysis, glucose uptake and macrophage 
chemotaxis [254-256]. In addition, human chemerin is expressed at a relatively 
high level in the fetal and adult liver and omental fat but its mRNA expression is 
lower in the placenta [257]. There are three chemerin receptors: CMKLR1, CCRL2 
and GPR1 [258-260]. In this study, a non-signalling decoy receptor CCRL2 was 
downregulated in the islets on gestational day 12 compared to non-pregnant 
controls. Gene expression of CMKLR1, the physiological receptor for chemerin, in 
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the islets did not change on gestational days 12 and 18 compared to non-pregnant 
mice while GPR1 expression was not detectable in the islets at both days 12 and 
18.  
 
Serum chemerin of pregnant women is positively associated with insulin 
resistance, BMI, and the plasma triglycerides concentration [251, 257]. In addition, 
serum chemerin is elevated in pregnant women and obese women with normal 
glucose tolerance compared to normal weight women with normal glucose 
tolerance [251]. A potential positive role of chemerin during human pregnancy is 
confirmed by analysis of circulating chemerin levels in women with GDM, which 
revealed that those women have decreased serum levels of chemerin compared 
to normal pregnancy levels [261]. Those observations suggest that, chemerin may 
act to reduce pregnancy-induced insulin resistance and prevent glucose 
intolerance in humans. Interestingly, chemerin was shown to increase insulin 
resistance in cultured human myocytes by disrupting insulin signalling and AKT 
phosphorylation [262]. Furthermore, chemerin improves glucose-dependent insulin 
secretion in mice but has counteracting modes of action in liver, adipose and 
skeletal muscle cells, which is manifested by inhibition of glucose production in the 
liver, impairment of insulin sensitivity in the muscle and improved insulin signaling 
in the adipose tissue [255]. Consequently, chemerin deficient mice and wild type 
controls have comparable total insulin sensitivity, demonstrated by intraperitoneal 
glucose tolerance test (IPGTT) [255]. In addition, islet area and morphology is not 
changed in chemerin knockout mice compared to the wild type control. Those 
observations suggest that chemerin plays different roles in the muscle, adipose 
tissue, and liver in the context of glucose homeostasis. Chemerin was not chosen 
for further analysis because the knockout of this gene in mice has no effect on β-
cell mass [255].   
 
Fractalkine (CX3CL1) is expressed in neurons, adipocytes, endothelial cells, 
hepatocytes vascular smooth muscle cells and the placenta. This molecule can 
exist in two forms: a soluble and a membrane-attached form. Fractalkine is 
involved in regulating chemotaxis of macrophages and can suppress inflammatory 
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activation of liver macrophages as well as pro-inflammatory cytokine release in the 
brain [263-265]. The fractalkine receptor CX3CR1 mediates fractalkine functions in 
pancreatic β-cells [266]. In this study, placental fractalkine gene expression did not 
change on days 12 and 18 whereas CX3CR1 expression did not change in islets 
on gestational day 12 but was upregulated on day 18 compared to non-pregnant 
expression levels. Circulating fractalkine levels are negatively associated with 
markers of insulin resistance and positively associated with markers of 
inflammation in pregnant women with GDM [252]. Moreover, human islets secrete 
fractalkine, which inhibits glucagon secretion and stimulates glucose-mediated 
insulin release [266, 267]. A stimulatory effect of fractalkine on insulin secretion 
has been also observed in mouse and rat islets [266, 267]. Human pancreatic β-
cells express both fractalkine and its receptor. In addition, fractalkine has an anti-
apoptotic effect in human β-cells [267]. There are species specific differences in 
the fractalkine mechanism of action as it has been reported that this protein has no 
effect on rat β-cell apoptosis [267]. Circulating fractalkine is positively associated 
with markers of inflammation in pregnant women with GDM and therefore it was 
not chosen for further analysis [252].  
 
Post-translationally carboxylated osteocalcin (cOC) is one of the main organic 
components of the bone matrix secreted by osteoblasts and odontoblasts [268]. 
This protein is responsible for binding of calcium and hydroxyapetite, the mineral 
components of the bone. The circulating under-carboxylated osteocalcin (ucOC) 
has a lower affinity for the bone and plays a role in the regulation of energy 
metabolism. Osteocalcin exerts its functions in β-cells through activation of 
GPRC6A receptor [269, 270]. In this study, expression of the osteocalcin gene 
(BGLAP) in the placentas did not change on gestational day 12 compared to day 
18. In addition, GPRC6A expression did not change on gestational day 12 but was 
downregulated on day 18 compared to non-pregnant expression levels. Some 
researchers reported that total circulating osteocalcin is increased in women with 
GDM compared to healthy pregnant women whilst others have not found any 
difference between women with and without GDM [253, 271]. On the other hand, 
decreased serum osteocalcin is observed in men with T2DM compared with non-
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diabetic subjects [272]. Women who develop diabetes postpartum have lower 
serum levels of under-carboxylated osteocalcin [273]. Furthermore, human serum 
ucOC levels correlate with insulin resistance during pregnancy [271]. Orally 
administered ucOC indirectly improves glucose tolerance and basal insulin 
secretion in mice through stimulation of GLP-1 secretion [274]. In addition, ucOC 
can stimulate insulin secretion by upregulation of adiponectin release in mice [275, 
276]. Intraperitoneally injected osteocalcin can also directly stimulate insulin 
secretion [270]. Moreover, ucOC increases β-cell proliferation and islet β-cell area 
[269, 274]. Interestingly, there is a link between fractalkine and osteocalcin. Both 
fractalkine and osteocalcin have two forms, a soluble and a plasma membrane- 
(fractalkine) or bone matrix-bound (cOC) forms. Furthermore, both proteins play 
important roles in bone physiology. Mouse fractalkine produced in the bone is 
implicated in osteoclast recruitment and osteoclastogenesis in mice [277]. 
Osteocalcin was not chosen for further analysis because its functions in β-cells 
have already been established.  
 
Similarly to the placental ligand expression analysis, an expression profile of 
differentially expressed islet GPCR genes on gestational day 12 compared to non-
pregnant levels was different from the day 18 profile. Although a comparable 
number of GPCR genes, whose ligands were expressed in the placentas, was 
differentially expressed on day 12 and 18 vs non-pregnant (18 and 17 genes 
respectively), more receptor genes were upregulated on day 18 than 12 vs non-
pregnant expression levels (10 and 7 genes respectively). The observed 
differences between the GPCR gene expression profiles of these time points may 
be due to a different physiological dynamics of mid- and late pregnancy. 
 
The most interesting islet GPCR receptor genes in the context of potential 
involvement in the stimulation of β-cells mass expansion during pregnancy are 
genes with expression profiles mimicking islet prolactin receptor expression, a 
positive β-cell regulator, and whose ligands are expressed in the placentas on 
gestational day 12. Receptor genes upregulated on gestational day 12 vs non-
pregnant levels include AVPR2, NMBR, RAMP2 and SSTR1. In addition, genes 
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which are upregulated on day 12 vs either non-pregnant (AVPR2, NMBR, RAMP2) 
or day 18 (AVPR1B, CRHR1, CCKBR, F2RL2) expression levels may also have a 
positive effect on β-cell function during pregnancy. Interestingly, the only islet 
GPCR gene upregulated on day 12 compared to non-pregnant expression levels, 
whose placental ligand expression was upregulated at that time point vs 
gestational day 18 levels, was a somatostatin receptor SSTR1. Somatostatin, the 
SSTR1 ligand, inhibits proliferation of various cell types and inhibits insulin 
secretion [235]. 
 
NMB has been detected in the central nervous system, placenta, pituitary gland, 
pancreas, gastrointestinal tissues, and several types of cancer cells [278]. NMB is 
involved in smooth muscle contraction, lowers body temperature acting on the 
brain and increases plasma glucose [279-281]. NMB by NMBR receptor activation 
in the myometrium initiates the onset of labour in pregnant mice [282, 283]. 
Moreover, NMB stimulates insulin secretion and has no effect on glucagon and 
somatostatin release in the canine pancreas whereas in the rat pancreas this 
protein has no effect on insulin and a stimulatory effect on glucagon secretion 
[284, 285]. NMB expression in mouse pituitary corticotrophs, secreting NMB into 
the systemic circulation, is upregulated by administration of CRH and suppressed 
by treatment with a glucocorticosteroid dexamethasone [286]. In addition, a pro-
proliferative effect of NMBR receptor activation by NMB has been observed in rat 
osteoblasts [287]. Although, NMBR gene expression was upregulated in the islets 
on day 12 compared to non-pregnant levels and NMB gene expression was 
detectable in the placentas on day 12, the NMB/NMBR system was not chosen for 
further analysis because of species-dependent differences in its activation effects 
on insulin secretion and the established role in the onset of labour [282-285]. 
 
CCKBR receptor binds cholecystokinin (CCK) and gastrin (GAST) with similar 
affinity [288]. CCK is a satiety reducing factor in most mammals including humans 
[289]. Serum CCK levels are decreased in pregnant women with severe vomiting 
syndrome (hyperemesis gravidarum, HG) compared to normal pregnancy controls 
[290]. Furthermore, CCKBR-deficient mice are characterized by obesity, insulin 
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resistance and impaired insulin secretion [291]. CCK also stimulates somatostatin 
secretion in rat RIN-14B ∆-cell line, expressing CCKBR [292]. Both CCK and 
GAST upregulate insulin secretion in rodents and humans [115, 293]. Treatment of 
mouse and human pancreatic islets with CCK promotes β-cell proliferation 
whereas gastrin induces β-cell neogenesis in rats after 90% pancreatectomy [294, 
295]. The CCK/CCKBR system was not chosen for further analysis because CCK 
gene expression in the placentas was downregulated on day 12 compared to day 
18 expression levels and CCKBR gene expression in the islets was not changed 
on day 12 compared to non-pregnant levels. 
  
A heterodimer of RAMP2 and calcitonin receptor-like receptor (CRLR) forms AM1 
receptor. The main endogenous ligand of AM1 is adrenomedullin (ADM) but 
amylin and calcitonin can also bind AM1 with weaker potency. ADM is expressed 
in a wide range of organs including the placenta, brain, smooth muscles 
endothelial cells and  testis [296]. In this study, ADM gene expression in the 
placentas on gestational day 12 did not differ from day 18 expression levels 
whereas RAMP2 gene expression in the islets was upregulated on day 12 
compared to non-pregnant levels. During pregnancy vascular resistance and 
mean arterial pressure are reduced, whereas cardiac output, heart rate, and blood 
volume are elevated [297]. As a result, the placental vasculature remains in a state 
of near-maximal dilatation. ADM exerts natriuretic action on kidneys and peripheral 
vasculature to control fluid and electrolyte homeostasis and 
antagonizes angiotensin II secretion [298]. There is a three- to five-fold increase in 
ADM plasma levels of pregnant women in gestational week 8 compared to non-
pregnant levels, which is maintained until parturition [299]. ADM plasma levels are 
also increased in non-pregnant patients with hypertension compared to 
normotensive controls [300]. In addition, a hypothetical role of ADM in the 
cardiovascular adaptation to pregnancy is supported by the evidence that rat 
plasma ADM concentrations increase progressively from early pregnancy to term 
and drop post-partum [301]. ADM is a potent vasodilator and plays a role in uterine 
receptivity, implantation and vascular remodelling of spiral arteries during 
pregnancy [302, 303]. Moreover, placental ADM is involved in the regulation of 
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placental vascularization [304]. ADM administration in rats inhibits insulin secretion 
but has no effect on glucagon secretion [305, 306]. Furthermore, ADM promotes 
proliferation of human colorectal cancer (CRC) cells and osteoblasts [307, 308]. 
The role of ADM in reducing blood pressure during pregnancy suggests that ADM 
in β-cells may act as a blood pressure sensor. Patients with hypertension are 
characterised by peripheral insulin resistance and hyperinsulinemia [309, 310]. 
Interestingly, treatment with some antihypertensive drugs, including thiazides, has 
been linked to insulin resistance and T2DM in humans [311, 312]. Conversely, 
improved peripheral blood flow to skeletal muscles facilitates glucose disposal to 
the tissues and α-blockers, which promote peripheral vasodilation, may improve 
glucose uptake and insulin sensitivity [313]. ADM-mediated downregulation of 
insulin secretion may counterbalance the vasodilation-mediated effect on plasma 
glucose and insulin sensitivity. ADM was not chosen for further analysis because 
of its inhibitory effect on insulin secretion [305, 306]. 
 
Thrombin, encoded by F2 gene, also known as activated blood-coagulation factor 
II, is one of the elements of the coagulation cascade, whose activation ultimately 
results in the stemming of blood loss. In addition, thrombin and its receptors have 
been implicated in placentation and myometrium contractility during labor in 
humans [314, 315]. Human plasma thrombin levels increase during early 
pregnancy compared to non-pregnant levels and remain stable throughout later 
stages of gestation [316]. Thrombin exerts its functions through activation of 
F2RL1, F2RL2, F2RL3 and F2R receptors. In the present study, thrombin gene 
expression in the placentas was upregulated on gestational day 12 compared to 
day 18 expression levels while F2RL2 gene expression in the islets did not change 
on day 12 compared to non-pregnant levels. A cryptic domain of F2RL2 (protease-
activated receptor-3, PAR3) is cleaved by thrombin, generating a 6-amino acid 
sequence that acts as a “tethered ligand” to initiate the receptor or other thrombin 
receptors activation [317]. F2RL2 expression is associated with glycated 
haemoglobin in humans while thrombin treatment and F2RL2 activation result in 
potentiated insulin secretion in human β-cells and mouse islets [318]. 
Furthermore, hyperlipidemia, hyperglycemia and hyperinsulinemia have been 
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shown to enhance the coagulation activity and increase levels of circulating 
coagulation markers, including thrombin [319, 320]. A mechanism of thrombin 
action in T2DM has been proposed in which elevated thrombin leads to F2RL2 
activation and subsequent PLC stimulation, resulting in an increase in intracellular 
Ca2+ levels and potentiation of insulin release [318]. Interestingly, F2RL1 activation 
results in suppression of insulin secretion in mice [107]. Furthermore, a “tethered 
ligand” generated during F2RL2 activation can also activate F2R and F2RL1, 
which highlights the complexity of the thrombin-mediated regulation of insulin 
secretion [317]. Although, it is not known if thrombin affects β-cell proliferation, a 
pro-proliferative effect of thrombin has been observed in human vascular 
endothelial cells [321]. Thrombin was not chosen for further analysis because it 
has either stimulatory or inhibitory effects on insulin secretion depending on the 
receptor involved in mediating its effects in β-cells [318].  
 
Another group of islet GPCR receptors, upregulated on gestational day 12 
compared to non-pregnant or/and day 18 expression levels, is the chemokine 
receptors group, consisting of CCR3, CXCR3, CXCR5, DARC, GPR77. 
Chemokines are implicated in placentation, protection against infections and 
confer the mother’s immune tolerance of the fetus [83, 322]. A non-specific CC 
chemokine receptor CCR3 is involved in triggering β-cell apoptosis and has been 
shown to be downregulated in mouse RIN-5AH β-cells by interleukin-1β (IL-1β) 
[323]. CXCR3 and its ligand CXCL10 suppress β-cell proliferation in mice whereas 
CXCL10 neutralization with a specific antibody prevents occurrence of diabetes in 
mice [324]. The CXCR3/CXCL10 system is involved in pathogenesis of T1DM in 
mice [325]. Furthermore, CXCL10 plasma levels are elevated in type 1 diabetic 
patients compared with healthy controls [326]. CXCL13, a CXCR5 receptor ligand, 
mediates a pro-proliferative and anti-apoptotic effect of GLP-1 in type 2 diabetic 
mice [327]. GPR77 binds complement system factors C3a, C4a and C5a, whose 
plasma levels are increased in patients suffering from T1DM compared to normal 
controls [328]. The β-cell function of a non-signaling DARC receptor is unknown. 
Chemokines were not chosen for further analysis because of their negative effects 




Synthesised locally in β-cells serotonin is a known mediator of the pro-proliferative 
and insulinotropic action of lactogenic hormones in maternal β-cells during 
pregnancy [56, 58]. Because serotonin is a tryptophan deriverative, it is not 
possible to measure serotonin levels using quantitative RT-PCR. Similarly to the 
results obtained by Kim and colleagues, in this study, elevated expression of the 
serotonin receptor HTR2B was observed on gestational day 12 compared to both 
non-pregnant and day 18 levels [56]. In addition, only trace, non-quantifiable 
expression of HTR1D receptor was detected in the islets on days 12 and 18. Kim 
observed elevated expression of HTR1D on gestational day 17, compared to day 
12 levels in C57bl mice which may be related to differences in timing and the 
methodology of his RT-PCR analysis (glucuronidase used as a reference gene) as 
well as a different mouse strain used. 
 
R-spondins (RSPO1, RSPO2, RSPO3, RSPO4) potentiate WNT/β-catenin 
signalling, which plays an important role in cell proliferation and embryogenesis 
[158, 178, 329]. Mutations in the human RSPO4 gene are associated with 
inherited anonychia, manifested by the absence of fingernails and toenails [168, 
169, 330]. In this study, RSPO4 was the only R-spondin gene whose expression 
was detectable in the placentas on gestational day 12 and its expression at that 
time point was not significantly different from the day 18 expression levels. In 
addition, the R-spondins receptor LGR4 was expressed in the islets at relatively 
high levels on both gestational days 12 and 18 although its expression at both time 
points was lower than non-pregnant levels. High expression levels of LGR4 in 
mouse pancreatic islets have been reported during pregnancy but its role in β-cell 
adaptation to pregnancy have not been investigated [331]. Moreover, the RSPO1 
protein stimulates insulin secretion, cell proliferation and suppresses cytokine 
induced apoptosis in MIN6 β-cells [162]. Therefore, RSPO4 was chosen for further 
analysis and functional studies in β-cells. 
 
Most of the GPCR genes differentially expressed on gestational day 12 play 
important roles in islet physiology and pregnancy adaptations. Some ligand and 
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receptor genes have pro-proliferative effects in β-cells but have not been 
implicated in β-cell expansion during pregnancy (CCK, CRH, CXCL13, GHRH, 
ucOC). Others have unknown effects on β-cell proliferation but pro-proliferative 
effects in other cell types (ADM, AVP, F2, NMB). Chemerin has no effect on β-cell 
proliferation. In addition, some of the analysed genes have negative effects on β-
cell and/or other cell types proliferation (SST, CXCL10). Fractalkine stimulates or 
suppresses cell proliferation depending on the cell type [332, 333]. A further 
functional analysis of GPCR ligands and their receptors during pregnancy, which 
have known effects on β-cells, will help to broaden our understanding of β-cell 








































































Chapter 5  
5.1 Introduction 
 
Analysis of placental GPCR ligand secretome and islet GPCRome revealed that 
there were 18 islet GPCR genes differentially expressed on gestational day 12 
compared to non-pregnant expression levels, whose ligands were expressed in 
the placentas on day 12 (section 4.3.2, Figure 4.7). Within that group of GPCR 
genes I decided to further analyse β-cell function of the R-spondin 4 (RSPO4) 
protein because a literature search suggested that this protein may have a 
stimulatory effect on β-cells. The RSPO1 protein, a member of the same protein 
family as RSPO4, has been shown to exert insulinotropic and pro-proliferative 
effects in MIN6 cells [162]. 
R-spondins belong to a superfamily of thrombospondin type 1 repeat (TSR-1)-
containing proteins. R-spondin 1 (roof plate specific spondin 1, RSPO1) was first 
discovered in the neural tube of developing mouse embryos [156]. The R-spondin 
protein family consists of RSPO1, RSPO2, RSPO3 and RSPO4, which share 60% 
sequence homology in vertebrates [146]. R-spondins potentiate WNT/β-catenin 
signalling, that plays a key role in cell proliferation, embryogenesis and stem cell 
maintenance [158, 178, 329]. In addition, R-spondins are involved in sex 
determination during embryogenesis, differentiation and placenta vasculature 
development [160, 164, 167]. Mutations in the human RSPO4 gene are implicated 
in inherited anonychia, a mild disorder characterised by the absence of fingernails 
and toenails [168, 169, 330]. R-spondins exert their functions through activation of 
leucine-rich repeat containing GPCRs: LGR4, LGR5 and LGR6.  
The RSPO1 protein stimulates insulin secretion, cell proliferation and suppresses 
cytokine-induced apoptosis in mouse MIN6 cells [162]. Interestingly, RSPO1 is a 
negative regulator of mouse pancreatic β-cell neogenesis [163]. Furthermore, 
RSPO1 and RSPO3 genes are expressed in rat hypothalamic neurons where their 
expression is upregulated by insulin [171]. Injection of RSPO1 and RSPO3 
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proteins into the rat hypothalamus brain area results in inhibition of food intake 
[171]. 
 
Positive effects of RSPO1 and RSPO3 on β-cells and glucose homeostasis 
suggest that RSPO4, acting through the same receptors as RSPO1 and RSPO3, 
may play a stimulatory role in β-cell proliferation and secretory functions.  
 
For a placental ligand to be involved in maternal β-cell adaptive responses to 
pregnancy we would predict high levels of expression of the ligand mRNA at the 
appropriate time point during gestation (early to mid-gestation) rather than late 
gestation, as well as maintained or increased expression of the β-cell receptor for 
the ligand at the appropriate phase of pregnancy. Moreover, we would anticipate 
increased concentration of the placenta-derived ligand in the maternal circulation, 
stimulatory effects of the ligand on β-cell proliferation and secretory responses as 
opposed to the inhibitory effect on β-cell apoptosis. The aim of the experiments 



























Pancreatic islets (non-pregnant mice) or placentas and pancreatic islets (pregnant 
mice on gestational days 12 or 18) were isolated from female CD1 mice at 8 
weeks of age, followed by isolation of placental and islet total RNA (sections 2.1.2, 
2.3, 2.4). mRNAs isolated from mouse placentas on gestational day 12 and 18 as 
well as mRNAs isolated from islets of non-pregnant, the gestational day 12 and 18 
mice were converted into cDNAs (section 2.5). The cDNAs were then analysed 
utilising RT-PCR to quantify expression of ligand (RSPO1, RSPO2, RSPO3, 
RSPO4) and receptor (LGR4, LGR5, LGR6) genes (section 2.6). Relative gene 
expression levels were calculated using the 2-∆∆Ct method with GAPDH as a 
reference gene.  
 
Maternal plasma levels of the RSPO4 protein were measured using a colorimetric 
mouse RSPO4 ELISA kit (section 2.7).  
 
The effect of the RSPO4 protein on proliferation of MIN6 cells was evaluated using 
a colorimetric ELISA assay based on BrdU incorporation into DNA (sections 2.8 
and 2.9). The effect of the RSPO4 protein on apoptosis of MIN6 cells was 
analyzed using Caspase Glo® 3/7 assay kit (sections 2.8 and 2.10). The effect of 
the RSPO4 protein on insulin secretion from MIN6 cells was measured using an 




















RSPO4 was the only R-spondin gene expressed in the placentas on gestational 
day 12 whereas on gestational day 18, RSPO1, RSPO3 and RSPO4 expression 
was observed in the placentas, which was consistent with a role for RSPO4, but 
not RSPO1 and RSPO3, in adaptive responses of β-cells to pregnancy (Figure 
5.1.A). RSPO4 expression in the placentas did not change between gestational 
day 12 and 18. In addition, RSPO3 was the most highly expressed placental R-
spondin gene on gestational day 18, late pregnancy. Since metabolic adaptive 
responses to pregnancy in the mouse occur during early and mid-pregnancy, 
RSPO3 is not likely to be involved.    
Furthermore, RSPO1, RSPO2, RSPO3 and RSPO4 genes were expressed in 
non-pregnant pancreatic islets, with RSPO4 as the most highly expressed R-
spondin gene (Figure 5.1.C). Expression of RSPO1, RSPO3 and RSPO4, but not 
RSPO2, was detectable in MIN6 cells, which was consistent with the previously 
published results [162] (Figure 5.1.B). RSPO4 gene expression in MIN6 cells was 
higher than expression of RSPO1 and RSPO3. 
An analysis of RSPO4 protein concentration in plasma samples of non-pregnant, 
gestational day 12 and gestational day 18 mice revealed that there was a 6-fold 
increase in the plasma RSPO4 protein concentration on gestational day 12, 
compared to the non-pregnant levels (Figure 5.2). There was no significant 
difference in the RSPO4 protein concentration between non-pregnant and 
gestational day 18 levels although a rising trend could be observed on day 18. 
Likewise, there was no significant difference between the gestational day 12 and 
18 levels of plasma RSPO4 protein. These data are consistent with the increased 
placental production and secretion of RSPO4 during pregnancy to influence β-cell 
function. 
The LGR4 gene was the only R-spondin receptor differentially expressed in the 
islets during pregnancy, compared to non-pregnant gene expression levels (Figure 
5.3.A). LGR4 expression dropped both on gestational day 12 and 18 compared to 
114 
 
non-pregnant expression levels but there was no difference between day 12 and 
18 expression levels. LGR5 expression was only observed in the islets of non-
pregnant mice (Figure 5.3.A). LGR6 expression was not detectable in the islets of 
both non-pregnant and pregnant mice (Figure 5.3.A). Furthermore, only LGR4, but 
not LGR5 and LGR6, was expressed in MIN6 cells (Figure 5.3.B). Together, these 
data suggest that LGR4, but not LGR5 and LGR6, is the islet receptor responsible 
for transducing the effect of RSPO4 on β-cells during pregnancy. 
Analysis of the effect of the RSPO4 protein on BrdU incorporation into DNA of 
MIN6 cells revealed that RSPO4 caused a concentration-dependent increase in β-
cell proliferation, with the maximal effect at 3.5 nM concentration (Figure 5.4). The 
stimulatory effect of the 3.5 nM RSPO4 protein was more defined in MIN6 cells 
cultured without FBS-derived growth factors (- FBS) than those cultured in medium 
supplemented with FBS (+ FBS), which corresponded to an 28% and 16% 
increase in the β-cell proliferation rate respectively.   
In contrast, the RSPO4 protein had no detectable inhibitory effect on β-cell 
apoptosis. Thus, there was no significant effect of RSPO4 used at 35 pM, 350 pM 
and 3.5 nM concentrations on MIN6 cell apoptosis (Figure 5.5). While the highest 
tested RSPO4 protein concentration, 35 nM, resulted in an unexpected 
upregulation of the MIN6 cell apoptosis rate.   
The RSPO4 protein had a small but significant effect on insulin secretion from 
MIN6 cells. Thus, the 3.5 nM and 35 nM RSPO4 protein significantly increased 
basal insulin secretion at 2 mM glucose (Figure 5.6). However, the RSPO4 protein 
did not have any effect on glucose-stimulated insulin secretion from MIN6 cells at 















Figure 5.1. Analysis of mouse R-spondin gene family expression on gestational 
days 12 and 18 in the placentas (A), MIN6 cells (B) and non-pregnant pancreatic 
islets (C). N – not detectable/not quantifiable expression. Values are expressed as means 





















Figure 5.2. Concentration of RSPO4 protein in plasma samples of non-pregnant, 
gestational day 12 and gestational day 18 mice. Values are expressed as a mean 
















Figure 5.3. Analysis of mouse R-spondin receptors expression in pancreatic islets 
during pregnancy (A) and in MIN6 cells (B). N – not detectable/not quantifiable 















Figure 5.4. The effect of RSPO4 protein on the MIN6 cell proliferation rate. MIN6 cells 
were cultured in medium containing FBS-derived growth factors (+ FBS) or without them 
(- FBS); medium without RSPO4 protein (- RSPO4) or medium containing 35 pM RSPO4 
protein (+ 35 pM RSPO4), 350 pM RSPO4 protein (+ 350 pM RSPO4), 3.5 nM RSPO4 
protein (+ 3.5 nM RSPO4) or 35 nM RSPO4 protein (+ 35 nM RSPO4). Values are 
expressed as a mean fold change over the control proliferation rate of MIN6 cells cultured 





























Figure 5.5. The effect of RSPO4 protein on the MIN6 cell apoptosis rate. MIN6 cells 
were cultured in medium containing pro-apoptotic cytokines (+ cytokines) or without them   
(- cytokines); medium without RSPO4 protein (- RSPO4) or medium containing   35 pM 
RSPO4 protein (+ 35 pM RSPO4), 350 pM RSPO4 protein (+ 350 pM RSPO4), 3.5 nM 
RSPO4 protein (+ 3.5 nM RSPO4) or 35 nM RSPO4 protein (+ 35 nM RSPO4). Values 
are expressed as a mean fold change over the control apoptosis rate of MIN6 cells 
cultured in medium without RSPO4 protein and pro-apoptotic cytokines (IL-1β, TNF-α, 
















Figure 5.6. The effect of RSPO4 protein on insulin secretion from MIN6 cell. MIN6 
cells were cultured in medium containing 2 mM glucose (2 mM glucose) or 20 mM glucose 
(20 mM glucose); medium without RSPO4 protein (- RSPO4) or medium containing 350 
pM RSPO4 protein (+ 350 pM RSPO4), 3.5 nM RSPO4 protein (+ 3.5 nM RSPO4), 35 nM 
RSPO4 protein (+ 35 nM RSPO4) or 500 nM PMA (500 nM PMA), a PKC activator and 
stimulator of insulin secretion (positive control). Values are expressed as nanograms of 
insulin secreted by 25000 MIN6 cells cultured for one hour ± SEM, n = 3-8; two-way 


























RSPO4 was the only R-spondin gene expressed in the placenta on gestational 
day 12, when β-cell proliferation is increased in pregnant mice. Furthermore, 
expression of the LGR4 receptor gene in the islets was downregulated at both the 
gestational day 12 and 18 compared to non-pregnant expression levels. 
Therefore, the RSPO4 and its LGR4 receptor expression patterns do not mimic 
the expression patterns of prolactin and its receptor PRLR, which play a central 
role in increasing β-cell proliferation during pregnancy. This may suggest that if 
RSPO4 is involved in the regulation of β-cell function during pregnancy it may 
have a different role to that of prolactin. RSPO4 has been shown to be a protein 
secreted by human embryonic kidney 293 cells and mice [146, 156, 169]. In 
addition, the present study confirmed presence of RSPO4 protein in maternal 
circulation. Although LGR4 expression was decreased during pregnancy, 
compared to non-pregnant levels, the RSPO4/LGR4 system may play a positive 
role in maternal β-cell adaptation as expression levels themselves may not be the 
best indication of gene involvement in the given physiological process. The GPCR 
receptor activity can be modulated at many levels, including gene expression, 
formation of receptor complexes, receptor recycling and degradation. CRLR is a 
G-protein coupled receptor, which forms heterodimers with the activity-modifying 
proteins RAMP1, RAMP2 or RAMP3. The CRLR/RAMP1 complex functions as a 
receptor for CGRP1 whereas CRLR/RAMP2 (AM1) and CRLR/RAMP3 (AM2) 
complexes mediate adrenomedullin actions [334]. Moreover, CRHR1, a receptor 
for CRH, interacts with AVP1B, a receptor for AVP, in the brain and pancreatic β-
cells, which is manifested by a synergistic upregulation by CRH and AVP of CRH 
secretion in the brain and insulin in β-cells  [242].  
The maternal plasma concentration of the RSPO4 protein increased by 6-fold on 
day 12 compared to the non-pregnant levels. Although, the gestational day 18 
RSPO4 protein plasma concentration did not differ significantly from the non-
pregnant levels, a rising trend could be observed. Moreover, RSPO4 gene 
expression was detected in mother’s pancreatic islets and MIN6 cells. Those 
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observations and the fact that RSPO4 has a developmental role suggest that the 
RSPO4 protein may be secreted by the placenta into the maternal circulation and 
may exert endocrine and paracrine functions in the mother’s body and the fetus 
[168, 169, 330]. In addition, placental RSPO4 gene expression on day 12 was not 
significantly different from day 18 expression levels, which mimics the plasma 
RSPO4 protein concentration similarity at both time points. It is likely that the 
RSPO4 protein, secreted by the placenta, contributes to the increased RSPO4 
protein levels during pregnancy. However, it remains to be determined if the 
plasma RSPO4 protein is involved in the regulation of β-cell mass expansion 
during pregnancy. 
The lack of RSPO3 expression in the placentas on gestational day 12, with 
relatively high expression on day 18, suggests that this protein may play a less 
important role than RSPO4 in the β-cell adaptive responses to pregnancy. Human 
β-cells, cultured in WNT3A, RSPO3 and Noggin protein conditioned medium, have 
a 20-fold higher cell proliferation rate than cells cultured in non-conditioned control 
medium [335]. All four R-spondins stimulate proliferation of small intestine crypt 
epithelial cells by potentiation of WNT/β-catenin potentiation [146]. Although, 
RSPO3 expression was not detectable in the placentas on gestational day 12 
when β-cell proliferation is increased. Moreover, the WNT3A protein enhances 
proliferation of MIN6 cells [154]. Noggin stimulates growth and patterning of the 
neural tube during embryogenesis as well as cartilage morphogenesis and joint 
formation [336, 337]. Combined actions of RSPO3, WNT3A and Noggin contribute 
to the enhanced proliferation rate of human β-cells [335]. 
The RSPO4 protein stimulated proliferation and basal insulin secretion in MIN6 
cells. RSPO4 has lower binding affinity to LGR4 and a weaker ability to potentiate 
WNT/β-catenin signalling compared to the other R-spondins but a significant effect 
of RSPO4 protein in β-cells was observed in this study [173]. It was previously 
reported that the 35 nM RSPO1 protein increased MIN6 cell proliferation rate by 
2.5-fold while, in this study, concentrations of 3.5 nM and 35 nM RSPO4 protein 
enhanced the β-cell proliferation rate only by 0.2 to 0.3-fold, depending on the 
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RSPO4 concentration [162]. However, the concentration of RSPO4 protein 
measured in the maternal circulation on gestational day 12 was 571 times lower 
than the lowest most effective RSPO4 concentration which stimulated MIN6 cell 
proliferation (3.5 nM). The RSPO4 protein also upregulated insulin secretion from 
MIN6 cells at low glucose (2 mM). On the contrary, the RSPO1 protein has been 
shown to stimulate insulin secretion from MIN6 cells at both low (2 mM) and high 
(20 mM) glucose concentrations [162].  The observed differences may be a result 
of 8-fold higher binding affinity of RSPO1 protein to LGR4 compared to RSPO4 
binding [173]. R-spondins potentiate the canonical WNT/β-catenin and non-
canonical WNT/PCP signalling pathways, which are implied in embryogenesis, 
determining cell polarity as well as cell proliferation and survival [157]. Disruption 
of WNT signalling leads to birth defects and cancer [142]. Experiments on RSPO1 
revealed that R-spondins potentiate WNT/β-catenin signalling by a direct 
interaction of their LGR receptors with the WNT receptor complex FZD and by 
suppressing FZD complex degradation [159, 181]. Moreover, the WNT3A protein 
promotes MIN6 cells proliferation while β-cell-specific β-catenin overexpression in 
mice results in a 2.5-fold increase in β-cell mass [154]. Analysis of R-spondins 
distribution in the mouse brain revealed that RSPO4 is expressed only in the 
thalamus while RSPO1 and RSPO3 are expressed more widely in the brain, 
including the hypothalamus where their expression is downregulated with fasting 
and upregulated by insulin injection into the third brain ventricle [171]. LGR4 gene 
expression has also been detected in the hypothalamus. In addition, injection of 
RSPO1 and RSPO3 into the third brain ventricle, bounded by the hypothalamus 
and thalamus, results in inhibition of food intake [171]. These observations allow 
us to assume that R-spondins, in addition to regulating embryogenesis and 
differentiation, may also be involved in modulating maternal adaptations to 
pregnancy.  
The RSPO4 protein did not have any effect on the basal level of the cell apoptosis 
rate of MIN6 cells but the highest concentration of the RSPO4 protein (35 nM) 
unexpectedly potentiated cytokine-induced cell apoptosis, suggesting that lower 
concentrations of the RSPO4 protein should be used for the future experiments. 
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Conversely, a protective effect of the 35 nM RSPO1 protein on cytokine-induced 
MIN6 cell apoptosis has been reported previously [162]. 
The presence of FBS-derived growth factors diminished the effect of RSPO4 
protein on β-cell proliferation. Fetal bovine serum used in cell culture provides a 
wide range of  important biological molecules including albumin, antichymotrpsin, 
apolipoproteins, biotin, and growth factors, which are essential for optimal cell 
growth [338]. Transforming growth hormone β1 (TGF-β1), fibroblast growth factor 
(FGF) and insulin-like growth factor 1 (IGF-1), present in FBS, have a stimulatory 
effect on the β-cell proliferation rate [339-343]. Cells cultured in “starving” medium, 
not supplemented with FBS, are more sensitive to potential pro-proliferative or pro-
survival factors.   
To summarise, RSPO4 fulfils some of the criteria set for determining if a placental 
ligand may be involved in β-cell adaptive responses to pregnancy. RSPO4 gene 
was expressed in the placenta during mid-pregnancy (gestational day 12). Its 
receptor LGR4 was expressed in mouse islets and MIN6 cells, although LGR4 
gene expression in the islets during mid- and late pregnancy was lower than in the 
islets of non-pregnant mice. However, results of experiments presented in Chapter 
4 and published by other researchers showed that LGR4 is one of the most highly 
expressed islet GPCR receptors during mid-pregnancy [331]. The RSPO4 protein 
concentration is elevated in maternal circulation during mid-pregnancy compared 
to non-pregnant levels. Furthermore, the RSPO4 protein has pro-proliferative and 
insulinotropic effects in MIN6 β-cells. Unexpectedly, the RSPO4 does not reduce 
the rate of MIN6 β-cell apoptosis. Elucidating if RSPO4 plays a part in the 




























































Chapter 6  
6.1 General discussion  
It is estimated that 415 million people worldwide suffered from diabetes mellitus in 
2015 and that the number will be 642 million by 2040, making diabetes one of the 
biggest challenges for medicine in the twenty-first century [344]. Recent studies 
into the causes of T2DM suggest that the development of the disease depends on 
inability of the β-cell mass to respond to increased insulin resistance, often as a 
consequence of obesity [18]. Thus, in normal individuals, increased insulin 
resistance is compensated for by increased insulin secretion and an increase in 
the β-cell mass. Individuals who are unable to expand their β-cell mass sufficiently 
will become glucose intolerant, finally progressing to T2DM. Therapies which are 
aimed at expanding the β-cell mass therefore offer a targeted way of preventing 
the onset of T2DM in susceptible, glucose-intolerant patients. However, the 
mechanisms involved in β-cell adaptive responses to insulin resistance are not 
well understood, partly because there are few physiological circumstances under 
which the β-cell mass increases, mainly obesity, which is slow to develop, and 
pregnancy. During pregnancy, a wide range of adaptive changes is activated in 
pancreatic β-cells, which is manifested by upregulated cell proliferation and insulin 
secretion. The modulation of signalling pathways, responsible for the enhanced 
activity of β-cells during pregnancy, may help to develop new methods for the 
T2DM treatment. In order to compensate for maternal insulin resistance both 
humans and rodents activate adaptive mechanisms, involving an increase in β-cell 
mass and a change in expression of various genes, and the mechanisms of β-cell 
adaptation to an increased insulin demand in pregnant humans and rodents are 
thought to be similar. Therefore, research results obtained in rodents could help to 
broaden our understanding of human β-cell adaptation to pregnancy.  
 
It has been well established that prolactin and placental lactogens play a crucial 
role in the increase in the β-cell mass during pregnancy, but other physiological 
signals are likely to play a role as well, and the main aim of the work described in 
127 
 
this thesis was to identify potential candidate molecules. The first aim of the 
studies was to test the hypothesis that “pregnancy and lactation stimulate β-cell 
proliferation, with selective loss of new β-cells post-partum” by studying changes 
in the β-cell mass in pregnant mice. The experiments described in Chapter 3 of 
this thesis clearly demonstrate that the mouse pregnancy model offers an 
opportunity to study increases in the β-cell mass under controlled conditions. 
Therefore, this experimental model was used for subsequent studies investigating 
potential abilities of placenta-derived signals to regulate β-cell function during 
pregnancy. 
 
In addition, these studies showed that the post-partum reduction in the β-cell mass 
is not dependent on the selective loss of “new” β-cells formed during pregnancy. 
This implies that there is not a sub-set of β-cells that have the capacity to 
proliferate when physiological circumstances demand, but rather that all islet β-
cells have the ability to expand and retract as required by metabolic demand. This 
information may be important when we consider how best to manipulate the β-cell 
mass in people with T2DM. 
Identifying novel genes involved in the regulation of β-cell function during 
pregnancy is difficult due to the complexity of direct and indirect effects of 
GPCR/ligand actions in β-cells. The studies presented in Chapter 4 of this thesis 
show that there are numerous potential interactions between the placenta and β-
cells during pregnancy, determining a number of candidates worth of further 
investigation for their roles in adaptive responses to pregnancy and for their 
therapeutic potential in treating T2DM. However, a polygenic disease like T2DM 
involves small expression changes in a large group of genes, which may be 
difficult to identify by expression analysis of individual genes. An alternative 
approach, based on analysis of coordinated changes in gene co-expression 
networks, can provide molecular insights for complex polygenic diseases [345]. A 
network-based approach, using global microarray expression data from healthy 
and T2DM human islets donors, revealed that thrombin receptor F2RL2 gene 
expression is associated with expression of a module of 192 GPCR genes and 
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correlates with glycated haemoglobin [318]. On the contrary, F2RL2 expression 
alone is not altered in patients suffering from T2DM compared to healthy subjects 
[318]. 
Using available information about the known functions of the candidate genes is 
helpful in choosing the most suitable target genes for β-cell functional studies. The 
most interesting candidate genes would have a pro-proliferative and anti-apoptotic 
function in various cell types. In addition, knowing which G protein class is coupled 
to the receptor of interest or which G protein class pathway is activated by a given 
ligand can help to predict the effect of the analysed gene in β-cells. In general, 
Gαs and Gαq protein coupling has a stimulatory effect on β-cell proliferation and/or 
insulin secretion whereas Gαi coupling downregulates those processes in β-cells 
[102, 105, 113]. Furthermore, the number of known functions of the analysed gene 
can help to foresee potential side effects of the target gene used as a drug in a 
therapy for diabetes. Genes involved in regulation of multiple important 
physiological processes may be more difficult to use as a drug because of a risk of 
off-target effects and impairment of their innate functions in the body. Therefore, a 
better option is to choose genes with a narrower range of functions and well-
known signalling mechanisms. The fact that the human RSPO4 gene is implicated 
in inherited anonychia, a mild disorder, and is not implied in other physiological 
processes, makes it an interesting candidate gene for an anti-diabetes therapy  
[168, 169, 330]. 
Stimulation of Gαs protein-dependent and cAMP/PKA signalling has opposing 
effects in β and α-cells and is useful for developing therapies against T2DM. 
Pancreatic Gαs protein knockout mice are characterized by decreased 
proliferation of β-cells and increased proliferation of α-cells, which leads to 
development of early-onset insulin-deficient diabetes [346, 347]. PKA-mediated 
phosphorylation of ATP-sensitive potassium channels in INS-1 cells results in 
plasma membrane depolarization and stimulation of insulin secretion [348]. 
Moreover, phosphorylation of snapin, a secretory vesicle-associated protein, 
initiated by GLP-1 analogues and mediated by PKA, promotes insulin exocytosis 
in mouse islets [349]. However, leptin, through PKA activation, stimulates 
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trafficking of ATP-dependent potassium channels to the plasma membrane in INS-
1 cells, causing inhibition of insulin secretion [350]. Different effects of PKA 
activation in the same cell type may be related to the subcellular localization of 
PKA, which depends on binding to A kinase anchoring proteins (AKAPs) [351]. 
Notably, inactivating mutations in the regulatory subunit of human PKA, 
responsible for inhibition of the catalytic subunit of the kinase, are linked to 
enhanced glucose-stimulated insulin secretion, without affecting fasting plasma 
glucose levels [349]. GLP-1 inhibits glucagon secretion in healthy humans and rats 
in a PKA-dependent fashion [352-354]. Consequently, GLP-1 administration in 
patients suffering from T2DM promotes insulin secretion and lowers post-meal 
plasma glucose levels [355, 356]. Agonists of GLP-1 receptor (GLP1R), a Gαs 
protein coupled receptor, (exenatide and liraglutide) are used in therapies against 
T2DM [214, 215]. Interestingly, metformin, used in treatment for T2DM, reduces 
glucose synthesis in hepatocytes by inhibiting adenylate cyclase, reducing cAMP 
levels and downregulating PKA activity [357]. Furthermore, blocking of the liver 
glucagon receptor (GCGR), which is also coupled to Gαs proteins, by its 
antagonists betters glucose homeostasis in diabetic patients [358]. 
 
FFAR1, also known as GPR40, is a Gαq protein-coupled receptor taking part in 
potentiation of GSIS in the response to stimulation by long-chain free fatty acids 
(e.g. myristic and palmitic acids) [359]. Moreover, FFAR1 activation in 
enteroendocrine cells increases GLP-1 release, which indirectly enhances insulin 
secretion from mouse β-cells [360]. Agonists of FFAR1 augment glucose-
dependent insulin secretion in rodents and humans [360-362]. Therefore, targeting 
FFAR1 by synthetic ligands in diabetic patients has generated promising 
therapeutic results. Therapies based on some of these agonists have been 
advanced into phase II or III of clinical trials [362].    
 
Inhibition of Gαi protein-coupled receptors can have therapeutic applications in 
treating diabetes. Chronic tissue inflammation has been linked to insulin resistance 
in obese individuals [363]. Inhibiting the pro-inflammatory leukotriene B4 (LTB4) 
receptor LTB4R1, which is coupled to Gαi proteins, has been effective in reducing 
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inflammation, improving glucose tolerance and insulin sensitivity in diabetic mice 
[364]. On the contrary, activation of fractalkine receptor CX3CR1 leads to 
augmented glucose-, amino acid- and GLP1-induced insulin secretion in mice and 
isolated human islets, the effects mediated by Gαi protein action [266, 365]. In 
addition, mutations in the human CX3CR1 gene are associated with an elevated 
risk of developing T2DM [366]. These findings underline the complex nature of 
GPCR signalling in β-cells. 
 
Using the selection criteria described in Chapter 4 we decided to investigate 
RSPO4 as a potential placenta/β-cell signal. The data presented in Chapter 5 
suggest that RSPO4 may play a role in regulating β-cell secretory and proliferative 
responses, at least in vitro. These observations for one molecule identified in our 
screening validate the experimental approach adopted for these studies. 
Moreover, obtained results demonstrate that placenta-derived molecules other 
than lactogens and growth hormone are likely to be involved in metabolic 
responses to pregnancy. Further studies may identify a “cocktail” of biologically 
active, placenta-derived protein factors which may be used in regulating the β-cell 
functional mass. 
6.2 Future perspectives 
The studies described in this thesis have shown that this experimental approach 
has the potential to identify new biologically active molecules, which may be used 
to regulate the functional β-cell mass in GDM or, more importantly, in T2DM. 
RSPO4 function in mouse and human pancreatic islets as well as signalling 
pathways and receptors involved in RSPO4 action in β-cells require further 
analysis. As a complementary approach it would be worth assessing the additive 
or synergistic effects of modulating both stimulatory (Gαs, Gαq) or inhibitory (Gαi) 
pathways to regulate β-cell functions. Thus, the β-cell effect of downregulating 
GPCRs coupled to Gαi proteins, which were upregulated in the islets on 
gestational day 18 compared to the non-pregnant controls, needs further analysis. 
These GPCRs may be involved in reversing β-cell adaptation to pregnancy at 
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term, including downregulation of insulin secretion and β-cell mass. Inhibition of 
Gαi protein-coupled GPCRs may be used to address various aspects of β-cell 
dysfunction related to T2DM, such as decreased β-cell mass, impaired insulin 
secretion and signalling [102, 367]. The aforementioned strategies may help to 
broaden our understanding of β-cell adaptations to pregnancy and an increased 
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ADCYAP1 Adenylate Cyclase Activating Polypeptide 1 QT00100317 92 
ADM Adrenomedullin QT00249676 105 
ADM2 Adrenomedullin 2 QT00269003 150 
AGT Angiotensinogen QT00164745 61 
ANXA1 Annexin A1 QT00145915 170 
APLN Apelin QT00111762 103 
AVP Arginine Vasopressin QT00249389 93 
BGLAP Bone Gamma-Carboxyglutamate (Gla) Protein QT00259406 102 
C1QL1 Complement Component 1, Q Subcomponent-Like 1 QT00259238 90 
C1QL2 Complement Component 1, Q Subcomponent-Like 2 QT00318227 126 
C1QL3 Complement Component 1, Q Subcomponent-Like 3 QT00282478 64 
C1QL4 Complement Component 1, Q Subcomponent-Like 4 QT01038520 100 
C3 Complement Component 3 QT00109270 108 
C4A Complement Component 4A QT01074948 187 
CALCA Calcitonin-Related Polypeptide Alpha QT01747865 96 
CALCB Calcitonin-Related Polypeptide Beta QT00162078 94 
CARTPT CART Prepropeptide QT00130396 82 
CCK Cholecystokinin QT00250145 91 
CCL1 Chemokine (C-C Motif) Ligand 1 QT01044421 111 
CCL11 Chemokine (C-C Motif) Ligand 11 QT00114275 109 
CCL17 Chemokine (C-C Motif) Ligand 17 QT00131572 103 
CCL19 Chemokine (C-C Motif) Ligand 19 QT02532173 68 
CCL2 Chemokine (C-C Motif) Ligand 2 QT00167832 118 
CCL20 Chemokine (C-C Motif) Ligand 20 QT02326394 71 
CCL21a Chemokine (C-C Motif) Ligand 21A QT00284753 96 
CCL22 Chemokine (C-C Motif) Ligand 22 QT00108031 92 
CCL24 Chemokine (C-C Motif) Ligand 24 QT00126021 116 
CCL25 Chemokine (C-C Motif) Ligand 25 QT00110173 143 
CCL26 Chemokine (C-C Motif) Ligand 26 QT01559481 99 
CCL27a Chemokine (C-C Motif) Ligand 27A QT00325003 190 
CCL27b Chemokine (C-C Motif) Ligand 27B QT02281895 113 
CCL28 Chemokine (C-C Motif) Ligand 28 QT01752625 102 
CCL3 Chemokine (C-C Motif) Ligand 3 QT00248199 107 
CCL4 Chemokine (C-C Motif) Ligand 4 QT00154616 110 
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CCL5 Chemokine (C-C Motif) Ligand 5 QT01747165 107 
CCL7 Chemokine (C-C Motif) Ligand 7 QT00171458 117 
CCL8 Chemokine (C-C Motif) Ligand 8 QT00128548 87 
CD55 CD55 Molecule QT00133994 121 
CGA Glycoprotein Hormones, Alpha Polypeptide QT00098084 81 
COL3A1 Collagen Type III, Alpha 1 QT02331301 73 
CORT Cortistatin QT00104272 149 
CRH Corticotropin Releasing Hormone QT01055789 183 
CTSG Cathepsin G QT00112112 118 
CX3CL1 Chemokine (C-X3-C Motif) Ligand 1 QT00128345 98 
CXCL1 Chemokine (C-X-C Motif) Ligand 1 QT00115647 93 
CXCL10 Chemokine (C-X-C Motif) Ligand 10 QT00093436 92 
CXCL11 Chemokine (C-X-C Motif) Ligand 11 QT00265041 86 
CXCL12 Chemokine (C-X-C Motif) Ligand 12 QT00161112 71 
CXCL13 Chemokine (C-X-C Motif) Ligand 13 QT00107919 64 
CXCL16 Chemokine (C-X-C Motif) Ligand 16 QT00171535 129 
CXCL2 Chemokine (C-X-C Motif) Ligand 2 QT00113253 81 
CXCL3 Chemokine (C-X-C Motif) Ligand 3 QT00151599 133 
CXCL4 Chemokine (C-X-C Motif) Ligand 4 QT00312529 82 
CXCL5 Chemokine (C-X-C Motif) Ligand 5 QT01658146 62 
CXCL9 Chemokine (C-X-C Motif) Ligand 9 QT00097062 98 
EDN1 Endothelin 1 QT00253512 116 
EDN2 Endothelin 2 QT00198814 77 
EDN3 Endothelin 3 QT00107905 140 
F2 Thrombin QT00128870 137 
FSHB Follicle Stimulating Hormone, Beta Polypeptide QT00150262 109 
GAL Galanin QT00109970 69 
GALP Galanin-Like Peptide QT02532796 121 
GAST Gastrin QT00107702 150 
GCG Glucagon QT00124033 94 
GHRH Growth Hormone Releasing Hormone QT00136787 121 
GHRL Ghrelin/Obestatin Prepropeptide QT00137536 73 
GIP Gastric Inhibitory Polypeptide QT00146692 140 
GNRH1 Gonadotropin-Releasing Hormone 1 QT01062600 124 
















HCRT Hypocretin (Orexin) Neuropeptide Precursor QT00112252 156 
INSL3 Insulin-Like 3 QT00286741 148 
INSL5 Insulin-Like 5 QT00261345 146 
KISS1 Kisspeptin QT01764259 146 
KNG1 Kininogen 1 QT00106260 99 
LHB Luteinizing Hormone Beta Polypeptide QT00262829 150 
NMB Neuromedin B QT00105945 92 
NMS Neuromedin S QT01043672 127 
NMU Neuromedin U QT00133091 100 
NPFF Neuropeptide FF-Amide Peptide Precursor QT00319984 120 
NPS Neuropeptide S QT02251396 69 
NPVF Neuropeptide VF Precursor QT01054340 118 
NPW Neuropeptide W QT00295400 119 
NPY Neuropeptide Y QT00134302 150 
NTS Neurotensin QT00127225 142 
OXT Oxytocin/Neurophysin I Prepropeptide QT00252203 184 
PDYN Prodynorphin QT00110117 143 
PENK Proenkephalin QT00240961 95 
PMCH Pro-Melanin-Concentrating Hormone QT01060339 106 
PNOC Prepronociceptin QT00102480 85 
POMC Proopiomelanocortin QT00162218 99 
PPBP Pro-Platelet Basic Protein QT00160993 96 
PPY Pancreatic Polypeptide QT00103999 150 
PRLH Prolactin Releasing Hormone QT01564941 99 
PROK1 Prokineticin 1 QT02326296 184 
PROK2 Prokineticin 2 QT00133910 62 
PRSS1 Trypsin I QT01757651 113 
PTH Parathyroid Hormone QT00161539 96 
PTH2 Parathyroid Hormone 2 QT00284102 80 
PTHLH Parathyroid Hormone-Like Hormone QT00114982 119 
PYY Peptide YY QT00123277 79 
QRFP Pyroglutamylated RFamide Peptide QT00136395 83 
RARRES2 Chemerin QT00117166 84 
RLN1 Relaxin 1 QT01071112 73 
















RSPO1 R-spondin 1 QT00124831 67 
RSPO2 R-spondin 2 QT00154182 129 
RSPO3 R-spondin 3 QT00127988 138 
RSPO4 R-spondin 4 QT00136234 119 
SCT Secretin QT00249361 134 
SST Somatostatin QT01046528 89 
TAC1 Preprotachykinin QT01037141 154 
TRH Thyrotropin-Releasing Hormone QT01745023 109 
TSHB Thyroid Stimulating Hormone Beta QT00135303 95 
UCN Urocortin QT00326879 112 
UCN2 Urocortin 2 QT01556534 125 
UCN3 Urocortin 3 QT00302267 125 
UTS2 Urotensin 2 QT00124278 92 
VIP Vasoactive Intestinal Peptide QT00133966 96 
WNT1 Wingless-Type MMTV Integration Site Family Member 1 QT00103985 86 
WNT2 Wingless-Type MMTV Integration Site Family Member 2 QT00118503 119 
WNT3 Wingless-Type MMTV Integration Site Family Member 3 QT00133686 71 
WNT3A Wingless-Type MMTV Integration Site Family Member 3A QT00250439 94 
WNT4 Wingless-Type MMTV Integration Site Family Member 4 QT00104622 134 
WNT5A Wingless-Type MMTV Integration Site Family Member 5A QT00164500 130 
WNT7B Wingless-Type MMTV Integration Site Family Member 7B QT00168812 114 





























Adenylate Cyclase Activating Polypeptide 1 Receptor 
Type I 
QT00120561 115 
ADORA1 Adenosine A1 Receptor QT00301119 68 
ADORA2A Adenosine A2a Receptor QT02527308 112 
ADORA2B Adenosine A2b Receptor QT00257558 112 
ADORA3 Adenosine A3 Receptor QT01068347 142 
ADRA1A Adrenoceptor Alpha 1A QT00129584 100 
ADRA1B Adrenoceptor Alpha 1B QT01051876 89 
ADRA1D Adrenoceptor Alpha 1D QT00147315 99 
ADRA2A Adrenoceptor Alpha 2A QT00287063 60 
ADRA2B Adrenoceptor Alpha 2B QT00311675 83 
ADRA2C Adrenoceptor Alpha 2C QT01749328 95 
ADRB1 Adrenoceptor Beta 1 QT00258692 109 
ADRB2 Adrenoceptor Beta 2 QT00253967 85 
ADRB3 Adrenoceptor Beta 3 QT01756160 102 
AGTR1 Angiotensin II Receptor Type 1 QT00261464 85 
AGTR2 Angiotensin II Receptor Type 2 QT00197540 81 
APLNR Apelin Receptor QT00254275 92 
AVPR1A Arginine Vasopressin Receptor 1A QT00113169 133 
AVPR1B Arginine Vasopressin Receptor 1B QT01753941 134 
AVPR2 Arginine Vasopressin Receptor 2 QT00315315 102 
BAI1 Adhesion G Protein-Coupled Receptor B1 QT00123228 85 
BAI2 Adhesion G Protein-Coupled Receptor B2 QT00158732 129 
BAI3 Adhesion G Protein-Coupled Receptor B3 QT01062873 117 
BDKRB1 Bradykinin Receptor B1 QT00326886 70 
BDKRB2 Bradykinin Receptor B2 QT00111027 84 
BRS3 Bombesin-Like Receptor 3 QT00250222 100 
C3AR1 Complement Component 3a Receptor 1 QT02380581 150 
C5AR1 Complement Component 5a Receptor 1 QT01164723 119 
CALCR Calcitonin Receptor QT00108864 100 
CALCRL Calcitonin Receptor-Like QT00128786 146 
CASR Calcium-Sensing Receptor QT00134015 61 
CCBP2 Atypical Chemokine Receptor 2 QT00154105 129 
CCKAR Cholecystokinin A Receptor QT00099673 101 
CCKBR Cholecystokinin B Receptor QT00128597 122 
















CCR10 Chemokine (C-C Motif) Receptor 10 QT00260673 125 
CCR2 Chemokine (C-C Motif) Receptor 2 QT02522849 149 
CCR3 Chemokine (C-C Motif) Receptor 3 QT00262822 109 
CCR4 Chemokine (C-C Motif) Receptor 4 QT00250432 146 
CCR5 Chemokine (C-C Motif) Receptor 5 QT00114569 60 
CCR6 Chemokine (C-C Motif) Receptor 6 QT02379181 120 
CCR7 Chemokine (C-C Motif) Receptor 7 QT00240975 95 
CCR8 Chemokine (C-C Motif) Receptor 8 QT01059184 82 
CCR9 Chemokine (C-C Motif) Receptor 9 QT01165038 67 
CCRL2 Chemokine (C-C Motif) Receptor-Like 2 QT01040179 114 
CD97 Adhesion G Protein-Coupled Receptor E5 QT00198919 104 
CELSR1 Cadherin EGF LAG Seven-Pass G-Type Receptor 1 QT01748096 89 
CELSR2 Cadherin EGF LAG Seven-Pass G-Type Receptor 2 QT01536724 100 
CELSR3 Cadherin EGF LAG Seven-Pass G-Type Receptor 3 QT00123865 108 
CHRM1 Cholinergic Receptor Muscarinic 1 QT01753311 112 
CHRM2 Cholinergic Receptor Muscarinic 2 QT00290297 93 
CHRM3 Cholinergic Receptor Muscarinic 3 QT01772169 141 
CHRM4 Cholinergic Receptor Muscarinic 4 QT00313712 86 
CHRM5 Cholinergic Receptor Muscarinic 5 QT00298452 100 
CMKLR1 Chemerin Chemokine-Like Receptor 1 QT01060430 91 
CNR1 Cannabinoid Receptor 1 QT02522457 163 
CNR2 Cannabinoid Receptor 2 QT00159558 150 
CRHR1 Corticotropin Releasing Hormone Receptor 1 QT00106232 117 
CRHR2 Corticotropin Releasing Hormone Receptor 2 QT00151543 75 
CX3CR1 Chemokine (C-X3-C Motif) Receptor 1 QT00259126 63 
CXCR1 Chemokine (C-X-C Motif) Receptor 1 QT01778434 100 
CXCR2 Chemokine (C-X-C Motif) Receptor 2 QT00283696 80 
CXCR3 Chemokine (C-X-C Motif) Receptor 3 QT00249438 109 
CXCR4 Chemokine (C-X-C Motif) Receptor 4 QT00249305 106 
CXCR5 Chemokine (C-X-C Motif) Receptor 5 QT00253449 118 
CXCR6 Chemokine (C-X-C Motif) Receptor 6 QT02528806 135 
CXCR7 Chemokine (C-X-C Motif) Receptor 7 QT00254443 88 
CYSLTR1 Cysteinyl Leukotriene Receptor 1 QT01756503 68 
CYSLTR2 Cysteinyl Leukotriene Receptor 2 QT00136885 99 
















DRD1A Dopamine Receptor D1 QT00263396 104 
DRD2 Dopamine Receptor D2 QT01169063 126 
DRD3 Dopamine Receptor D3 QT00170527 78 
DRD4 Dopamine Receptor D4 QT00125489 137 
DRD5 Dopamine Receptor D5 QT00281596 142 
EDNRA Endothelin Receptor Type A QT00121625 101 
EDNRB Endothelin Receptor Type B QT00139384 129 
ELTD1 
EGF Latrophilin And Seven Transmembrane Domain-
Containing Protein 1 
QT00170051 92 
EMR1 
Egf-Like Module Containing Mucin-Like Hormone 
Receptor-Like 1 
QT00099617 87 
F2R Coagulation Factor II (Thrombin) Receptor QT00119812 125 
F2RL1 Coagulation Factor II (Thrombin) Receptor-Like 1 QT02255330 88 
F2RL2 Coagulation Factor II (Thrombin) Receptor-Like 2 QT00101178 146 
F2RL3 Coagulation Factor II (Thrombin) Receptor-Like 3 QT00252168 129 
FFAR1 Free Fatty Acid Receptor 1 QT00308833 70 
FFAR2 Free Fatty Acid Receptor 2 QT00128226 61 
FFAR3 Free Fatty Acid Receptor 3 QT00303499 99 
FPR1 Formyl Peptide Receptor 1 QT01165899 123 
FPR2 Formyl Peptide Receptor 2 QT00171514 73 
FPR3 Formyl Peptide Receptor 3 QT01063216 111 
FSHR Follicle Stimulating Hormone Receptor QT00122472 92 
FZD1 Frizzled Class Receptor 1 QT00290542 126 
FZD10 Frizzled Class Receptor 10 QT00279979 72 
FZD2 Frizzled Class Receptor 2 QT00261485 148 
FZD3 Frizzled Class Receptor 3 QT00147917 101 
FZD4 Frizzled Class Receptor 4 QT00260526 125 
FZD5 Frizzled Class Receptor 5 QT01063461 149 
FZD6 Frizzled Class Receptor 6 QT00109998 98 
FZD7 Frizzled Class Receptor 7 QT00307797 120 
FZD8 Frizzled Class Receptor 8 QT02328151 83 
FZD9 Frizzled Class Receptor 9 QT00248906 108 
GABBR1 Gamma-Aminobutyric Acid (GABA) B Receptor 1 QT01052541 114 
GABBR2 Gamma-Aminobutyric Acid (GABA) B Receptor 2 QT01045912 105 
GALR1 Galanin Receptor 1 QT00108969 107 
GALR2 Galanin Receptor 2 QT00262836 61 
GALR3 Galanin Receptor 3 QT00326081 113 
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GCGR Glucagon Receptor QT00112560 84 
GHRHR Growth Hormone Releasing Hormone Receptor QT01062243 107 
GHSR Growth Hormone Secretagogue Receptor QT00138439 121 
GIPR Gastric Inhibitory Polypeptide Receptor QT01564913 132 
GLP2R Glucagon-Like Peptide 2 Receptor QT01744197 116 
GNRHR Gonadotropin-Releasing Hormone Receptor QT00107205 109 
GPBAR1 G Protein-Coupled Bile Acid Receptor 1 QT01038471 95 
GPER G Protein-Coupled Estrogen Receptor 1 QT00260659 110 
GPR1 G Protein-Coupled Receptor 1 QT00124341 110 
GPR101 G Protein-Coupled Receptor 101 QT00309512 89 
GPR110 G Protein-Coupled Receptor 110 QT00198170 62 
GPR111 G Protein-Coupled Receptor 111 QT01162679 121 
GPR112 G Protein-Coupled Receptor 112 QT02327584 119 
GPR113 G Protein-Coupled Receptor 113 QT01168748 140 
GPR114 G Protein-Coupled Receptor 114 QT01161699 75 
GPR115 G Protein-Coupled Receptor 115 QT01753808 91 
GPR116 G Protein-Coupled Receptor 116 QT01070272 77 
GPR119 G Protein-Coupled Receptor 119 QT01758953 99 
GPR12 G Protein-Coupled Receptor 12 QT01062656 140 
GPR120 G Protein-Coupled Receptor 120 QT00257033 97 
GPR123 G Protein-Coupled Receptor 123 QT01069404 94 
GPR124 G Protein-Coupled Receptor 124 QT00129731 91 
GPR125 G Protein-Coupled Receptor 125 QT01057294 88 
GPR126 G Protein-Coupled Receptor 126 QT01065862 145 
GPR128 G Protein-Coupled Receptor 128 QT02248449 110 
GPR132 G Protein-Coupled Receptor 132 QT00249900 103 
GPR133 G Protein-Coupled Receptor 133 QT01775907 105 
GPR135 G Protein-Coupled Receptor 135 QT01040977 137 
GPR137 G Protein-Coupled Receptor 137 QT00158263 73 
GPR139 G Protein-Coupled Receptor 139 QT00306803 111 
GPR141 G Protein-Coupled Receptor 141 QT01163561 85 
GPR142 G Protein-Coupled Receptor 142 QT01040298 66 
GPR143 G Protein-Coupled Receptor 143 QT00494613 126 
GPR144 G Protein-Coupled Receptor 144 QT02303084 90 
















GPR149 G Protein-Coupled Receptor 149 QT00123578 116 
GPR15 G Protein-Coupled Receptor 15 QT00283717 77 
GPR150 G Protein-Coupled Receptor 150 QT00279293 98 
GPR151 G Protein-Coupled Receptor 151 QT00281085 136 
GPR152 G Protein-Coupled Receptor 152 QT00267477 83 
GPR153 G Protein-Coupled Receptor 153 QT00117859 98 
GPR156 G Protein-Coupled Receptor 156 QT00140784 73 
GPR157 G Protein-Coupled Receptor 157 QT01061284 135 
GPR158 G Protein-Coupled Receptor 158 QT01059142 101 
GPR160 G Protein-Coupled Receptor 160 QT01075375 90 
GPR161 G Protein-Coupled Receptor 161 QT01064399 81 
GPR162 G Protein-Coupled Receptor 162 QT00098973 68 
GPR17 G Protein-Coupled Receptor 17 QT01043707 77 
GPR171 G Protein-Coupled Receptor 171 QT01050700 96 
GPR173 G Protein-Coupled Receptor 173 QT01164716 111 
GPR174 G Protein-Coupled Receptor 174 QT01542695 149 
GPR176 G Protein-Coupled Receptor 176 QT00126532 78 
GPR179 G Protein-Coupled Receptor 179 QT02243598 84 
GPR18 G Protein-Coupled Receptor 18 QT00129227 129 
GPR182 G Protein-Coupled Receptor 182 QT01163666 87 
GPR183 G Protein-Coupled Receptor 183 QT00295785 100 
GPR19 G Protein-Coupled Receptor 19 QT02242415 106 
GPR20 G Protein-Coupled Receptor 20 QT00266735 141 
GPR21 G Protein-Coupled Receptor 21 QT00322035 108 
GPR22 G Protein-Coupled Receptor 22 QT00131775 63 
GPR25 G Protein-Coupled Receptor 25 QT02270226 109 
GPR26 G Protein-Coupled Receptor 26 QT00285215 68 
GPR27 G Protein-Coupled Receptor 27 QT01062754 105 
GPR3 G Protein-Coupled Receptor 3 QT00249732 92 
GPR34 G Protein-Coupled Receptor 34 QT00168938 101 
GPR35 G Protein-Coupled Receptor 35 QT00495411 107 
GPR37 G Protein-Coupled Receptor 37 QT01062747 95 
GPR37L1 G Protein-Coupled Receptor 37 Like 1 QT00157409 77 
GPR39 G Protein-Coupled Receptor 39 QT00315028 140 
















GPR45 G Protein-Coupled Receptor 45 QT00258657 99 
GPR50 G Protein-Coupled Receptor 50 QT00124117 98 
GPR52 G Protein-Coupled Receptor 52 QT01071847 148 
GPR56 G Protein-Coupled Receptor 56 QT01060472 98 
GPR6 G Protein-Coupled Receptor 6 QT00296044 119 
GPR61 G Protein-Coupled Receptor 61 QT00125755 97 
GPR62 G Protein-Coupled Receptor 62 QT00302393 67 
GPR63 G Protein-Coupled Receptor 63 QT00136920 73 
GPR64 G Protein-Coupled Receptor 64 QT00142149 131 
GPR65 G Protein-Coupled Receptor 65 QT00144774 84 
GPR68 G Protein-Coupled Receptor 68 QT02392397 85 
GPR75 G Protein-Coupled Receptor 75 QT02530157 154 
GPR77 G Protein-Coupled Receptor 77 QT02532803 87 
GPR82 G Protein-Coupled Receptor 82 QT00126784 144 
GPR83 G Protein-Coupled Receptor 83 QT00104216 85 
GPR84 G Protein-Coupled Receptor 84 QT00279888 117 
GPR85 G Protein-Coupled Receptor 85 QT00281022 128 
GPR87 G Protein-Coupled Receptor 87 QT01038856 150 
GPR88 G Protein-Coupled Receptor 88 QT02263681 121 
GPR97 G Protein-Coupled Receptor 97 QT01053227 169 
GPR98 G Protein-Coupled Receptor 98 QT01061340 95 
GPRC5A G Protein-Coupled Receptor Class C Group 5 Member A QT00104832 141 
GPRC5B G Protein-Coupled Receptor Class C Group 5 Member B QT00124348 75 
GPRC5C G Protein-Coupled Receptor Class C Group 5 Member C QT00148582 157 
GPRC5D G Protein-Coupled Receptor Class C Group 5 Member D QT00132363 93 
GPRC6A 
G Protein-Coupled Receptor Class C Group 5 Member 
6A 
QT00147098 149 
GRM1 Glutamate Receptor Metabotropic 1 QT00175042 84 
GRM2 Glutamate Receptor Metabotropic 2 QT02327822 123 
GRM3 Glutamate Receptor Metabotropic 3 QT00171542 68 
GRM4 Glutamate Receptor Metabotropic 4 QT01072855 60 
GRM5 Glutamate Receptor Metabotropic 5 QT01552117 146 
GRM6 Glutamate Receptor Metabotropic 6 QT00133525 148 
GRM7 Glutamate Receptor Metabotropic 7 QT01167509 83 
GRM8 Glutamate Receptor Metabotropic 8 QT00169267 92 
















HCRTR1 Hypocretin (Orexin) Receptor 1 QT01755054 128 
HCRTR2 Hypocretin (Orexin) Receptor 2 QT00171430 89 
HRH1 Histamine Receptor H1 QT01161300 109 
HRH2 Histamine Receptor H2 QT01039157 80 
HRH3 Histamine Receptor H3 QT00158375 85 
HRH4 Histamine Receptor H4 QT00135884 150 
HTR1A 5-hydroxytryptamine receptor 1A QT00250516 76 
HTR1B 5-hydroxytryptamine receptor 1B QT01039913 119 
HTR1D 5-hydroxytryptamine receptor 1D QT01759156 101 
HTR1F 5-hydroxytryptamine receptor 1F QT00102242 76 
HTR2A 5-hydroxytryptamine receptor 2A QT00282947 125 
HTR2B 5-hydroxytryptamine receptor 2B QT00144704 151 
HTR2C 5-hydroxytryptamine receptor 2C QT00144403 175 
HTR4 5-hydroxytryptamine receptor 4 QT00108143 104 
HTR5A 5-hydroxytryptamine receptor 5A QT00248290 133 
HTR6 5-hydroxytryptamine receptor 6 QT00261870 126 
HTR7 5-hydroxytryptamine receptor 7 QT00150346 100 
KISS1R Kisspeptins Receptor QT00140427 123 
LGR4 








Leucine-Rich Repeat Containing G Protein-Coupled 
Receptor 6 
QT02525292 93 
LHCGR Luteinizing Hormone/Choriogonadotropin Receptor QT00101990 83 
LPAR1 Lysophosphatidic Acid Receptor 1 QT00107709 94 
LPAR2 Lysophosphatidic Acid Receptor 2 QT00106008 94 
LPAR3 Lysophosphatidic Acid Receptor 3 QT00264320 99 
LPAR4 Lysophosphatidic Acid Receptor 4 QT00125888 96 
LPAR5 Lysophosphatidic Acid Receptor 5 QT00312571 100 
LPAR6 Lysophosphatidic Acid Receptor 6 QT00325668 118 
LPHN1 Calcium-Independent Alpha-Latrotoxin Receptor 1 QT01048292 91 
LPHN2 Calcium-Independent Alpha-Latrotoxin Receptor 2 QT02284037 119 
LPHN3 Calcium-Independent Alpha-Latrotoxin Receptor 3 QT01066856 104 
LTB4R Leukotriene B4 Receptor QT00197897 110 
LTB4R2 Leukotriene B4 Receptor 2 QT01054935 158 
MAS1 Mas-Related G Protein-Coupled Receptor A QT02257157 72 
MC1R Melanocortin 1 Receptor QT00305011 110 
144 
 












MC2R Melanocortin 2 Receptor QT01066338 89 
MC3R Melanocortin 3 Receptor QT00264404 108 
MC4R Melanocortin 4 Receptor QT00280861 106 
MC5R Melanocortin 5 Receptor QT01166494 90 
MCHR1 Melanin-Concentrating Hormone Receptor 1 QT00312291 134 
MRGPRD MAS-Related GPR Member D QT01078917 115 
MRGPRE MAS-Related GPR Member E QT00282205 80 
MRGPRF MAS-Related GPR Member F QT01078924 126 
MRGPRG MAS-Related GPR Member G QT00298480 77 
MRGPRX1 MAS-Related GPR Member X1 QT02330237 67 
MRGPRX2 MAS-Related GPR Member X2 QT02530808 139 
MTNR1A Melatonin Receptor 1A QT00253029 82 
MTNR1B Melatonin Receptor 1B QT01040648 84 
NMBR Neuromedin B Receptor QT00312494 112 
NMUR1 Neuromedin U Receptor 1 QT00174006 110 
NMUR2 Neuromedin U Receptor 2 QT00137998 106 
NPBWR1 Neuropeptides B/W Receptor 1 QT00299040 84 
NPFFR1 Neuropeptide FF Receptor 1 QT02528113 113 
NPFFR2 Neuropeptide FF Receptor 2 QT00303975 69 
NPSR Neuropeptide S Receptor 1 QT00152180 121 
NPY1R Neuropeptide Y Receptor Y1 QT00249746 134 
NPY2R Neuropeptide Y Receptor Y2 QT01744036 91 
NPY5R Neuropeptide Y Receptor Y5 QT00109088 146 
NTSR1 Neurotensin Receptor 1 QT00163373 104 
NTSR2 Neurotensin Receptor 1 QT00165151 81 
OPN3 Opsin 3 QT00120218 112 
OPN5 Opsin 5 QT00140406 101 
OPRD1 Opioid Receptor Delta 1 QT00103250 147 
OPRK1 Opioid Receptor Kappa 1 QT00101549 73 
OPRL1 Opiate Receptor-Like 1 QT00300811 114 
OPRM1 Opioid Receptor Mu 1 QT01770811 119 
OXGR1 Oxoglutarate (Alpha-Ketoglutarate) Receptor 1 QT01160943 78 
OXTR Oxytocin Receptor QT01778427 75 
P2RY1 Purinergic Receptor P2Y1 QT00158340 96 
P2RY10 Purinergic Receptor P2Y, G-Protein Coupled 10 QT00494732 300 
P2RY12 Purinergic Receptor P2Y, G-Protein Coupled 12 QT02527000 125 
145 
 












P2RY13 Purinergic Receptor P2Y, G-Protein Coupled 13 QT00124285 73 
P2RY14 Purinergic Receptor P2Y, G-Protein Coupled 14 QT00173264 149 
P2RY2 Purinergic Receptor P2Y, G-Protein Coupled 2 QT00097202 102 
P2RY4 Purinergic Receptor P2Y, G-Protein Coupled 4 QT02332764 107 
P2RY6 Purinergic Receptor P2Y, G-Protein Coupled 6 QT00150010 63 
PPYR1 Pancreatic Polypeptide Receptor 1 QT00128121 122 
PRLHR Prolactin Releasing Hormone Receptor QT00326172 60 
PROKR1 Prokineticin Receptor 1 QT00314846 91 
PROKR2 Prokineticin Receptor 2 QT00157654 78 
PTAFR Platelet-Activating Factor Receptor QT00262990 89 
PTGDR Prostaglandin D2 Receptor QT00114310 69 
PTGER1 Prostaglandin E Receptor 1 QT00173936 134 
PTGER2 Prostaglandin E Receptor 2 QT00115276 68 
PTGER3 Prostaglandin E Receptor 3 QT00254303 116 
PTGER4 Prostaglandin E Receptor 4 QT00248948 93 
PTGFR Prostaglandin F Receptor QT00170562 150 
PTGIR Prostaglandin I2 (Prostacyclin) Receptor QT00160062 120 
PTH1R Parathyroid Hormone 1 Receptor QT01057784 107 
PTH2R Parathyroid Hormone 2 Receptor QT00164647 89 
QRFPR Pyroglutamylated RFamide Peptide Receptor QT02331175 106 
RAMP1 Receptor (G Protein-Coupled) Activity Modifying Protein 1 QT02279109 150 
RAMP2 Receptor (G Protein-Coupled) Activity Modifying Protein 2 QT00161056 150 
RAMP3 Receptor (G Protein-Coupled) Activity Modifying Protein 3 QT00118657 74 
RXFP1 Relaxin/Insulin-Like Family Peptide Receptor 1 QT00172382 89 
RXFP2 Relaxin/Insulin-Like Family Peptide Receptor 2 QT00131124 80 
RXFP3 Relaxin/Insulin-Like Family Peptide Receptor 3 QT00285222 103 
RXFP4 Relaxin/Insulin-Like Family Peptide Receptor 4 QT01040375 146 
S1PR1 Sphingosine-1-Phosphate Receptor 1 QT00243628 129 
S1PR2 Sphingosine-1-Phosphate Receptor 2 QT00262773 87 
S1PR3 Sphingosine-1-Phosphate Receptor 3 QT00132160 154 
S1PR4 Sphingosine-1-Phosphate Receptor 4 QT00260141 98 
S1PR5 Sphingosine-1-Phosphate Receptor 5 QT00282744 134 
SCTR Secretin Receptor QT01066646 72 
SMO Smoothened Frizzled Class Receptor QT00494683 104 
SSTR1 Somatostatin Receptor 1 QT01761137 98 
SSTR2 Somatostatin Receptor 2 QT01539111 150 
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SSTR3 Somatostatin Receptor 3 QT01162637 97 
SSTR4 Somatostatin Receptor 4 QT02264661 128 
SSTR5 Somatostatin Receptor 5 QT01162630 124 
SUCNR1 Succinate Receptor 1 QT00127582 118 
TAAR1 Trace Amine Associated Receptor 1 QT01041936 93 
TAAR2 Trace Amine Associated Receptor 2 QT01066968 140 
TAAR5 Trace Amine Associated Receptor 5 QT01064007 127 
TAAR6 Trace Amine Associated Receptor 6 QT00360990 133 
TAAR8A Trace Amine Associated Receptor 8A QT00361382 88 
TAAR8B Trace Amine Associated Receptor 8B QT00354837 88 
TAAR8C Trace Amine Associated Receptor 8C QT00331485 88 
TAAR9 Trace Amine Associated Receptor 9 QT01071490 97 
TACR1 Tachykinin Receptor 1 QT00103334 110 
TACR2 Tachykinin Receptor 2 QT00493199 120 
TACR3 Tachykinin Receptor 3 QT00134036 109 
TAS1R1 Taste Receptor, Type 1, Member 1 QT00121870 92 
TAS1R3 Taste Receptor, Type 1, Member 3 QT00309890 110 
TAS2R31 Taste Receptor, Type 2, Member 31 QT00327621 68 
TBXA2R Thromboxane A2 Receptor QT01160873 92 
TRHR Thyrotropin-Releasing Hormone Receptor QT00161931 108 
TSHR Thyroid Stimulating Hormone Receptor QT00136955 63 
UTS2R Urotensin 2 Receptor QT01040263 112 
VIPR1 Vasoactive Intestinal Peptide Receptor 1 QT00167160 149 
VIPR2 Vasoactive Intestinal Peptide Receptor 2 QT00106463 97 

























GAPDH Glyceraldehyde 3-phosphate Dehydrogenase QT01658692 144 
PRL1 Prolactin QT00102977 92 
PRL3B1 Placental Lactogen-II QT00123060 64 
PRL3D1 Placental Lactogen-I QT01052219 133 









































Table A3.1 Quantifiable GPCR gene expression in mouse pancreatic islets on 
gestational day 12, compared to non-pregnant and gestational day 18 expression 
levels. Trace – detectable but not quantifiable gene expression, Not detectable – not 




Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in  
gestational day 12 
islets relative to 
GAPDH 
Mean expression in  
gestational day 18 
islets relative to 
GAPDH 
ADCYAP1R1 2.45E-03 2.82E-03 6.28E-03 
ADORA1 2.01E-02 9.03E-03 3.35E-02 
ADORA2A 4.48E-03 7.14E-03 6.09E-03 
ADORA2B 7.58E-03 6.56E-03 1.18E-02 
ADORA3 2.20E-02 9.15E-03 1.60E-02 
ADRA1A 6.65E-04 3.66E-03 3.34E-03 
ADRA1D 7.90E-04 5.64E-04 Not detectable 
ADRA2A 6.71E-02 5.22E-02 2.02E-01 
ADRA2C 3.33E-04 1.18E-03 Not detectable 
ADRB1 7.74E-03 2.57E-03 8.54E-03 
ADRB2 6.94E-03 3.81E-03 1.78E-02 
AGTR1 5.05E-03 6.31E-03 9.42E-03 
APLNR 6.94E-03 3.39E-03 3.16E-03 
AVPR1A 5.83E-04 6.20E-04 1.28E-02 
AVPR1B 2.47E-03 4.38E-03 1.27E-03 
AVPR2   Not detectable 5.49E-04 Not detectable 
BAI1 7.97E-04 9.27E-04 Not detectable 
BAI2 1.09E-03 1.10E-03 8.74E-04 
BAI3 2.58E-02 1.47E-02 2.15E-02 
BDKRB1 3.05E-04 8.85E-05 2.36E-03 
BDKRB2 6.50E-03 5.81E-03 3.00E-02 
BRS3 5.03E-04 6.51E-04 Trace 
C3AR1 8.00E-03 1.05E-02 5.47E-03 
C5AR1 4.82E-04 6.49E-04 5.51E-04 
CALCRL 2.25E-02 1.70E-02 3.16E-02 
CASR 6.88E-02 4.55E-02 5.06E-02 
CCKAR 3.42E-01 2.46E-02 7.93E-04 
CCKBR 1.14E-03 4.75E-04 Not detectable 
CCR1 7.34E-04 6.05E-04 1.31E-03 
CCR10 2.32E-03 1.59E-03 2.50E-03 
CCR2 1.03E-03 9.65E-04 3.82E-03 
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Table A3.1. Continued.  
 
Gene 
Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in  
gestational day 12 
islets relative to 
GAPDH 
Mean expression in  
gestational day 18 
islets relative to 
GAPDH 
CCR3 2.37E-03 3.05E-04 Trace 
CCR4 9.97E-04 7.27E-04 6.09E-04 
CCR5 1.62E-03 6.34E-04 1.88E-03 
CCR6 7.33E-04 5.51E-04 1.25E-02 
CCRL2 1.70E-02 8.27E-03 1.58E-02 
CD97 1.44E-02 1.02E-02 2.59E-02 
CELSR1 9.50E-02 6.30E-03 1.37E-02 
CELSR2 9.98E-03 1.08E-02 1.88E-02 
CELSR3 3.95E-02 9.36E-02 1.40E-01 
CHRM1 1.03E-03 1.27E-03 7.68E-04 
CHRM2 4.33E-03 3.79E-03 1.17E-02 
CHRM3 3.76E-02 4.31E-02 8.69E-02 
CHRM4 5.56E-03 1.36E-02 8.74E-03 
CMKLR1 2.86E-03 2.62E-03 3.64E-03 
CRHR1 7.08E-03 5.98E-03 1.49E-03 
CRHR2 1.84E-03 2.42E-03 1.25E-03 
CX3CR1 4.08E-03 5.46E-03 1.15E-02 
CXCR3 Not detectable 3.92E-04 Trace 
CXCR4 1.38E-02 7.66E-03 1.91E-02 
CXCR5 2.15E-03 1.03E-03 Trace 
CXCR7 1.25E-02 1.84E-02 9.39E-03 
CYSLTR1 1.71E-03 1.01E-03 2.12E-03 
DARC 1.19E-03 7.38E-03 1.56E-03 
Drd1a 1.33E-03 5.22E-04 Trace 
DRD2 1.20E-03 1.64E-03 1.74E-03 
DRD3 2.58E-04 3.16E-04 3.68E-04 
EDNRA 1.79E-02 1.56E-02 2.06E-02 
EDNRB 1.37E-02 1.05E-02 4.43E-02 
ELTD1 3.96E-02 3.34E-02 5.64E-02 
EMR1 3.04E-03 2.49E-03 6.78E-03 
F2R 1.33E-02 1.54E-02 1.56E-02 
F2RL2 7.92E-04 1.26E-03 4.28E-04 
F2RL3 2.50E-03 9.54E-04 2.73E-03 
FFAR1 2.58E-01 2.04E-01 2.21E-01 
FFAR2 1.15E-02 5.25E-03 1.62E-02 
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Table A3.1. Continued.  
 
Gene 
Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in  
gestational day 18 
islets relative to 
GAPDH 
FFAR3 3.45E-02 1.79E-02 4.86E-02 
FZD1 4.14E-03 1.88E-03 3.17E-03 
FZD3 7.89E-02 4.73E-02 7.03E-02 
FZD4 1.18E-02 2.73E-03 2.22E-02 
FZD6 8.62E-03 4.42E-03 6.86E-03 
FZD7 1.07E-02 2.87E-03 2.68E-02 
FZD8 1.45E-02 1.52E-02 1.72E-02 
FZD9 1.42E-03 3.43E-04 3.36E-04 
GABBR1 4.51E-02 1.91E-02 1.42E-01 
GABBR2 6.02E-02 9.78E-02 3.25E-01 
GALR1 9.72E-02 1.14E-01 9.98E-02 
GALR2 2.88E-03 1.72E-03 6.56E-03 
GALR3 1.14E-01 1.00E-01 2.39E-01 
GCGR 3.87E-02 3.33E-02 7.32E-02 
GIPR 8.33E-02 1.46E-01 5.14E-01 
GPBAR1 1.36E-03 9.63E-04 9.86E-04 
GPER 1.76E-02 3.99E-03 4.49E-03 
GPR112 Trace 2.26E-04 Not detectable 
GPR116 8.04E-02 2.76E-02 5.14E-02 
GPR119 1.33E-02 2.30E-02 7.08E-03 
GPR12 Not detectable 1.14E-03 Not detectable 
GPR120 1.45E-02 2.60E-02 8.38E-03 
GPR123 2.16E-03 1.34E-03 1.92E-03 
GPR124 3.21E-02 9.82E-03 4.24E-03 
GPR125 3.73E-02 7.35E-03 1.51E-02 
GPR126 9.53E-03 2.75E-03 2.07E-03 
GPR132 2.59E-03 1.45E-03 1.57E-03 
GPR133 5.05E-03 1.05E-03 1.57E-03 
GPR135 5.60E-03 6.71E-03 2.59E-03 
GPR139 9.76E-04 7.93E-04 Not detectable 
GPR141 Not detectable 1.10E-04 Not detectable 
GPR142 3.83E-02 2.83E-02 2.63E-02 
GPR15 7.81E-04 1.91E-04 2.96E-04 
GPR150 2.56E-03 7.36E-04 7.21E-04 
GPR151 5.51E-03 7.33E-04 6.92E-03 
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Table A3.1. Continued.  
 
Gene 
Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in  
gestational day 18 
islets relative to 
GAPDH 
GPR152 1.09E-03 4.33E-04 Not detectable 
GPR153 1.15E-02 5.47E-03 8.89E-03 
GPR157 1.03E-02 1.76E-02 2.06E-02 
GPR158 1.01E-01 2.08E-01 1.78E-01 
GPR160 1.16E-03 1.31E-03 4.39E-04 
GPR161 2.91E-02 2.24E-02 2.02E-02 
GPR162 Not detectable 2.58E-03 5.68E-03 
GPR17 Trace 7.27E-05 Trace 
GPR171 1.80E-02 6.10E-04 7.45E-03 
GPR173 Not detectable 3.50E-04 Not detectable 
GPR179 3.04E-03 1.53E-03 2.33E-03 
GPR18 1.06E-02 5.74E-04 6.03E-04 
GPR182 1.78E-02 1.34E-03 1.82E-03 
GPR183 5.21E-02 1.15E-03 4.21E-03 
GPR19 8.17E-02 1.15E-02 2.85E-02 
GPR20 7.05E-03 4.87E-04 4.52E-03 
GPR25 5.35E-03 1.13E-03 Not detectable 
GPR26 4.71E-04 1.68E-03 7.53E-03 
GPR27 8.96E-02 6.37E-02 5.40E-02 
GPR3 4.38E-03 4.36E-04 6.09E-04 
GPR34 4.92E-03 4.61E-04 9.88E-04 
GPR37L1 1.61E-03 5.50E-04 6.28E-04 
GPR39 2.43E-01 1.55E-02 4.33E-02 
GPR4 1.31E-01 7.29E-03 3.50E-02 
GPR52 1.72E-02 1.27E-03 4.73E-03 
GPR56 6.03E-01 6.19E-01 5.14E-01 
GPR62 1.07E-02 4.69E-03 9.82E-03 
GPR65 Trace 3.05E-03 1.32E-02 
GPR77 Trace 1.48E-03 7.52E-04 
GPR84 3.54E-03 1.27E-03 Trace 
GPR85 3.59E-02 9.24E-03 2.88E-02 
GPR87 1.35E-02 6.65E-04 6.50E-03 
GPR88 Not detectable 1.24E-04 Not detectable 
GPR98 6.21E-02 1.24E-03 2.58E-02 
GPRC5A 6.17E-03 3.19E-03 3.72E-03 
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Table A3.1. Continued.  
 
Gene 
Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in  
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
GPRC5C 1.18E-01 1.59E-02 8.85E-02 
GPRC6A 8.35E-03 3.05E-03 2.08E-03 
GRM7 4.54E-03 7.32E-04 Not detectable 
HRH3 2.91E-03 5.97E-04 Trace 
HTR1B 3.44E-03 6.48E-04 1.64E-03 
HTR2B Not detectable 2.97E-04 Not detectable 
KISS1R 8.20E-03 1.67E-03 7.71E-03 
LGR4 7.42E-02 4.33E-02 3.52E-02 
LPAR3 2.13E-03 7.20E-04 Not detectable 
LPAR4 3.21E-04 2.05E-04 5.33E-04 
LPAR5 3.17E-03 9.81E-04 4.84E-04 
LPAR6 7.99E-02 1.56E-02 5.41E-02 
LPHN1 5.08E-01 9.20E-02 2.49E-01 
LPHN2 2.15E-02 5.90E-03 1.46E-02 
MC1R 1.10E-03 8.06E-04 Not detectable 
MC4R 2.59E-03 2.84E-03 2.07E-03 
MRGPRE 6.51E-02 2.81E-02 3.06E-02 
MRGPRF 4.87E-03 6.54E-03 Not detectable 
MRGPRG 6.57E-04 1.44E-04 6.79E-04 
NMBR Not detectable 1.09E-03 4.91E-04 
NPFFR2 Trace 1.14E-03 9.07E-04 
NPY1R 1.31E-03 1.79E-04 1.82E-03 
OPN3 7.65E-03 6.44E-03 2.54E-03 
OPRL1 1.59E-02 2.80E-03 1.89E-03 
OXTR 5.56E-02 3.35E-02 2.09E-02 
P2RY1 2.02E-02 6.57E-03 9.87E-03 
P2RY12 1.28E-02 2.40E-03 2.28E-03 
P2RY13 2.59E-03 1.33E-03 9.19E-04 
P2RY14 5.53E-03 4.23E-03 Not detectable 
P2RY2 6.78E-03 1.50E-03 3.69E-03 
P2RY4 2.16E-03 1.71E-03 Trace 
P2RY6 3.10E-03 1.63E-03 2.45E-03 
PTGER1 Not detectable 5.95E-04 Not detectable 
PTGIR 2.87E-03 9.57E-04 1.73E-03 
RAMP1 2.04E-02 1.66E-02 1.48E-02 
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Mean expression in  
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12  
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
RAMP2 Not detectable 5.33E-03 4.99E-02 
RAMP3 2.93E-03 5.29E-03 2.50E-02 
S1PR1 5.36E-02 3.73E-02 4.67E-02 
S1PR2 2.49E-03 3.19E-04 1.14E-03 
S1PR4 Not detectable 9.10E-04 1.85E-03 
SCTR 2.32E-03 6.43E-04 1.84E-03 
SMO 1.48E-02 3.81E-03 6.08E-03 
SSTR1 Trace 6.26E-04 1.19E-03 
SSTR2 1.31E-02 7.77E-03 4.39E-03 
SSTR4 2.19E-03 1.85E-04 8.95E-03 
SUCNR1 Trace 8.85E-04 Not detectable 
TAAR1 8.27E-02 7.71E-03 1.14E-02 
TACR1 No expr 7.85E-04 Not detectable 
TAS1R3 5.17E-02 7.25E-03 1.51E-02 
TBXA2R 4.47E-03 4.51E-04 1.01E-03 
VIPR1 1.75E-01 2.92E-02 5.09E-02 
VIPR2 2.12E-03 2.56E-03 2.72E-03 
XCR1 6.28E-03 1.46E-03 6.47E-04 
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Table A3.2. Quantifiable GPCR gene expression in mouse pancreatic islets on 
gestational day 18, compared to non-pregnant and gestational day 12 expression 
levels. Trace – detectable but not quantifiable gene expression, Not detectable – not 
detectable gene expression, n = 3-8. 
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
ADCYAP1R1 2.45E-03 2.82E-03 6.28E-03 
ADORA1 2.01E-02 9.03E-03 3.35E-02 
ADORA2A 4.48E-03 7.14E-03 6.09E-03 
ADORA2B 7.58E-03 6.56E-03 1.18E-02 
ADORA3 2.20E-02 9.15E-03 1.60E-02 
ADRA1A 6.65E-04 3.66E-03 3.34E-03 
ADRA2A 6.71E-02 5.22E-02 2.02E-01 
ADRA2B 1.95E-03 Trace 1.31E-03 
ADRB1 7.74E-03 2.57E-03 8.54E-03 
ADRB2 6.94E-03 3.81E-03 1.78E-02 
AGTR1 5.05E-03 6.31E-03 9.42E-03 
APLNR 6.94E-03 3.39E-03 3.16E-03 
AVPR1A 5.83E-04 6.20E-04 1.28E-02 
AVPR1B 2.47E-03 4.38E-03 1.27E-03 
BAI2 1.09E-03 1.10E-03 8.74E-04 
BAI3 2.58E-02 1.47E-02 2.15E-02 
BDKRB1 3.05E-04 8.85E-05 2.36E-03 
BDKRB2 6.50E-03 5.81E-03 3.00E-02 
C3AR1 8.00E-03 1.05E-02 5.47E-03 
C5AR1 4.82E-04 6.49E-04 5.51E-04 
CALCRL 2.25E-02 1.70E-02 3.16E-02 
CASR 6.88E-02 4.55E-02 5.06E-02 
CCBP2 Trace Trace 2.69E-03 
CCKAR 3.42E-01 2.46E-02 7.93E-04 
CCR1 7.34E-04 6.05E-04 1.31E-03 
CCR10 2.32E-03 1.59E-03 2.50E-03 
CCR2 1.03E-03 9.65E-04 3.82E-03 
CCR4 9.97E-04 7.27E-04 6.09E-04 
CCR5 1.62E-03 6.34E-04 1.88E-03 
CCR6 7.33E-04 5.51E-04 1.25E-02 
CCRL2 1.70E-02 8.27E-03 1.58E-02 
CD97 1.44E-02 1.02E-02 2.59E-02 
CELSR1 9.50E-02 6.30E-03 1.37E-02 
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Table A3.2. Continued.  
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18  
islets relative to 
GAPDH 
CELSR2 9.98E-03 1.08E-02 1.88E-02 
CELSR3 3.95E-02 9.36E-02 1.40E-01 
CHRM1 1.03E-03 1.27E-03 7.68E-04 
CHRM2 4.33E-03 3.79E-03 1.17E-02 
CHRM3 3.76E-02 4.31E-02 8.69E-02 
CHRM4 5.56E-03 1.36E-02 8.74E-03 
CMKLR1 2.86E-03 2.62E-03 3.64E-03 
CNR1 5.40E-03 Not detectable 5.19E-03 
CNR2 Not detectable Trace 1.67E-03 
CRHR1 7.08E-03 5.98E-03 1.49E-03 
CRHR2 1.84E-03 2.42E-03 1.25E-03 
CX3CR1 4.08E-03 5.46E-03 1.15E-02 
CXCR4 1.38E-02 7.66E-03 1.91E-02 
CXCR6 3.48E-04 Not detectable 4.75E-03 
CXCR7 1.25E-02 1.84E-02 9.39E-03 
CYSLTR1 1.71E-03 1.01E-03 2.12E-03 
DARC 1.19E-03 7.38E-03 1.56E-03 
DRD2 1.20E-03 1.64E-03 1.74E-03 
DRD3 2.58E-04 3.16E-04 3.68E-04 
EDNRA 1.79E-02 1.56E-02 2.06E-02 
EDNRB 1.37E-02 1.05E-02 4.43E-02 
ELTD1 3.96E-02 3.34E-02 5.64E-02 
EMR1 3.04E-03 2.49E-03 6.78E-03 
F2R 1.33E-02 1.54E-02 1.56E-02 
F2RL1 Trace Not detectable 2.68E-03 
F2RL2 7.92E-04 1.26E-03 4.28E-04 
F2RL3 2.50E-03 9.54E-04 2.73E-03 
FFAR1 2.58E-01 2.04E-01 2.21E-01 
FFAR2 1.15E-02 5.25E-03 1.62E-02 
FFAR3 3.45E-02 1.79E-02 4.86E-02 
FZD1 4.14E-03 1.88E-03 3.17E-03 
FZD10 1.04E-03 Not detectable 2.30E-04 
FZD2 3.33E-03 Trace 1.15E-03 
FZD3 7.89E-02 4.73E-02 7.03E-02 
FZD4 1.18E-02 2.73E-03 2.22E-02 
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Table A3.2. Continued.   
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
FZD5 4.84E-04 Not detectable 2.88E-04 
FZD6 8.62E-03 4.42E-03 6.86E-03 
FZD7 1.07E-02 2.87E-03 2.68E-02 
FZD8 1.45E-02 1.52E-02 1.72E-02 
FZD9 1.42E-03 3.43E-04 3.36E-04 
GABBR1 4.51E-02 1.91E-02 1.42E-01 
GABBR2 6.02E-02 9.78E-02 3.25E-01 
GALR1 9.72E-02 1.14E-01 9.98E-02 
GALR2 2.88E-03 1.72E-03 6.56E-03 
GALR3 1.14E-01 1.00E-01 2.39E-01 
GCGR 3.87E-02 3.33E-02 7.32E-02 
GHSR 1.02E-02 Not detectable 3.73E-03 
GIPR 8.33E-02 1.46E-01 5.14E-01 
GPBAR1 1.36E-03 9.63E-04 9.86E-04 
GPER 1.76E-02 3.99E-03 4.49E-03 
GPR110 1.20E-03 Trace 3.91E-04 
GPR116 8.04E-02 2.76E-02 5.14E-02 
GPR119 1.33E-02 2.30E-02 7.08E-03 
GPR120 1.45E-02 2.60E-02 8.38E-03 
GPR123 2.16E-03 1.34E-03 1.92E-03 
GPR124 3.21E-02 9.82E-03 4.24E-03 
GPR125 3.73E-02 7.35E-03 1.51E-02 
GPR126 9.53E-03 2.75E-03 2.07E-03 
GPR132 2.59E-03 1.45E-03 1.57E-03 
GPR133 5.05E-03 1.05E-03 1.57E-03 
GPR135 5.60E-03 6.71E-03 2.59E-03 
GPR137 3.14E-03 Not detectable 2.48E-03 
GPR142 3.83E-02 2.83E-02 2.63E-02 
GPR146 1.49E-02 Not detectable 1.56E-02 
GPR15 7.81E-04 1.91E-04 2.96E-04 
GPR150 2.56E-03 7.36E-04 7.21E-04 
GPR151 5.51E-03 7.33E-04 6.92E-03 
GPR153 1.15E-02 5.47E-03 8.89E-03 
GPR157 1.03E-02 1.76E-02 2.06E-02 




Table A3.2. Continued.   
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
GPR160 1.16E-03 1.31E-03 4.39E-04 
GPR161 2.91E-02 2.24E-02 2.02E-02 
GPR162 Not detectable 2.58E-03 5.68E-03 
GPR171 1.80E-02 6.10E-04 7.45E-03 
GPR179 3.04E-03 1.53E-03 2.33E-03 
GPR18 1.06E-02 5.74E-04 6.03E-04 
GPR182 1.78E-02 1.34E-03 1.82E-03 
GPR183 5.21E-02 1.15E-03 4.21E-03 
GPR19 8.17E-02 1.15E-02 2.85E-02 
GPR20 7.05E-03 4.87E-04 4.52E-03 
GPR21 8.23E-03 Not detectable 1.17E-03 
GPR22 5.92E-03 Not detectable 1.10E-03 
GPR26 4.71E-04 1.68E-03 7.53E-03 
GPR27 8.96E-02 6.37E-02 5.40E-02 
GPR3 4.38E-03 4.36E-04 6.09E-04 
GPR34 4.92E-03 4.61E-04 9.88E-04 
GPR37L1 1.61E-03 5.50E-04 6.28E-04 
GPR39 2.43E-01 1.55E-02 4.33E-02 
GPR4 1.31E-01 7.29E-03 3.50E-02 
GPR52 1.72E-02 1.27E-03 4.73E-03 
GPR56 6.03E-01 6.19E-01 5.14E-01 
GPR6 Not detectable Not detectable 6.82E-05 
GPR62 1.07E-02 4.69E-03 9.82E-03 
GPR65 Trace 3.05E-03 1.32E-02 
GPR77 Trace 1.48E-03 7.52E-04 
GPR85 3.59E-02 9.24E-03 2.88E-02 
GPR87 1.35E-02 6.65E-04 6.50E-03 
GPR97 1.29E-03 Not detectable 3.75E-03 
GPR98 6.21E-02 1.24E-03 2.58E-02 
GPRC5A 6.17E-03 3.19E-03 3.72E-03 
GPRC5B 3.19E-02 Not detectable 6.96E-03 
GPRC5C 1.18E-01 1.59E-02 8.85E-02 
GPRC6A 8.35E-03 3.05E-03 2.08E-03 
GRM8 Not detectable Not detectable 4.45E-05 
HTR1B 3.44E-03 6.48E-04 1.64E-03 




Table A3.2. Continued.  
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
LGR4 7.42E-02 4.33E-02 3.52E-02 
LPAR1 8.12E-03 Not detectable 5.81E-03 
LPAR2 5.26E-03 Not detectable 1.86E-03 
LPAR4 3.21E-04 2.05E-04 5.33E-04 
LPAR5 3.17E-03 9.81E-04 4.84E-04 
LPAR6 7.99E-02 1.56E-02 5.41E-02 
LPHN1 5.08E-01 9.20E-02 2.49E-01 
LPHN2 2.15E-02 5.90E-03 1.46E-02 
LPHN3 Trace Trace 2.96E-04 
LTB4R2 Not detectable Trace 3.46E-04 
MC4R 2.59E-03 2.84E-03 2.07E-03 
MCHR1 4.93E-03 Not detectable 2.28E-03 
MRGPRE 6.51E-02 2.81E-02 3.06E-02 
MRGPRG 6.57E-04 1.44E-04 6.79E-04 
NMBR Not detectable 1.09E-03 4.91E-04 
NPFFR2 Trace 1.14E-03 9.07E-04 
NPY1R 1.31E-03 1.79E-04 1.82E-03 
OPN3 7.65E-03 6.44E-03 2.54E-03 
OPRK1 Trace Not detectable 7.94E-05 
OPRL1 1.59E-02 2.80E-03 1.89E-03 
OXTR 5.56E-02 3.35E-02 2.09E-02 
P2RY1 2.02E-02 6.57E-03 9.87E-03 
P2RY12 1.28E-02 2.40E-03 2.28E-03 
P2RY13 2.59E-03 1.33E-03 9.19E-04 
P2RY2 6.78E-03 1.50E-03 3.69E-03 
P2RY6 3.10E-03 1.63E-03 2.45E-03 
PTAFR 1.69E-02 Not detectable 1.68E-03 
PTGER3 1.57E-02 Not detectable 8.77E-03 
PTGIR 2.87E-03 9.57E-04 1.73E-03 
PTH1R Not detectable No expression 3.47E-03 
QRFPR Not detectable Trace 7.75E-05 
RAMP1 2.04E-02 1.66E-02 1.48E-02 
RAMP2 Not detectable 5.33E-03 4.99E-02 
RAMP3 2.93E-03 5.29E-03 2.50E-02 
RXFP4 Trace Not detectable 6.46E-04 




Table A3.2. Continued.   
 
Gene 
Mean expression in   
non-pregnant islets 
relative to GAPDH 
Mean expression in 
gestational day 12 
islets relative to 
GAPDH 
Mean expression in 
gestational day 18 
islets relative to 
GAPDH 
S1PR2 2.49E-03 3.19E-04 1.14E-03 
S1PR3 Trace 7.36E-03 2.83E-02 
S1PR4 Not detectable 9.10E-04 1.85E-03 
S1PR5 8.67E-04 Trace 7.08E-04 
SCTR 2.32E-03 6.43E-04 1.84E-03 
SMO 1.48E-02 3.81E-03 6.08E-03 
SSTR1 Trace 6.26E-04 1.19E-03 
SSTR2 1.31E-02 7.77E-03 4.39E-03 
SSTR4 2.19E-03 1.85E-04 8.95E-03 
TAAR1 8.27E-02 7.71E-03 1.14E-02 
TAAR8a 4.87E-03 Not detectable 1.14E-03 
TACR3 1.15E-03 Not detectable 1.25E-03 
TAS1R3 5.17E-02 7.25E-03 1.51E-02 
TBXA2R 4.47E-03 4.51E-04 1.01E-03 
VIPR1 1.75E-01 2.92E-02 5.09E-02 
VIPR2 2.12E-03 2.56E-03 2.72E-03 






















Table A4.1. Effects of GPCR genes, and their ligands, differentially expressed in 
pancreatic islets on gestational day 12 and 18 compared to non-pregnant 




Effect on cell 
proliferation 




Effect on cell 
proliferation 




ADORA3 Adenosine  
Anti-proliferative in 
mouse testicle Leydig 
tumour cells [368].  
No data 
Pro-proliferative in 
zebra fish pancreatic 
β-cells [369]. 
Upregulation of 
insulin secretion in 
T1DM mice [370], 
inhibition of insulin 
secretion at 50 uM 
concentration and 




















colon cancer cells 
[374, 375]. 
Adrenaline: 
inhibition of insulin 
and somatostatin 
secretion [376-









cells [380, 381]. 
Inhibition of insulin 
secretion in rats [380]. 
Inhibition of insulin 
secretion, stimulation of 
glucagon secretion in 






colon cancer cells 
[374, 375]. 
Adrenaline: 
inhibition of insulin 
and somatostatin 
secretion [376-










proliferative in mice 
and human breast 
cancer cells [384].  
Inhibition of insulin 
secretion in rat and 
mouse pancreatic islets 
[376, 377], inhibition of 
somatostatin secretion 






colon cancer cells 
[374, 375]. 
Adrenaline: 
inhibition of insulin 
and somatostatin 
secretion [376-















colon cancer cells 
[374, 375]. 
Adrenaline: 
inhibition of insulin 
and somatostatin 
secretion [376-











Effect on cell 
proliferation 




Effect on cell 
proliferation 
















stimulation of insulin 
and glucagon secretion 
in mice [244], 
stimulation of glucagon 
















glucagon secretion in 
In-R1-G9 α-cells 
[245]. Stimulation of 
insulin and glucagon 







stimulation of insulin 
and glucagon secretion 
in mice [244], 
stimulation of glucagon 














stimulation of insulin 
and glucagon secretion 
in mice [244], 
stimulation of glucagon 
secretion in In-R1-G9 
cells [245]. 












mouse glial cells 






stimulation of insulin 
and glucagon secretion 
in the perfused rat 
pancreas [389, 390], 
inhibition of 
somatostatin secretion 











A decoy receptor, 
non-signalling 












Stimulation of insulin 




stimulation of β-cell 
proliferation in 




stimulation of insulin 
secretion in rat 










Effect on cell 
proliferation 




Effect on cell 
proliferation 


















Upregulation of insulin 
secretion in mice 
[293]. Upregulation of 
somatostatin secretion 
in rat pancreatic RIN-
14B ∆-cells [292].  
CCK: 







stimulation of insulin 














in human breast 
cancer cells [394]. 
Chemerin: 
pro-proliferative 





secretion in diabetic 
mice [396].  
CELSR1 Orphan No data No data No data No data 
CHRM2 Acetylcholine No data No data 
Pro-proliferative 
in pancreatic 
cancer cells [397]. 
Stimulation through 
CHRM1 and CHRM3 
receptors, or 
suppression through 
CHRM2 and CHRM4 
receptors, of insulin 
secretion in mouse and 
rat pancreatic islets 
[398, 399]. Upregulation 
of insulin secretion 
through CHRM3 and 
CHRM5 receptors in 
human pancreatic islets 
[400]. Stimulation of 
somatostatin secretion 
via CHRM1 receptor in 









cancer cells [397]. 
Stimulation, through 
CHRM1 and CHRM3 
receptors, or 
suppression, through 
CHRM2 and CHRM4 
receptors, of insulin 
secretion in mouse and 
rat pancreatic islets 
[398, 399]. Upregulation 
of insulin secretion 
through CHRM3 and 
CHRM5 receptors in 
human pancreatic islets 
[400]. Stimulation of 
somatostatin secretion 
via CHRM1 receptor in 








Effect on cell 
proliferation 




Effect on cell 
proliferation 







Acetylcholine No data 
Inhibition of insulin 
secretion in 














receptors, of insulin 
secretion in mouse 
and rat pancreatic 

































insulin secretion in 
rat and mouse 
pancreatic islets as 
well as rat INS-1 β-
cells [239, 241]. 
Stimulation of 
glucagon secretion 






human gastric cancer 
cells [333]. 
Stimulation of 












































Effect on cell 
proliferation 




Effect on cell 
proliferation 




CXCR5 CXCL13  
Pro-proliferative in 
human colon 



















CCR3 and CCR7 
ligands 
Check CXCR3, 
CXCR5, CXCR6, CCR3 
and CCR7 ligands 
FFAR3 














in Chinese hamster 
ovary (CHO) cells 
[407]. 
Inhibition of insulin 











insulin secretion in 
mice [409]. 
Propanoic acid: 
inhibition of insulin 












































Effect on cell 
proliferation 




Effect on cell 
proliferation 

































































































Effect on cell 
proliferation 




Effect on cell 
proliferation 





























(forms a functional 
complex with GABBR1, 
does not bind the ligand 
GABA, mediates coupling 
to G-proteins) 































inhibition of insulin 
secretion in mice 
[423]. 
GCGR Glucagon No data 
Stimulation of 
somatostatin 








pancreas [425].  
Stimulation of 


























Effect on cell 
proliferation 




Effect on cell 
proliferation 












insulin secretion in 
rat pancreatic 














secretion in mice 





in isolated mouse 




insulin secretion in 
mouse pancreatic 
β-cells exposed to 
cytokines [430]. 
























insulin secretion in 
humans and mice 
[433, 435, 436]. 













[437].   
Stimulation of 





insulin release and 
improved glucose 




insulin release and 
improved glucose 













Effect on cell 
proliferation 




Effect on cell 
proliferation 




















insulin secretion in 
mouse pancreatic 
MIN6 β-cells and 
hamster HIT-T 15 β-
cells [440-442]. 
Inhibition of GLP-1- 
mediated 
stimulation of 
insulin secretion in 
rat pancreatic islets 




(GAGs) of the extracellular 
membrane  













GPR125 Orphan  No data No data No data No data 
GPR126 Type IV collagen (ColIV) No data No data No data 





type I mixed 
with collagen type 
III, type IV, and 
laminin, suppresses 
islet cell death 
[445]. 
GPR141 Orphan  No data No data No data No data 
GPR15 Orphan  No data No data No data No data 
GPR150 Orphan  No data No data No data No data 
GPR151 Orphan  No data No data No data No data 
GPR162 Orphan  No data No data No data No data 
GPR17 




Leukotriene D  
Leukotriene C  
No data No data 
UDP-glucose:   
pro-proliferative 




insulin and glucagon 
secretion in isolated 
mouse pancreatic 
islets, acting via 








Effect on cell 
proliferation 




Effect on cell 
proliferation 















and appetite [448]. 
GPR173 Orphan  No data No data No data No data 
GPR18 Orphan No data No data No data No data 
GPR182 Orphan No data No data No data No data 
GPR25 Orphan No data No data No data No data 
GPR26 Orphan No data No data No data No data 
GPR27 Orphan No data 
Stimulation of 
insulin secretion in 
mouse MIN6 β-cells 
[449].  




















insulin secretion in 
mouse pancreatic 
MIN6 β-cells and 
hamster HIT-T 15   
β-cells [440-442]. 
Inhibition of GLP-1- 
mediated 
stimulation of 
insulin secretion in 
rat pancreatic islets 




Proposed ligand:  
Zink ions   
No data No data No data No data 




















insulin secretion in 
mouse pancreatic 
MIN6 β-cells and 
hamster HIT-T 15   
β-cells [440-442]. 
Inhibition of GLP-1- 
mediated 
stimulation of 
insulin secretion in 
rat pancreatic islets 








Effect on cell 
proliferation 




Effect on cell 
proliferation 




GPR65 Proton sensing 
Pro-proliferative in 
NCI-H460 human 
non-small cell lung 
































GPR88 Orphan No data No data No data No data 
GPR98 Orphan No data No data No data No data 



















β-cells [453, 454]. 
Stimulation of 
insulin secretion in 













insulin secretion in 




L-glutamic acid (Glu) (the 














































Effect on cell 
proliferation 




Effect on cell 
proliferation 






















in mouse β-cells 
[56]. 
Stimulation of 
insulin secretion in 
mice and isolated 
























thyroid and breast 




insulin secretion in 
mouse and human 
pancreatic islets, no 
effect on the basal 
rate of insulin 
secretion [468]. 









insulin secretion in 
mouse and human 
pancreatic islets, no 
effect on the basal 
rate of insulin 







insulin secretion, no 
effect on glucagon 
and somatostatin 

























Effect on cell 
proliferation 




Effect on cell 
proliferation 













multiple cancer cell 































vitro [335].  
RSPO1: 
stimulation of 
insulin secretion in 
mouse pancreatic 



























β-cells and mouse 











β-cells and mouse 
MIN6 β-cells  [478, 
479].  
LPHN3 
Fibronectin leucine rich 
transmembrane protein 3 
(FLRT3) 
No data No data No data No data 
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Effect on cell 
proliferation 




Effect on cell 
proliferation 

















and bladder cancer 











insulin secretion in 
rat pancreatic islets 
[483].  
NMBR 
Neuromedin B (NMB) 
 
Gastrin releasing peptide 
(GRP) 
 







Neuromedin B:  
pro-






and no effect on 
glucagon and 
somatostatin 
release in the 
canine pancreas 
[285], no effect on 
insulin and a 
stimulatory 
effect on glucagon 
secretion in the rat 
pancreas [284].  
GRP: 
stimulation of 




















No data No data No data 
Neuropeptide AF: 
inhibition of insulin 
and somatostatin 




inhibition of insulin 
and somatostatin 











Effect on cell 
proliferation 




Effect on cell 
proliferation 







(dynorphin A and 
dynorphin B are the most 
potent ligands) 









rat glial cells 
[487]. 
Dynorphin A: 
inhibition of insulin 





and no effect on 
somatostatin 
release in rat 
pancreatic islets 
[489], stimulation of 
glucagon secretion 














[491].   
Anti-
proliferative in 









































secretion in mouse 
islets [496].  
AVP: 
stimulation of 
insulin and glucagon 
secretion in mice 
[244], stimulation of 
glucagon secretion 














Effect on cell 
proliferation 




Effect on cell 
proliferation 













of insulin secretion 
in mouse pancreatic 














retina [499].   
ADP: 
inhibition of insulin 
and glucagon 




of insulin secretion 
in mouse pancreatic 




























inhibition of insulin 
and glucagon 




of insulin secretion 
in mouse pancreatic 




















Effect on cell 
proliferation 
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